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Within the past fifty years, drugs from the sea have become an increasing
industry for the identification and isolation of new medicinal agents. Bryozoa, sea
squirts and corals are examples of many organisms that have been collected and
tested for medicinal activity. Clinical testing’s of drugs such as bryostatin 1 and
Et-743  have  shown  much  success against  various  cancers  such  as  kidney,
prostate, and leukemia, etc.. However, there are many problems affecting the
economical availability of such drugs such as: 1. the potential endangerment of
marine organisms due to massive quantities required for clinical use; 2. seasonal
availability  of  the organisms and  3.  numerous  synthetic steps  resulting  in  low
percent yields to name a few.
Detailed  analyses  conducted  of  the  environment  of  these  marine
organisms resulted in the composition of chemicals that were used as an artificial
property to mimic  the  host  organisms  and their  environments,  resulting  in  the
cultivation  of  the  bacteria suggestively  responsible for  the production of  these
active compounds. Other experiments conducted, involved the esterification of
bryostatin  1  under  various  conditions, in  order  to show  that  such  compounds
produced,  are  more  environmentally obtainable as opposed  to  being  specie
dependent. Computational  studies binding  Fe
3+  to different marine  natural
products was also conducted in order to determine any siderophore properties
that each may have. From this study cell line tests were conducted in order to
determine the efficacy of a bryostatin-Fe
3+ complex in comparison to bryostatin 1.
Preliminary results from all the artificial media used to isolate and produce
the  bryostatins  and  Et-743 showed prominence;  however,  results were
inconclusive due low detection values and marginal errors.SYMBOLS AND ABBREVIATIONS
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History of Bryostatin 1, Et-743 and TaxolCHAPTER 1
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1.1 Introduction
In the 1960’s, Jack Rudloe, a marine specimen collector appeared on the
television  promoting  his  new  book, The  Sea  Brings  Forth.
(1) Following  his
appearance on the show, he was contacted by David Newman from the National
Cancer Institute (NCI), requesting over three hundred marine organisms ranging
from sponges to sharks. From all the marine organisms that were tested against
the PS-100 leukaemia virus strain in mice, Bugula neritina, a bryozoa showed the
most prominent activity.
Since then, the ocean has become a treasure chest for compounds with
potential medicinal activity, with approximately a third of all drugs marketed today
extracted  from  natural  resources.
(2) Extracting,  collecting  and identifying  drugs
from marine organisms has opened a new door for the pharmaceutical industry
and gives possible hope to patients suffering from various cancers as well as
Alzheimer’s and other diseases.
(3,4)
Marine  organisms  such  as  bryozoa,  tunicates,  and  sponges etc., all
around the world, have been isolated for the extraction of medicinal agents, many
of which have shown efficacy against various cell lines.
(5) Considering that the
ocean contains a huge pool of microbial populations, it has been suggested that
many of these natural products (NPs), which have been isolated from different
invertebrates, are secondary metabolites produced by the marine bacteria found
in these marine organisms.
(6,7) Secondary metabolites are compounds produced
by organisms that have no effect on the growth, development or reproduction of
the  organisms. The  functions  of  these  secondary  metabolites  are  still  being
determined but many  marine  organisms  are  believed  to produce  these
biologically active compounds as a chemical defence mechanism (prey, predator
or compete for territory due to the overgrowth of species), and/or as a secondary
method for survival.
(8) These secondary metabolites fall into different chemicalCHAPTER 1
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classes,  such  as  terpenoids,  alkaloids,  polyketides, peptides,  sugars,  and
steroids etc..
(9)
Fig.  1.  Okadaic  acid  (C44H68O13, 804.4654  g/mol) is  a  toxin  produced  by
Dinophysis and Prorocentrum dinoflagelatesm which causes diarrhetic shellfish
poisoning in humans.
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Fig.  2.  Borophycin  (C45H70BO13, 829.4904 g/mol)  is  a  natural  product  isolated
from Nostoc linkia and N. spongaeforme.
There are two types of marine secondary metabolites: 1) toxins produced
by phytoplanktons, which have severe effects in humans and 2) bioactive natural
products produced by cyanobacteria found in marine invertebrates with potency
as medicinal agents. For example, phytoplanktons produce phytotoxins, such as
okadaic acid 1 (Fig. 1), that are ingested by filter feeders (e.g. shellfish), which
can be toxic to humans when consumed.
(10) On the other hand, borophycin 2
(Fig. 2) originally isolated from Nostoc linkia and N. spongaeforme has shown
efficacy as an anti-cancer agent against human colorectal adenocarcinoma cell
line.
(10)
Marine invertebrates are filter feeders and can therefore ingest bacteria
from the ocean, which can later settle in the marine organism. It is suggested that
marine bacteria can account for up to 40% of the volume of sponges.
(11) ManyCHAPTER 1
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groups  are  now  studying  the  ocean  to  further  understand  the  source  of
production of these NPs. In a study conducted by Toledo et al., 42% of bacteria
isolated from encapsulated sponge symbionts and sediment extracts were novel,
compared with  7%  obtained from plating  samples placed directly into  marine
agar.
(12)
Based on studies showing the true source of NPs from marine bacteria,
new  attempts  are  being  made  to  develop  methods  for  the  isolation  and
identification of the marine bacteria responsible for the production of bioactive
agents. Despite the identification of several marine bacteria as the true source of
bioactive  compounds,  the  identification  and isolation  of  such  compounds  still
remains a problem.
Table 1, below, shows examples of marine natural products (MNPs), that
have been isolated from various marine invertebrates, each showing potency as
medicinal agents.CHAPTER 1
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Table 1. A summary of MNPs that have shown efficacy as medicinal agents.
Drug name Medicinal activity Source
Dolastatins 3
(Fig. 3)
(13)
A potent anti-proliferative agent with an ED50 = 4.6X10
-5
µg/mL  against  murine  PS  leukaemia  cells.
(14) Dolastatin
acts as a potent non-competitive inhibitor of tubulin.
(15)
Isolated from the sea hare, Dolabella auricularia in the
1970s. It was later shown that the natural product was
actually  produced  by  the  cyanobacterium Symploca,
found in the sea hare.
(16)
Peloruside A 4
(Fig. 4)
(17,18)
Is  a  16-membered polyketide  macrocyclic  lactone  with
potent  anti-mitotic  activity.  Peloruside  A  binds  to  tubulin
with microtubule-stabilizing  properties  that  arrest  cells  in
the G2/M phase of the cell cycle.
Isolated  from  the  sponge, M.  hentscheli  in  New
Zealand  in  2000.  Aquaculture  systems  of  sponge is
conducted  by Marlborough  Mussels  Ltd.,  to  produce
the drug more efficiently.
(19)
Trunkamide 5
(Fig. 5)
(20,21)
A cyclic heptapeptide with cytotoxic activity. Isolated from the tropical Indo-Pacific aplousobranch
ascidian Lissoclinum patella in 1996.
Aplidine 6
(Fig. 6)
(10,22)
Aplidine  interferes with cell-cycle  progression  at the G1
phase. It entered Phase I clinical trials for the treatment of
solid tumours and lymphoma and Phase II for relapsing or
refractory multiple myeloma.
(5)
Isolated  from  the  Mediterranean  tunicate, Aplidium
albicans.
Onnamide A 7
(Fig. 7)
(23,24,25)
Induces  plasminogen  activator  inhibitor-1 (PAI-1),  gene
expression in Mv1Lu cells, at concentrations of 50 nM.
Originally  isolated  from the sponge, Theonella
swinhoei.  Recent  study  has  shown  that  the  bioactive
compound  is  produced  by  the  polyketide  synthase
genes  from the  uncultured bacteria  symbiont,
Pseudomonas spp. in the sponge.CHAPTER 1
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Fig.  3.  Dolastatin  10  (C42H70N6O6S, 786.5072  g/mol),  isolated  from
the sea hare, Dolabella auricularia.
Fig.  6.  Aplidine  (C57H87N7O15, 1109.6255 g/mol),
isolated from the Caribbean tunicate, Tridedemnum
solidum.
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Fig.  5.  Trunkamide  (C44H64N6O8S,
836.4501  g/mol), tropical  Indo-Pacific
aplouobranch  ascidian Lissoclinum
patella.
Fig. 4. Peloruside A (C27H48O11, 548.3191 g/mol),
isolated from the sponge, M. hentscheli.
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Fig. 7. Onnamide A (C39H63N5O12, 793.4468 g/mol) isolated from Pseudomonas spp., bacteria symbiont
of the sponge, Theonella swinhoei.CHAPTER 1
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1.2 Bryozoa
Bryozoa are classified as sessile invertebrates and colonial feeders found
in both fresh and salt water environments. Bugula neritina (Fig. 8 (a, b), 9) a salt
water species, is very temperature dependent (18 to 22°C), contains CaCO3 on
its outer most layer and is a seasonal organism commonly found from October to
April along the coast of California, the Gulf of México and other coastal areas.
However,  it  is  also  found  during  the  summer  season  along  the  Gulf  of
México.
(26,27)
Fig. 8a. Right-lateral view of the midsagittal section of the larvae, B. neritina. The
structure  is  classified  as  an  (AEO)  Aboral,  Equatorial  and  Oral  larval  type
because its surface is formed by the orally-aborally elongate coronal cells, and as
its equatorial neuromuscular rings contract, the larva appears to have a dumbbell
appearance.
(28)
Fig. 8b. Detailed structure of B. neritina.
(28)CHAPTER 1
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Fig. 9. An SEM image of a branch of the colonial filter feeder Bugula neritina.
In May and June Bugula may be impossible to find attached to different
substrates such as rocks, docks and/or boat bottoms as it usually is in winter.
Bugula  can,  however,  be found  washed  up  on beaches  suggesting  that deep
water Bugula  have  a  longer  season  due  to  the  cooler  temperatures  found  at
these depths. As mentioned previously, the outer layer of Bugula has a calcified
layer (CaCO3), which must be dissolved before any extraction can take place.
The role of the bryostatins found in Bugula is not known as yet but it has been
suggested by other groups, that it is produced by symbiotic bacteria that reside
within the organism. The bryostatins may play a role in the defense mechanism
of  the  animal,  similar  to  other  secondary  metabolites  or it  may act  as  a
siderophore. Siderophores are iron chelating compounds, produced by marine
bacteria in marine organisms and secreted by marine organisms to bind iron; as
many  cannot  bind  iron  alone.
(29,30) Twenty  bryostatin  compounds  have  been
isolated  from  the  marine  organism,  since  the  discovery  of  its  efficacy  as  a
medicinal agent. Aside from the bryostatins, neristatin 8 (Fig. 10) has also been
isolated from Bugula neritina.
(31)CHAPTER 1
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Fig.  10.  Neristatin  (C41H60O15, 792.3927 g/mol),  is  a  marine  natural  product
isolated from Bugula neritina, in the Gulf of México.
Yields from the extraction of bryostatin 1 from Bugula are consistently very
low (10
-5 to 10
-7%). The harvesting, extraction and purification processes are time
consuming, expensive and pose many environmental concerns. For this reason,
the cost for high purity bryostatin 1 is several million USD per gram. Due to such
circumstances, several methods have been conducted to improve the isolation
and  production  of  bryostatin  1  from  the  marine  organism;  as  one  of  many
alternatives towards the production of bryostatin 1.
A recent study was conducted in order to try to modify the growth of the
larvae of Bugula neritina by first analyzing its behaviour under various conditions,
in the hope of developing an efficient method of maximizing the production of the
organism  in an artificial  setting.  Results  showed  that  conditions such  as  light,
water  flow  and  aeration  strongly  affect  the  overall  production  of  these  larvae;
however, the change in the schedule of feeding broths did not impact the overall
percent yield of the larvae produced; resulting in the harvesting of the marine
organism  for  several  weeks.
(32) Another  similar  study  looked  at  the  effects  of
different chemicals (potassium, calcium, serotonin, etc.) on larvae attachment, in
an  attempt  to  prolong  the  life  and  production  of  the  organism  when  using
aquaculture methods. Results showed that potassium induced the attachment of
larvae  to  containers,  as  did  chemicals  such  as  serotonin,  l-dopa and γ-
aminobutyric  acid, while chemicals  such  as  Mg
2+  inhibited  the  production  ofCHAPTER 1
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larvae,  and  others,  such  as  Ca
2+,  had  no  impact  on  the  larvae  within  the
system.
(33)
1.2.1 Bryostatin 1
Bryostatin 1 9a (Fig. 11) is a marine natural product extracted from the
bryozoa, Bugula  neritina. It  was  first  discovered  in  the  1960s  when  the  NCI
conducted  an  extensive  study  testing  hundreds  of  marine  organisms  for  any
potential medicinal applications. From all the marine organisms tested, Bugula
neritina,  showed  the  most  prominent  activity. In  1982  the  active  compound
isolated  from  the  marine  organism  was  identified  as  bryostatin  1,  a  cyclic
macrolide  structure  (Fig.  11),  by  Pettit et  al..
(34) X-Ray crystallography  and
spectroscopy were used to determine the macrolide’s unusual structure.
(34)
Fig. 11. Bryostatin 1 (C47H68O17, 904.4451 g/mol). The groups on bryostatin 1 are
an acetate group at R1 and a C8 group at R2.
In the extraction procedure for the isolation of bryostatin 1, 500 kg of wet
Bugula was used. This extract was fractionated by solvent partition sequencing,
purified  by  column  chromatography,  and recrystallized to  produce  crystal
formations of bryostatin 1.
(34) Since then, nineteen other bryostatin compounds
have been identified from the marine bryozoa, each differing in the R1 and R2
groups on the bryophan ring (Fig. 11). As shown above, bryostatin 1 has many
ester groups which maintain the basic frame of the bryostatin compound.CHAPTER 1
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1.2.2 Synthesis of bryostatin 7
Studies  have  been  conducted  on  the  complete  synthesis  of  the  C1-C16
portion of  bryostatin  1, in  order  to  prepare the  compound  more  efficiently in
higher percentage yield.
(35,36) The synthesis of bryostatin 7 by Masamune et al., is
shown in Fig. 12 and 13.
(37,38)
In the  figure  below,  fragments  (ring  synthons)  were  connected  in  the
sequence A′ (C3-C10), B, C and, finally, the introduction of the C1-C2 unit. All of
the fragments required were available from the previous work of this group. The
synthesis shown below focuses solely on the key steps for the coupling of these
fragments  or  those  which  lead  to  diastereoisomeric  discrimination.  The A′B
fragment was prepared via an initial aldol reaction of aldehyde 10 with ketone 11,
catalysed by (R,R)-2,5-dimethylborolanyl triflate, to give the β-hydroxyketone 12
in 86 % yield, with an 11S:11R ratio of 8:1 (Fig. 12). Construction of the two
pyran rings involved initial deacetonization to pyran 13, followed by a mercuric
acetate-mediated cyclization onto the alkene, to give a diastereoisomeric ratio of
alkylmercurials 14 of 1:1, from which the isomer 15 with the equatorial aldehyde
group was obtained via equilibration of the isomers on alumina.CHAPTER 1
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11
10
10 11
O
OH
OR OMe OH OR
O
OH
OR OMe
O
OR
HgCl
15
O
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MeOH, PPTS, (MeO)3CH 84 %
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93 %
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NaBH4, O2, DMF-CH2Cl2
then (COCl)2, DMSO, CH2Cl2
then Et3N, -78oC
then Al2O3, H2O, CH2Cl2
60 %
12
13
14
15
Fig. 12. Synthesis of A′B fragment (R = Si
tBuPh2).
Coupling of this aldehyde 15 (ring A′B synthon) with ring C synthon 16
under  Julia-Lythgoe  conditions  gave  the  tripyran 17.  Functional  group
interconversions (FGI) (Fig.  13)  then  gave  the  hydroxyacid 18, which  was
converted to  the  macrocyclic  lactone 19  using  dicyclohexyCHAPTER 1
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lcarbodiimide  and  pyridine  (in  51  %  yield).    Finally,  a  series  of  FGI  gave
bryostatin 7 (Fig. 13).
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then PhCOCl, DMAP
then Na-Hg, MeOH-EtOAc,
Na2HPO4, -20oC
60 %
O
OR1
O
CO2Me
OH
O
R3O
O CO2Me
OH O
R2
9
7
25
O OH
bryostatin 7
19
DCC, PPTS, pyridine
ClCH2CH2Cl, reflux
51 %
PPTS = pyridinium p-toluenesulphonate
Fig. 13. Synthesis of bryostatin 7.
1.2.3 Synthesis of bryostatin 2
The synthesis of bryostatin 1
(39,40) was followed by the total synthesis of
bryostatin 2 by Evans et al., which was then utilized by Pettit et al., to prepare
bryostatin 1 by a process involving the selective protection and de-protection of
the C-26 hydroxyl group.
(41,42) In the figure below, the retrosynthetic analysis ofCHAPTER 1
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the core bryostatin structure 20 led to three possible ring synthons 21-23, all of
which  could  be  derived  from anti-1,3-diol  subunits 24-26.  Since  this  stereo-
chemical motif is readily accessed via aldol reactions followed by stereo-selective
reduction, this methodology forms a key part of this synthetic route to bryostatin
2.
This  total  synthesis  will  now  be  discussed  in  three  main  sections;
synthesis  of  ring A-C  synthons 21-23,  macrocyclization,  and  functional  group
transformations (including the introduction of the enoate functions onto rings B
and C) on the substituted macrocycle. In discussing each of these sections, we
will  concentrate  upon  the  key  reactions  for  the  introduction  of  essential
functionality or for stereoisomer discrimination.CHAPTER 1
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Fig. 14. Retrosynthetic analysis of bryostatin core structure.
Synthesis  of  the  ring A  synthon 22 began  with  a  dibutylboron  triflate-
mediated aldol reaction of aldehyde 27 with the chloroacetyloxazolidinone 28 to
give  imide 29 (in  a  diastereoisomeric  ratio  of  90:10),  followed  by  subsequent
elaboration to give the β-alkoxyaldehyde 30 (Fig. 15).  Aldol condensation of this
aldehyde 30 with  the  diene 31,  catalysed  only  by  TiCl2(O
iPr)2  gave  the β-
hydroxyketone 32 in 83 % yield with high diastereoselectivity (94:6).  Subsequent
hydroxyl-directed  reduction  with  Me2NBH(Oac)3  at -35ºC  gave  the  diol 33.
Subsequent transformations, including cyclization, protection, oxidative cleavage,CHAPTER 1
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introduction of an α-sulphone (via nucleophilic substitution by a thiol followed by
oxidation with m-CPBA), and amidation (thereby allowing the metallation at C-9
required for the later coupling of rings A and B) gave the ring A synthon 22.
Ph2C
O
H
Cl
O
N
O
CH2Ph
O
Bu2BOTf, iPr2NEt
diastereoselection
90:10
O
N
O
CH2Ph
O
OH
Cl
Ph2C
O
H
PMBO
Ph2C
27
28
29
30
PMBO
Ph2C
TMSOOTMS
OMe
TiCl2(OiPr)2, -78oC
PhCH3
83 %
d. r. = 94:6
OMe
OH O O
PMBO
Ph2C OMe
OH O OH
1
9
31
32
12
Me4NBH(OAc)3
AcOH, MeCN
-35oC
92 %
d. r. 91:9
33
Fig. 15. Synthesis of ring A synthon 12.
Synthesis  of  the  ring B synthon  (C10-C16)  also  began  with  an
enantioselective aldol  reaction,  of  diene 34 with α-benzyloxyacetophenone 35
(Fig. 16), catalysed by 5 mol% of the copper complex 36.  Once again, hydroxyl-
directed  1,3-anti  reduction  of  the β-ketoester 37 gave  a  diol 38 (in  91:9
diasteroisomeric ratio), which, in this case, was further elaborated to the ring BCHAPTER 1
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synthon 21.  This  elaboration  included  homologation  (with p-
methoxybenzyloxymethyllithium) and, finally, debenzylation and Swern oxidation.
OtBu
TMSOOTMS
H
O
OCH2Ph OtBu
OCH2Ph
O O OH
OtBu
OCH2Ph
O OH OH
O
OTBS
O H
OTBS
34 35 37
38
21
5 mol % 36
75-85 %
N O
N N
O
Cu
Ph Ph
2 SbF6
2
36
> 99 % ee
Me4NBH(OAc)3, -35oC d. r. = 91:9
Fig. 16. Synthesis of ring B synthon 13.
Synthesis of the ring C synthon (Fig. 17) involved an initial aldehyde 39
homologation to give aldehyde 40 (via a reaction sequence including a Grignard
reaction  with  a  pentenylmagnesium  bromide,  Swern  oxidation  and  periodate
cleavage)  then  an  aldol  addition  with  ketone 41,  using  a  chiral  boryl  enolate
(chlorodiisopinocampheylborane) (in a diastereoisomeric ratio of 93:7) to give β-
hydroxyketone 42,  followed  by  a  samarium-promoted  Tishchenko  reduction  to
diol 43 (in a diastereoisomeric ratio of > 95:5). Further elaboration and cyclization
gave the pyran (ring C synthon).CHAPTER 1
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SO2Ph
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SO2Ph
O O
H 3 SO2Ph
O OH O
OPMB
O
OPMB
(-)-DIPCl
NEt3, CH2Cl2
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39 40
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SO2Ph
O OPNBz
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43
d. r. > 95:5
23
SmI2 (20 mol %)
p-O2NC6H4CHO, THF, 0oC
O
SO2Ph
OTBS
OPMB
C
H
17
25
Fig. 17. Synthesis of ring C synthon 14.
The preferred order of coupling of the ring synthons was established as C
 CB  CBA.  Coupling of the lithiated ring C synthon 23 with aldehyde 21 (ring
B synthon) gave a hydroxysulphone which was transformed into the trans-olefin
44 via a modified Julia procedure.  After selective deprotection of the 10-hydroxyl
group and trifluoromethylsulphonation, the ring CB fragment 45 was coupled with
the lithiated ring A synthon 22 (Fig. 18).CHAPTER 1
19
23
O
SO2Ph
OTBS
OPMB
C
H
17
25
O
OTBS
O H
OTBS
21
nBuli, THF -78oC
then Ac2O, DMAP, CH2Cl2
then Mg, HgCl2, EtOH
64 %
O OTBS
OPMB
C
H 25
O
OR
OTBS
16
O
PhO2S
CONHR
OTBS
OPMB
A
1
22
9
nBuli, THF, HMPA -78oC
87 %
O OTBS
OPMB
C
H 25
O
OTBS
16
O
CONHR
OTBS
OPMB
A
1
HO
44
Fig. 18. Coupling of the ring A-C synthons.
Refunctionalization to the optimal macrocycle precursor, to give acid 46,
and  lactonization via  a  modified  Yamaguchi  procedure  (using 2,4,6-
trichlorobenzoyl chloride) on the monohydroxyacid 46 gave the macrocycle 47
(Fig. 19).CHAPTER 1
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Fig. 19. Macrocyclization.
Finally,  introduction  of  the  ring B  and C  enoate  functionalities  included
Dess-Martin oxidation, reaction of ring B pyranone 48 with the sodiated Fuji’s
chiral phosphonate 49 gave the enoate 50 (diastereoisomeric ratio 86:14) (Fig.
20), base-catalysed enoate 51 formation on ring C with OHCCO2Me (Fig. 21),
reduction with a chiral boron reagent 52 (in a diastereoisomeric ratio of > 91:9) to
give the ester 53 after esterification, and acylation (with diisopropylcarbodiimide,
DMAP) / deprotection to give bryostatin 2.CHAPTER 1
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Fig. 20. Enoate formation on ring B.
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Fig. 21. Enoate formation on ring C and reduction.
The synthesis of bryostatin 2 by Evans and co-workers also constitutes a
formal total synthesis of bryostatin 1 as an earlier report from by Pettit et al.,
described the synthesis of bryostatin 1 from bryostatin 2 by selective protection
and de-protection involving the C-26 hydroxyl group.
(38)CHAPTER 1
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1.2.4 Bryostatin analogues
Numerous  studies  have  been  conducted  regarding  the preparation of
bryostatin 1 in an attempt to economically produce the drug for pharmaceutical
and clinical use. Synthetic bryostatin analogues (Fig. 22) have been developed,
with some having potency as effective as bryostatin 1.
(43,44,45)From the analogues
that have been prepared, 7b,c 54 and 8 55 all bind strongly to PKC isozymes,
with 7c showing the greatest potency of (1.8-170 ng/ml) against several human
cancer cell lines. Analogue 9 56 showed no binding affinity for PKC.
(43)
O O
O O O
O R3
O
O
O
R1
R2
H
O
OH H
54
O O
O O O
O CH3(CH2)6
O
O
O
OH
HO
O
OH H
55
O O
O O
O CH3(CH2)6
O
O
O
HO
O
OH
56
7(a-d) 8 9
7a: R1 = OH, R2 = OH, R3 = CH3
7b: R1 = H, R2 = OH, R3 = (CH2)6CH3
7c: R1 = OH, R2 = OH, R3 = (CH2)6CH3
7d: R1 = OH, R2 = OAc R3 = (CH2)6CH3
Fig. 22. Bryostatin analogues.
(43)
1.2.5 Aquaculture of B. neritina
Aside  from developing synthetic  applications  for  the  production  of
bryostatin 1, studies have also been conducted in order to further examine its
host organism. These findings have facilitated the development of an efficient
aquaculture system for the isolation of larger quantities of bryostatin 1.
Between  1990  and  1994,  larva  settlement  experiments  and  laboratory
facilities  for  grow-outs  were  maintained  along  the  shore  of  Aqua  Hedionda
lagoon, San Diego, CA. The tank cultured system included seawater filters (sand,
UV, carbon, 16 µm filters, and 0.2 µm filters, etc.), wastewater settling tank filters,CHAPTER 1
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algal and zooplankton production units, and a large raceway used as a culturing
tank.  The process started with wild stock of Bugula neritina being collected from
the coastal regions of Southern California and then the larvae were placed in a
hatchery on artificial substrates (PVC). The larvae and substrate were then tested
in greenhouse grow-outs, as well as on underwater platforms that were secured
in  the ocean.  The Bugula  was  harvested  and  extracted  and  the  bryostatin
purified. This was a fairly complex approach to producing Bugula that included a
greenhouse culture system with a capital intensive water treatment and feeding
system  and this  paper  provides  many  of  the  technical  details for  these  grow-
outs.
(46)
Several  important  results  were  discussed  in  this  paper.  Firstly,  the
production of bryostatin 1 was not consistent.  For example, in tank grow-outs the
yields were disappointing and ranged from 0 to 14.2 micrograms of bryostatin 1
per gram of Bugula. The limiting factor in this approach is the cost of the system,
the authors estimated that construction costs for a 50,000 kg/year unit would be
approximately $7.5 million and a 25,000 kg/year unit would cost $4.2 million to
construct. The start up cost for the first two years for the larger unit would be
approximately $3.8 million and it would not produce any bryostatin in the first two
years, costing approximately $2.4 million per year to maintain.
(46)
In  addition  to  the  high  capital  and  overhead  cost,  shifts  in  climate  can
dramatically impact the Bugula growth and the water temperature typically needs
to drop below 22
°C for an extended period of time for Bugula to grow. Climate
effects, such as El Niňo in the Pacific, can decimate a crop. In summary, this
article described a sophisticated approach to growing Bugula but the bryostatin
yields (approximately 10
-6 %), coupled with the capital cost, have precluded it
from being a viable production method.
(46)CHAPTER 1
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1.2.6 Symbiont bacteria in B. neritina
Based on the supposition that marine invertebrates ingest marine bacteria
which  produce the bioactive  compounds  found  in  marine  organisms  such  as
Bugula neritina,  studies  have  been  conducted  at  the  Scripps  Oceanography
Institute to investigate this theory for the production of the bryostatins in Bugula.
This group has proposed that a marine bacterium is responsible for production of
the  bryostatins  found  in  the  bryozoa.  This suggestion was  based  on  several
studies that have been conducted to determine a commonality of marine bacteria
in Bugula neritina found along the coast of California and Bugula found in the
Atlantic  ocean  (near North  Carolina). Several  attempts  have  been  made  to
cultivate the marine bacteria, Candidatus endobugula sertula, which has been
proposed as the key bacterium responsible for the production of bryostatin 1.
(47)
Other work by this group has been conducted to show that the marine
bacteria use polyketide synthase (pks) gene fragments to produce the bryophan
ring,  which  is  the  basic  structure  of  all  the  bryostatin  compounds.  To  further
support  this  work, Bugula  was  treated  with  antibiotics  which  resulted  in  a
decreased concentration of bryostatin 1 as well as a decrease in the function of
the pks genes.
(48,49,50)
The  different  bryostatin  compounds  that  have  been  isolated  from  the
marine organism were identified in Bugula found in different areas of the World.
For example, bryostatin 4 is extracted from Bugula found in the Gulf of México,
the Gulf of California and the Gulf of Sagami.
(51) Bryostatins 12 and 13 can be
extracted from Bugula collected off the Eastern Pacific Ocean.
(52) For this reason,
this same group has also suggested that the variation in the production of all
twenty known structures of the bryostatins is based on the chemotypes (M and
O) in the subspecies of the bryozoa, Bugula neritina.
(53) No conclusive evidence,
however,  has  yet  been  reported for  the  production  of the bryostatins  and  theCHAPTER 1
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bacterium  responsible  for  the  production  of the  drug  is  yet  to  be  isolated. In
addition,  all  of  the  approaches  mentioned  have  been  unsuccessful  in  their
attempts to produce bryostatin 1 in a cost efficient process.
1.2.7 Clinical trials
In 1984, the first European patent on the separation and purification of
bryostatin  1  was  published.
(54) Following  the  isolation  and  identification  of
bryostatin 1, the drug has been used in over thirty phase I and phase II clinical
trials for various cancers such as breast, kidney, prostate, and ovarian as well as
Alzheimer’s disease.
(5) Bryostatin 1 has hydrophobic properties which restricts it
from being administered easily and for this reason, it is used in an ethanol or a
polyethylene glycol formulation for delivery in patients.
(55) Bryostatin 1 has been
successful against various cancers in clinical trials, both as a sole agent and  as
part  of  combination  therapy  but a few  studies  have been less successful.
Modifications  to  these  trials  are ongoing in  order to  determine  if  any  possible
improvement in efficacy is possible. For example, the administering of paclitaxel
(Taxol) followed by bryostatin 1 for the treatment of renal cell carcinoma gave
promising  results. When  the  drug  order  was  reversed,  however,  the  results
showed reduced inhibition of tumour growth in comparison to Taxol alone, as
bryostatin’s effect on the mitosis of cancer cells resulted in decreased activity of
Taxol.
(56,57) Another study, investigating the use of bryostatin 1 against leukaemia
(HL-60) cells showed that bryostatin 1 alone enhanced ULBP1 (a binding protein
ligand of the NKG2D receptor, which is expressed in natural killer cells and T
cells) three  fold  and, in  combination  with  myeloid  GFs  (growth  factors)  and
interferon-γ enhanced ULBP1 by ten fold.
(58)
Studies have  shown bryostatin  1 to be  successful for  the  treatment  of
cervical cancer when administered synergistically  with cisplatin. Based on thisCHAPTER 1
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finding, 50 µg/m
2 of bryostatin 1 and 50 mg/m
2 of cisplatin was administered for 1
hr every 3 wk with the results showing that 71% of patients completed both cycle
treatments. The overall success of the treatment, however, was not as good in
comparison  to  data  on  the  use  of  cisplatin  alone. Further  studies  are  being
conducted with both these drugs and others to determine a feasible combination
for the treatment of patients with advanced carcinoma of the cervix.
(59)
Table 2 summarizes the clinical trials not yet recruiting patients,
(5) while
Table 3 summarizes some of the many clinical trials that have been completed.
(5)
Table 4 summarizes the clinical trials that are no longer recruiting patients for
treatment  using  bryostatin  1.
(5) Some  of  the clinical  trials  have  been  less
promising than others, but most suggest that bryostatin 1 is effective both, as a
sole agent and in synergy with other chemotherapeutic agents.
Table 2. Clinical trials of bryostatin not yet recruiting patients.
(5)
Title, Location, date Purpose Goals set
Safety, efficacy,
pharmacokinetics, and
pharmacodynamics study
of bryostatin 1 in patients
with Alzheimer’s disease
Chestnut Ridge Center,
West Virginia University,
Dep. Behavioural Med.
and Psychiatry,
Morgantown, WV
Started: April 2008
NCT00606164
Phase II randomized
study to determine the
safety, efficacy,
pharmacokinetics and
pharmacodynamics of
administering bryostatin
1 to patients with mild to
moderate Alzheimer's
disease.
To determine:
1. The safety and
efficacy of a single dose
of bryostatin 1 in
patients.
2. How bryostatin 1
works in the body and its
interaction with PKC
enzymes.
3. Levels of bryostatin 1
in blood.
Bryostatin 1 has only recently been proposed as a possible treatment for
Alzheimer’s disease (AD) and for the reduction of brain damage due to stroke.
(60)
Patients with AD have an abnormality in their PKC (protein kinase c) isozymes
and a deficiency of PKC function. Since bryostatin 1 is known to activate PKC
isozymes, and with results from preclinical data showing the efficacy of bryostatin
1 on learning and memory, the drug has been proposed as a possible treatmentCHAPTER 1
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for patients with AD. This area has potential as: the highest concentration of PKC
is  found  in  the  brain, PKC  is  involved  in  intracellular  signalling  of  information
passaging,  and PKC inhibition  impairs  learning  and  memory.  Bryostatin 1
restores dysfunction of PKC enzymes, activates classic PKC in active neurons,
and  stabilizes  growth  associated  proteins  necessary  for  long  term
memory.
(60,61,62,63,64,65) Patients with AD also showed abnormalities in the PKC
activated phosphorylation of mitogen activated protein kinase ERK1/2, a sign of
early stage AD in patients.
(66,67) The correlation of PKC to AD has been beneficial
in the search for a suitable drug to prevent or treat the disease, and knowing that
bryostatin  1 activates  PKC,  has  made  this  drug  a  substantial  marker  for  the
treatment of AD.
Initial pre-clinical studies have been conducted by administering bryostatin
1  to  Hermissenda  sea  slugs,  in  order  to  determine  whether  there  was  any
improvement  in  their  memory  in  comparison  to untreated sea  slugs,  and  the
results  showed  that  bryostatin  1  bio-chemically  enhanced  the  memory  of  sea
slugs.  Under  normal  conditions,  the  sea  slugs  lost  the  skill  of  reacting  in  the
presence  of  light  after  seven  minutes, but  those  that  were  administered with
bryostatin 1 retained the stimulus for at least 5 days.
(68,69)
Studies have also been conducted testing the memory capacity of rats and
rabbits,  by  teaching  them  to  perform  certain  functions  after  administering
bryostatin  1.  This  data  was  compared  to  rats  and  rabbits  not  treated  with
bryostatin 1 in order to determine the overall efficacy of bryostatin 1 in learning
and  memory  function.
(70,71,72,73) This study showed  that,  when  given  the
appropriate  dosage  levels,  the  rats  were  able  to  retain  the  ability  to  perform
certain tasks by memory. Treatment with bryostatin 1 also reduced any moods of
depression in these animals.
(72) Results from the study using rabbits showed thatCHAPTER 1
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the administration of bryostatin 1 has the ability to enhance classical conditioning
of the nictitating membrane response in rabbit
(73)
As a result of these encouraging results, more studies are currently being
conducted in order to determine the potential for bryostatin 1 as a treatment for
patients  with  AD.  With  approximately  5.1  million  people  reported  to  have
Alzheimer’s in the United States alone, the need for a prevention is imperative.
(74)CHAPTER 1
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Table 3. A few examples of clinical trials that have been completed.
(5)
Title, Location, Date Purpose Goals set
Bryostatin  1, paclitaxel and  cisplatin to
treat patients with advanced solid tumours
Memorial  Sloan-Kettering  Cancer
Center, NY
Started: February 1998
NCT00003242
Phase І  trial  to  determine  the
effectiveness  of administering paclitaxel,
bryostatin 1 and cisplatin to patients with
advanced solid tumours.
To determine:
1. The maximum tolerated dosage of bryostatin
1 when given with paclitaxel and cisplatin.
2.  The  pharmacokinetics  of  paclitaxel  when
combined with bryostatin 1.
3.  The  therapeutic  activity  of  these  drugs  in
patients.
Interleukin-2 plus bryostatin  1 to  treat
patients with melanoma or kidney cancer
Massey Cancer Center, Richmond, VA
Started: September 2000
NCT00006022
Phase І  trial  studying  the  modulation  of
the  biological responses having
administered bryostatin  1  for  the
treatment of interleukin-2.
To determine:
1. The tumour response rate and survival time
after treatment.
2. The immune response of the drug in patients.
3. The tolerated dosage for treatment.
Bryostatin 1 to treat patients with relapsed
non-Hodgkin's  lymphoma  or  chronic
lymphocytic leukaemia
Barbara  Ann  Karmanos  Cancer  Institute
Detroit, MI
Started: December 1996
NCT00002908
Phase І /II  trial  to  determine  the
effectiveness  of  bryostatin  1  in  patients
with relapsed non-Hodgkin's lymphoma or
chronic lymphocytic leukaemia.
To determine:
1.  The  duration  of  response  and  survival  rate
after treatment.
2. The qualitative and quantitative toxicity effect
of the drug in patients.
3. The efficacy of bryostatin 1 as a 72 hr infusion
drug.
Bryostatin  1  and  high  dose cytarabine  in
treating patients with refractory or relapsed
leukaemia or lymphoma
New  York  Presbyterian  Hospital,  Cornell
Campus, NY
Started: September 1997
NCT00003079
Phase І  trial  to  study  the  efficacy  of
bryostatin 1 and high doses of cytarabine
in  patients  with  refractory  or  relapsed
acute  myelocytic,  acute  lymphocytic
leukaemia,  chronic  myelogenous
leukaemia, and  refractory  or  relapsed
lymphoblastic lymphoma.
To determine:
1. The maximum tolerated dosage of bryostatin
1.
2.  The  toxicity  level  of  bryostatin 1 and  high
dose level of cytarabine in patients.
3. The time course of bryostatin 1 in patients.
4. The pharmacokinetics of bryostatin 1.CHAPTER 1
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Bryostatin  1  in  treating  patients  with
myelodysplastic syndrome
Barbara Ann Karmanos Cancer Institute
Detroit, MI
Started: May 1998
NCT00003171
Phase II trial to determine the efficacy of
administering bryostatin 1 in patients with
myelodysplastic syndrome.
To determine:
1. The response rate in patients.
2. The qualitative and quantitative toxicity levels
of bryostatin 1.
3. The duration of response and survival rate in
patients.
A study of  all-trans  retinoic  acid  (ATRA)
and  bryostatin  1  in  patients  with  acute
myeloid  leukaemia  (AML)  and
myelodysplastic syndrome (MDS)
Dana-Farber Cancer Institute, Boston, MA
Started: May 1997
Completed: August 2000
NCT00136461
Phase II trial to study the effects of ATRA
and one of two schedules of bryostatin 1
in patients with AML or MDS.
To determine:
1. The therapeutic effects of bryostatin 1.
2.  The  maximum  tolerated  dosage  of  retinoic
acid.
3.  The  effectiveness  of  bryostatin  1  when
combined with retinoic acid.
Bryostatin  1  plus  gemcitabine  in  treating
patients with advanced cancer
Barbara Ann Karmanos Cancer Institute
Detroit, MI
Started: May 2000
NCT00004144
Phase І trial to study the effectiveness of
giving  bryostatin  1  with  gemcitabine  to
patients with advanced cancer not having
responded  to  previous  chemotherapy
treatments.
To determine:
1. The maximum tolerated dosage of both drugs
respectively.
2. The response rate, duration of response, and
overall survival rate in patients.
3.  The  influence  of  bryostatin  1  on  the
pharmacokinetics of gemcitabine.
4. The pattern of toxicity of the drug in patients.
Bryostatin  1  plus  cladribine  in  treating
patients with relapsed chronic lymphocytic
leukaemia
Barbara Ann Karmanos Cancer Institute
Detroit, MI
Started: May 1998
NCT00003174
Phase І trial studying the side effects and
best  dosage  level  of  cladribine  with
bryostatin  1  to  patients  with  relapsed
chronic lymphocytic leukaemia.
To determine:
1. The maximum tolerated dosage of cladribine
when combined with bryostatin 1.
2. The qualitative and quantitative toxicity level
of both drugs in patients.CHAPTER 1
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Bryostatin  1  in  treating  patients  with
metastatic  or  recurrent  head  and  neck
cancer
Memorial  Sloan-Kettering  Cancer
Center, NY
Started: July 1998
NCT00003443
Phase  II  trial  studying  the efficacy of
bryostatin 1 in patients with metastatic or
recurrent head and neck cancer.
To determine:
1. The safety and toxicity levels of the drug in
patients.
2.  The  anti-tumour  activity  of  the  drug  in
patients.
3.  The  cyclin  dependent  kinase  2  and  PKC
activity and apoptosis levels of cells in patients.
Bryostatin  1  plus  paclitaxel  in  treating
patients  with  locally  advanced  or
metastatic  oesophageal  cancer  or
stomach cancer
Albert Einstein Clinical Cancer Center,
Bronx, NY
Started: February 2000
NCT00005599
Phase  II  trial  to  determine  the
effectiveness  of  giving  bryostatin  1  and
paclitaxel  to  patients  with  advanced  or
metastatic  oesophageal  cancer  or
stomach cancer.
To determine:
1. The toxicity level of both drugs in patients.
2. The survival rate in patients after treatment.
3. The quality of life for patients treated.
4.  The  complete  and  partial  response  rate  in
patients.
5.  The  pre  and  post-treatment  tissue biopsy
markers in patients.
Bryostatin  1  plus  fludarabine  in  treating
patients  with  chronic  lymphocytic
leukaemia  or  relapsed  indolent  non-
Hodgkin's lymphoma
New  York  Presbyterian  Hospital,  Cornell
Campus, NY
Started: September 1998
NCT00005580
Phase І trial studying the success rate of
bryostatin  1  and  fludarabine  in  patients
with  chronic  lymphocytic  leukaemia  or
relapsed,  indolent  non-Hodgkin's
lymphoma.
To determine:
1.  The  toxicity  effect  and  maximum  tolerated
dosage of both drugs in patients.
2. The anti-tumour activity of both drugs.
3. The apoptosis, differentiation and PKC activity
when both drugs are administered.
Bryostatin  1  plus  vincristine  in  treating
patients  with  recurrent  or  refractory  HIV-
related lymphoma
Herbert  Irving  Comprehensive  Cancer
Centre, NY
Started: August 2001
NCT00022555
Phase І trial to study the effectiveness of
administering bryostatin 1 and vincristine
in  patients  with  recurrent  or  refractory
lymphoma.
To determine:
1. The toxicity level of both drugs in patients.
2. The maximum tolerated dose of both drugs.
3.  The  objective  response  and  survival  rate  of
patients.
4.  The  immuno-modulatory  effects  on
interleukin-2  (IL-2),  IL-2  receptor  and  IL-6
cytokine levels.CHAPTER 1
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5. The effects on CD4+ lymphocyte count and
HIV load.
6. The effect on human herpes virus-8 load.
Bryostatin 1 in treating patients with stage
IV breast cancer
University of Colorado Cancer Center,
Denver, CO
Started: April 1998
NCT00003205
Phase II trial to determine the efficacy of
bryostatin  1  in  patients  with  stage  IV
breast cancer.
To determine:
1.  The  clinical  response  of  bryostatin  1  in
patients.
2. The efficacy of the drug in patients.
3. The pharmacokinetics of bryostatin 1 as a 24
hr infusion drug.
4. The ability of the drug to regulate lymphocyte
function.
5. The effects of the drug on platelet functions
and PKC activity.
Bryostatin  1  and rituximab in  treating
patients  with  b-cell non-Hodgkin's
lymphoma  or  chronic  lymphocytic
leukaemia
NIH -  Warren  Grant  Magnuson  Clinical
Center, Bethesda, MD
Started: July 2004
NCT00087425
Phase  II  trial  studying  the  efficacy of
bryostatin  1  and  rituximab  in  treating
patients  with  B-cell non-Hodgkin's
lymphoma  or  chronic  lymphocytic
leukaemia not having  responded  to
previous treatment with rituximab alone.
To determine:
1.  The  safety  and  efficacy  of both drugs  in
patients.
2. The effects of cells before and after treatment.
Paclitaxel  and  bryostatin  1  in  treating
patients with metastatic prostate cancer
Greater  Baltimore  Medical  Centre  and
Cancer Center, Baltimore, MD
Started: May 2000
NCT00005028
Phase II trial to determine the efficacy of
paclitaxel and bryostatin 1 in patients with
metastatic  prostate  cancer not  having
responded to hormone therapy.
To determine:
1. The toxicity level of both drugs in patients.
2. The overall survival rate of patients treated.
3. The onset, duration and degree of response
in patients.CHAPTER 1
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Table 4. Clinical trials of bryostatin that are no longer recruiting patients.
(5)
Title, Location, Date Purpose Goals set
Bryostatin 1 plus cisplatin in treating patients
with  recurrent  or  advanced  cancer of  the
cervix
Albert  Einstein Comprehensive  Cancer
Center, Bronx, NY
Started: August 2000
NCT00005965
Phase II trial to study the effectiveness
of cisplatin and bryostatin 1 in patients
with  recurrent  or  advanced  cancer  of
the cervix.
To determine:
1.  The efficacy  and  safety  of  both  drugs  in
patients.
2. The response rate, progression free interval
and duration of survival in patients.
Bryostatin  1  and  cytarabine  in  treating
patients  with  relapsed  acute  myelogenous
leukaemia
Herbert  Irving  Comprehensive  Cancer
Center, Columbia University, NY
Started: July 2001
NCT00017342
Phase II trial to determine the efficacy of
giving  bryostatin  1  and  cytarabine  to
patients  with  relapsed  primary  acute
myelogenous leukaemia.
To determine:
1. The toxic effect of both drugs in patients.
2. The relapse-free survival and overall survival
in patients.
3. The response rate in patients.
Bryostatin  1  plus  paclitaxel  in  treating
patients  with  stage  IIIB,  stage  IV,  or
recurrent NSCLC
Central  Illinois  Haematology  Oncology
Center, Springfield, IL
Started: April 2000
NCT00005849
Phase II trial to determine the efficacy of
both  drugs in patients  with  stage  IIIB,
stage IV or recurrent non-small cell lung
cancer.
To determine:
1. The overall survival and progression rate.
2. The T-cell subset analysis and serum levels
of interleukin-6 and tumour necrosis factor alpha
after receiving bryostatin 1.
3.  The  overall,  partial  and  complete  response
rate after treatment.
Bryostatin 1 and cisplatin in treating patients
with  metastatic  or  unresectable  stomach
cancer
City  of  Hope  Comprehensive  Cancer
Center, Duarte, CA
Started: November 2000
NCT00006389
Phase II trial to determine the efficacy of
bryostatin  1  and  cisplatin in patients
with metastatic or unresectable stomach
cancer.
To determine:
1. The toxicity levels of both drugs in patients.
2.  The  molecular  determinant  response  of  the
drugs in patients.
3. The response and survival rate in patients.CHAPTER 1
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Paclitaxel  and bryostatin 1  in treating
patients with locally advanced, unresectable
or metastatic pancreatic cancer
Albert  Einstein  Clinical  Cancer Center,
Bronx, NY
Started: January 2002
NCT00031694
Phase  II  trial to  determine  the
effectiveness  of  paclitaxel  and
bryostatin 1 for the treatment of locally
advanced  unresectable  or  metastatic
pancreatic cancer.
To determine:
1. The response and survival rate of both drugs
in patients.
2.  Any  toxicity  and  pharmacokinetic  effects  of
the drugs in patients.
Bryostatin  1  and  cisplatin  in  treating
advanced  recurrent  or  residual  ovarian
epithelial,  fallopian  tube,  or  primary
peritoneal cancer
Cedars-Sinai  Comprehensive  Cancer
Centre, Cedars-Sinai Medical Center, LA,
CA
Started: January 2001
NCT00006942
Phase  II  trial  to  study  the  efficacy  of
administering bryostatin 1 and cisplatin
to  patients  with  advanced  recurrent  or
residual  ovarian  epithelial,  fallopian
tube, or primary peritoneal cancer.
To determine:
1. The duration of response in patients.
2. The toxicity level of both drugs in patients.
3. The overall response rate and the complete
response rate of both drugs in patients.
Combination  chemotherapy  in  treating
patients with chronic lymphocytic leukaemia,
non-Hodgkin's  lymphoma,  or  multiple
myeloma
Ireland Cancer Center, Cleveland, OH
Started: May 1998
NCT00003166
Phase І trial to determine the efficacy of
bryostatin 1  and  vincristine in patients
with  chronic  lymphocytic  leukaemia,
non-Hodgkin's  lymphoma,  or  multiple
myeloma.
To determine:
1. The maximum tolerated dosage of bryostatin
1 when combined with vincristine.
2.  The  clinical  response  of  both  drugs  in
patients.
Combination  chemotherapy  in  treating
patients with unresectable locally advanced
or metastatic stomach cancer
University  of  Texas,  MD  Anderson  Cancer
Center, Houston, TX
Started: June 2000
NCT00006081
Phase II trial to study the effectiveness
of  both  bryostatin 1  and paclitaxel  to
treat patients  with  unresectable  locally
advanced  or  metastatic  stomach
cancer.
To determine:
1. The qualitative and quantitative toxicity levels
of both drugs in patients.
2. The response rate of the drugs in patients.CHAPTER 1
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1.2.8 Cell line tests
The first cell line testing on bryostatin 1 was conducted in the 1960s when
bryostatin 1 was injected into laboratory mice carrying a PS-100 leukaemia virus
strain and showed potency as a promising medicinal agent. Since then, in vitro
trials have shown bryostatin 1 to act synergistically with other anti-cancer drugs,
modulating PKC activity and having effective anti-leukaemia activity and efficacy
against lung, prostate and non-Hodgkin's lymphoma tumour cells. In vivo trials
have also shown that bryostatin 1, along with the calcium ionophore ionomycin,
activates T-cells from  murine  tumour  lymph  nodes, and  represents  a  possible
anti-tumour agent.
(75) Bryostatin 1 and IM (imatinib mesylate, a tyrosine kinase
inhibitor) were  recently  tested  for  activity (of  both compounds  alone  and
synergistically)  against  chronic  myeloid  leukaemia  of  stem  cell  origin.  Results
from this study showed that bryostatin 1 alone did not suppress the cell cycle
progression of K562 cells, but IM alone resulted in the inhibition of these cells (at
initial concentrations of 5 µM). The effects of both drugs in combination were no
different to results of IM alone, but the administration of bryostatin 1 prior to IM
led to a significant reduction in the K562 cell numbers.
(76) Tables 5 and 6 outline
the numerous cell line tests that have been conducted with bryostatin 1, both
synergistically and as a sole agent.CHAPTER 1
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Table 5. Some of the earliest recorded cell line tests using bryostatin 1 both as a sole agent and in combination with other anti-cancer
agents.
Title Purpose Results
Three activators of PKC, bryostatin, dioleins
and  phorbol  esters,  show  differing
specificities  of  action  on  GH4  pituitary
cells.
(77)
To examine the actions on GH4C5 cells
of TPA (12-O-tetradecanoylphorbol-13-
acetate)  and  two  other  classes  of
protein  kinase C  activators,  synthetic
cell  permanent  dioleins  and  bryostatin
1.
Data showed that bryostatin 1, diolein and phorbol
esters all bind to the same site on PKC. Each drug
altered the biological responses in GH4C5 cells,
with selectivity and efficacies that differ in each.
Bryostatin  1  antagonizes  the  terminal
differentiating  action  of  12-O-
etradecanoylphorbol-13-acetate  in  human
colon cancer cells.
(78)
Identification  of  the  cellular  processes
involved  in  the  induced  terminal
differentiation  of  human  colon  cancer
cells.
Bryostatin 1 completely counteracted  the  effects
of TPA and promoted continued replication of the
cells.
Bryostatin 1, an activator of protein kinase
C,  mimics  as  well  as  inhibits  biological
effects of the phorbol ester TPA in vivo and
in vitro.
(79)
To understand the TPA effects that can
be induced by bryostatin 1.
Results  showed  that  bryostatin  1 inhibited  the
specific Ca
2+ ion component of TPA action.
Bryostatin 1 activates protein kinase C and
induces  monocytic  differentiation  of  HL-60
cells.
(80)
To  determine  if  the  induction  of
differentiation may involve the activation
of  phorbol  ester  in PKC  (phospholipid
and calcium dependent).
Bryostatin 1 trans-located the activity of PKC from
the  cytosol  to  the  membrane  in  HL-60  cells.
Bryostatin  1  also  induced  the  growth  of  HL-60
cells.CHAPTER 1
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Table 6. Some of the most recent cell line tests on bryostatin, both as a sole agent and in combination with other drugs.
Title Purpose Results
Simplified analogues of bryostatin with anti-
cancer  activity  display  great  potency  for
translocation of PKC delta GFP.
(81)
To  highlight  the  importance  of  using
binding  affinity  in  conjunction  with
standard  measurements  of  protein
localization  for  the  pharmacological
profiling of biologically active agents.
The  potency  of  the  compounds  to  induce  the
translocation responses, which appeared to be
only  qualitatively  related  to  binding  affinity  of
PKC.
Bryostatin  1  and  UCN-01  potentiate  1β-D-
arabino furanosylcytosine induced apoptosis
in  human  myeloid  leukaemia  cells  through
disparate mechanisms.
(82)
To study the effects of bryostatin 1 and
7-hydroxystaurosporine (UCN-01) for
the treatment of human myelomonocytic
leukaemia cells.
The  potentiation  of  ara-C  lethality  in  human
leukaemia  cells  by  bryostatin 1 involves the
activation of PKC.
Bryostatin 1 a novel PKC inhibitor in clinical
development.
(83)
A  review  on  the  modulation  of PKC,
which  represents  a  novel  approach  to
cancer therapy.
Short-term exposure to bryostatin 1 showed to
promote  activation  of PKC, and  prolonged
exposure to bryostatin  1  significantly  promotes
the down-regulation of PKC.
The  anti-neoplastic  agent  bryostatin  1
differentially  regulates interferon γ  receptor
subunits  in  monocytic  cells:  transcriptional
and post transcriptional control of interferon
γ R2.
(84)
To  investigate  the effects  of bryostatin
on the expression and regulation of INF
(interferon) γ chains in monocytic cells.
Bryostatin  up-regulates  INF-γ  R2  expression  in
monocytic  cells. Bryostatin  1 also  showed  the
ability to overcome some of the immunological
defects observed in cancer patients.CHAPTER 1
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1.2.9 Bryostatin and Protein Kinase C
Protein  kinases  C  (PKC)  are  enzymes  that  regulate  the  activity  of
intracellular signalling pathways for hormones, growth factors, neurotransmitters
and cytokines. These enzymes catalyse the modification of amino acids such as
serine,  tyrosine and theonine by  phosphorylation.  Protein  kinases  play  a
significant role in cellular responses arbitrated by diacylglycerol 57 (DAG, Fig. 23)
and phorbol ester 58 (Fig. 24), two tumour promoters.
(85)
Fig. 23. Structure of 1,2 diacyl-sn-glycerol (DAG). The R groups represent alkyl
groups.
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Fig. 24. The most common phorbol ester, 12-O-tetradecanoylphorbol-13-acetate
(TPA), a tumour promoter that mimics the action of DAG on PKC.
The structure of PKC is unknown, but it is said to consist of a regulatory
and  a  catalytic  domain  (Fig. 25). The  regulatory  domain  consists  of  two  sub
regions, C1 and C2. The C1 domain contains the binding site for both DAG and
phorbol ester, and the C2 domain functions as a Ca
2+ sensor, which consists of
three  regions  (aPKC, nPKC, and cPKC) comprising  40%  of  the amino  acid
sequence.
(82) Uncontrolled proliferation resulting in cancerous cells is believed to
be related to the dysregulation of PKC signalling, however in other aspects it only
affects mitogenic signalling. This shift can be correlated to the different isozymes
of PKC, resulting in the formation of different uncontrolled proliferations.
(86)CHAPTER 1
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Fig 25. The activation of PKC towards the plasma membrane resulting in the
down-regulation  of  the  enzyme  by  separating  the  enzyme  into  two  regions
(catalytic and regulatory).
(87)
Bryostatin 1 transforms the activity of PKC in competing with DAG and
phorbol ester for the binding site on the enzyme, inducing the initial activation and
translocation  of  PKC by  binding  to  the  C1  regulatory  domain  on  the  kinase;
resulting in the down-regulation of the PKC enzyme at the plasma membrane and
the  sensitization  of  cancer  cells  in  the  body.
(88,89) For  example, bryostatin  1
activates PKC  from  leukaemia  cells in  vitro  and  decreases  the  cytoplasmic
activity in vivo.
(90) When the PKC enzymes are activated, they move towards the
plasma  membrane  and  bind to it, releasing  the  regulatory  domain,  where  the
process is repeated again.
In  addition  to  bryostatin  1 activating  PKC,  it  also  affects  cell  cycle
regulatory protein p21. Inhibition of p21, as well as cdk2 (cyclin d kinase 2), has
been correlated with the inhibition of tumour growth in cells treated with bryostatin
1.
(91) A recent study supported the claim that bryostatin 1, a PKC agonist, limits
the growth of K-Ras12V dependent tumours. This showed that bryostatin 1 has
specific  activity  against  these  cells  as  there  was  no  effect  on  K-Ras12V181A
cells. This specificity is proposed to be due to the presence of S181 in K-Ras12VCHAPTER 1
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cells (S181 are phosphate acceptors at the C-terminal region of K-Ras, which
mediates the localization of K-Ras as a direct substrate for PKC) resulting in the
degradation of those cells.
(92)
1.2.10 Problems with production
As  mentioned  earlier,  despite  bryostatin’s  activity  as  a  prominent  anti-
cancer agent, there are several factors that limit its production, availability and
universal application. The collections of approximately 14 tons of Bugula neritina
from its marine environment is needed to extract 18 g of the drug, with yields of
10
-6 %. Retrieving the drug by this method is time consuming, expensive and
poses numerous ecological concerns. For this reason, the accessibility and high
cost for quality pure bryostatin 1 is prohibitive, costing millions of USD per gram
of the drug. Several other techniques such as aqua culture (section 1.2.5), the
genetic determination of the bacteria in the marine organism (section 1.2.6), and
microbial  broths have  been attempted in  the  hope  of  making drug  production
more  economically  feasible. The  seasonal  availability and large  quantity of
Bugula needed for the extraction and purification results in the recovery of only
minute quantities of bryostatin 1.
1.3 Sea squirt
Tunicates (Fig. 26) are sessile filter feeders that grow to about 5 cm tall
and 4 cm inches wide. They have a flexible, tough outer surface, usually greyish
green in colour and can often be found attached to rocks and mangrove roots in
the Caribbean Sea and in the West Indies. These organisms have two cavities in
their body, an incurrent siphon for taking in food and an excurrent siphon for
excreting waste material from the body. Ecteinascidin 743 60b (Et-743, Fig. 27)
also known as Yolendis or Trabectedin, is a marine natural product extractedCHAPTER 1
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from  the  sea  squirt, Ecteinascidia  turbinata.
(3,93) This tetrahydroisoquinoline
marine  alkaloid was  first studied  for  medicinal  activity  in  the  1970s  and was
isolated in 1990 from sea squirt found in the West Indies by Rinehart et al..
(93,94)
Later, the drug was licensed by PharmaMar, Spain.
(95)
Fig. 26. Sea squirt, Ecteinascidia turbinata, attached to a crab trap in Panacea,
Fl.
A total of 8 ecteinascidin compounds (Fig. 27, Table 7) have been isolated
from  the  sea  squirt  and  a  total  of  4  analogues (Fig.  28,  Table  8) have  been
prepared as shown below.
(96)
Table 7.  Ecteinascidin compounds  characterized  by  different  R  groups.  The
numbers shown in brackets represent the different structures for each compound
shown below.
(96) Molecular formula (M+H-H2O)
+ determined by HRFABMS.
Et- compounds Molecular
formula
Molecular ion
formula
R1 R2
Et-729 (60a) C38H41N3SO11 C38H39N3SO10 H OH
Et-722 (59) C39H40N4O9S C39H38N4SO8 H OH
Et-736 (59) C40H42N4O9S C40H40N4SO8 CH3 OH
Et-743 (69b) C39H43N3O11S C39H41N3SO10 CH3 OH
Et-745 (60c) C39H45N3SO11 C39H43N3SO10 CH3 H2
Et-759A (60d) C39H43N3O12S C39H41N3SO11 CH3 OH
Et-759B (60e) C39H43N3O12S C39H41N3SO11 CH3 OH
Et-770 (60f) C40H42N4SO10 C40H42N4SO10 CH3 CN
Et-776 (60g) C40H45O11N3S C40H46O11N3S CH3 OMe
* Et-759A/B: S-oxideCHAPTER 1
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Fig. 27. The structures for the ecteinascidin compounds in Table 7.
Table 8.  Ecteinascidin  compounds  characterized  by  different  R  groups.  The
numbers shown in brackets represent the structures for each compound shown
below.
(96) Molecular formula (M+H-H2O)
+ determined by HRFABMS.
Et compounds Molecular
formula
Molecular ion
formula
R1 R2 X Y
Et-583 (c1) C29H33N3SO8 C29H33N3SO8 H OH OCH3 OH
Et-597 (c2) C30H35N3SO8 C30H35N3SO8 CH3 OH OCH3 OH
Et-594 (d1) C30H30N2SO9 C30H30N2SO9 CH3 OH XY: O-CH2-O-
Et-596 (d2) C30H32N2SO9 C30H32N2SO9 CH3 OH OCH3 OH
Et-637 (e1) C30H35N3SO9 C30H35N3SO9 CH3 OH XY: O-CH2-O-
Et-637-OBu (e2) C34H40N2SO11 C34H40N2SO11 CH3 OH XY: O-CH2-O-
(c) (d)
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(c1: R = H; c2: R = CH3) (d1: XY(C-CH2-O); d2: X = OCH3; Y - OH)CHAPTER 1
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Fig. 28. The structures for the ecteinascidin analogues in Table 8.
Aside  from  the  extraction  of  different  ecteinascidin  compounds  and
saframycin  metabolites  from  the  sea  squirt, Ecteinascidia turbinata,  other
compounds  have  been  isolated  with  potential  antibiotic  activity.  Two  of  the
antibacterial bisanthraquinone metabolites 65 and a cytotoxic artifact 66 (Fig. 29),
were  isolated  from  a  cyanobacterium associated  with  the sea  squirt. Both
metabolites showed  efficacy  against Staphylococcus  aureus,  with an  IC50 of
0.15−130 μM.
(97)The identification of these metabolites from the sea squirt further
supports the idea that these organisms ingest the bacteria responsible for the
production of such medicinal agents.
(a) (b)
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R1 = H; R2 = OH
Fig. 29. a) The two antibacterial metabolites identified by the change in R groups,
and b) the cytotoxic artifact isolated from the cyanobacterium associated with the
sea squirt, Ecteinascidia turbinata.
(97)CHAPTER 1
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1.3.1 Et-743
The total synthesis of Et-743 was carried out by Corey et al., in 1996.
(98)
Shortly  after,  a twenty  one  step semi-synthesis  of  the  drug  was  achieved  by
Corey, Martinez et al..
(99) In 2002 another route to the total synthesis of Et-743
was achieved  by  Fukuyama et  al..
(100) In  2003,  another  group  developed  an
asymmetric synthesis for the production of the ecteinascidin compounds by using
a tyrosine derivative as the basic building block in an overall yield of 39%.
(101)
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Fig. 30. Phthlascidin 650 (C36H34N4O8, 650.2371 g/mol), a synthetic analogue of
Et-743, with anti-tumour properties. Phthlascidin an IC50 of 5 0.1–1 nM agonist.
Phthlascidin 650 67 (Fig. 30), a synthetic analogue of Et-743, has been
prepared by Corey et al., and shows similar cytotoxic effects to Et-743.
(102) Since
the  discovery  of  Et-743,  other  ecteinascidin  compounds  have  been  identified,
along with the production of different analogues of the drug, with some having
greater activity than others, but Et-743 still remains the most potent.
(93,103)
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Fig. 31. Et-743 separated into three building blocks (A, B and C).
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Fig. 32. The three precursors for each building block used for the synthesis of Et-
743 by Chandrasekhar et al..
(104)
A recent study was conducted to determine a new method of synthesizing
Et-743 60, with the structure for Et-743 being considered as three blocks (A 68, B
69,  C 70)  as  shown  in  Fig.  31. Piperonal 71,  2-methylanisole 72,  and
veratraldehyde 73  were  used  as  precursors  to  produce  each  building  block
respectively, as shown in Fig. 32.
(104) This method could also be applied to other
tetrahydroisoquinoline natural products such as Safracin 74 and Saframycin 75
(Fig. 33).
(104)
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Fig. 33. a) Safracins A (R = H), safracin B (R = OH) and cyanosafracin (R = CN);
b) Saframycin  A.  Both  used  as  precursors  for  the  production  of  the  different
ecteinascidin compounds.
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Fig.  34.  The  formation  of  the  pentacyclic  framework  of  the  ecteinascidin
compounds via β-lactam.
Other  methods  are  also  being  used  to  reduce  the  number  of  synthetic
steps for the production of the ecteinascidin compounds. In 2007, Williams et al.,
developed a method for the production of the pentacyclic framework 76 of the
ecteinascidin  compounds  by  using β-lactam 77 as  a  precursor  (Fig.  34).
(105)
Methods used in the total synthesis, as mentioned above, include focusing on the
pentacyclic structure of the different ecteinascidin compounds; since the basic
framework for all the ecteinascidin compounds is the same, as shown in Fig. 27
and 28. The total synthesis still involves several steps in the preparation of the
ecteinascidin  compounds  and their analogues, hence  making  the  process
unviable for economical use.
(106)
1.3.2 Clinical trials
Since the  discovery of Et-743,  the  drug  has become  by  far  the  most
advanced marine  natural  product in  late  stage phase  II clinical  trials  and  has
already entered phase III clinical trials for the treatment of various tumours such
as soft tissue sarcoma, melanoma, osteosarcoma, etc..
(107)
A recent study was conducted in order to test the efficacy of administering
Et-743 to patients with advanced soft tissue sarcoma, demonstrating significant
success in treating patients with different forms of this type of tumour. Depending
on the patient’s condition, the overall progression free survival time and overallCHAPTER 1
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survival rate after approximately one year was 42.6% and 72% respectively.
(108)
Data  from  treating  myxoid  liposarcoma  signified  that  the  median  progression
survival  time  was fourteen  months with  88%  of  patients  showing  signs  of
progression free survival at six months after treatment.
(109) Many studies have
been unsuccessful in finding an effective agent to treat uterine leiomyosarcoma.
Et-743  was  administered  to  patients  with  uterine  leiomyosarcoma showing  a
response rate of 32% and a survival rate of 8 months after treatment.
(110)
The  effectiveness  of  Et-743 in  vivo was  shown  to  be  very  successful
against a human ovarian carcinoma xenograft.
(111) Table 9 summarizes a few
clinical trials that are currently recruiting patients in order to study the response of
Et-743  as  a  sole  agent  and in  combination with  other  drugs.
(5) Table 10
summarizes  the  clinical  trials  that  have  been  completed,
(5) and Table 11
summarizes the clinical trials that are no longer recruiting patients.
(5)CHAPTER 1
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Table 9. A few clinical trials of Et-743 that are currently recruiting patients.
(5)
Title, Location and Date Purpose Goals Set
Et-743  (Yondelis)  in  men  with  advanced
prostate cancer
Massachusetts  General  Hospital, Boston,
MA
Started: June 2002
Ended: April 2008
NCT00147212
Phase II trial to study the effectiveness of
administering Et-743 for 3 hr/weekly to men
with advanced prostate cancer.
To determine:
1. The response rate of the drug in patients.
2.  The  duration  of  response  and  time  of
progression of the drug over the designated time
period.
Et-743  in  men  with  advanced  prostate
cancer
Massachusetts General Hospital, Boston,
MA
Started: January 2004
NCT00072670
Phase II study of Et-743 given to men with
advanced prostate cancer.
To determine:
1. The safety and efficacy of the drug in patients.
2. The response rate of the drug.
3. The PSA (prostate specific antigen) levels in
patients
To  provide  access  to  Trabectedin  in
patients with soft tissue sarcoma who have
persistent  or  recurrent  disease and  who
are not expected to benefit from currently
available standard care treatment
Santa Monica, CA
Started: August 2005
End: May 2009
NCT00210665
Phase III study of Trabectedin administered
to  patients  with  locally  advanced  or
metastatic soft tissue sarcoma.
To determine:
1. The survival rate of patients treated.
2. Any physical change through lab tests, heart
rate, and any vital signs having taken the drug.
A study of the effectiveness of Trabectedin
for the treatment of patients with specific
subtypes of metastatic breast cancer
Johnson  &  Johnson  Pharmaceutical
Research & Development, L.L.C
Started: January 2007
Phase  III  trial  studying  the  effectiveness
and safety of administering Trabectedin to
patients with breast cancer.
To determine:
1. The response rate of the drug in patients.
2.  The  survival  and  response  rate  of  patients
after the treatment period.CHAPTER 1
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NCT00580112
A study of the safety and effectiveness of
Trabectedin for the treatment of localized
myxoid / round liposarcoma
Johnson  &  Johnson  Pharmaceutical
Research & Development, L.L.C
Started: May 2007
NCT00579501
A  phase  II  trial  studying  the  effects  of
Trabectedin on (MRCL) when administered
before the tumour is removed by surgery.
To determine:
1. The pathological response rate of the drug in
patients.
Trabectedin in treating young patients with
solid  tumours  that  have  relapsed  or  not
responded to treatment
Warren Grant Magnuson Clinical Center
Bethesda, MD
Started: June 2008
NCT00437047
Phase І trial studying the side effects and
best  dosage treatment of Trabectedin in
young patients with solid tumours that have
relapsed or not responded to treatment.
To determine:
1. The maximum tolerated dosage of the drug in
children.
2. Any toxicity levels of the drug in patients.
Table 10. Clinical trials of Et-743 that have been completed.
(5)
Title, Location, Date Purpose Goals Set
A  safety  study  utilizing  Yondelis  and
Doxorubicin  in  patients  with  soft  tissue
sarcoma
Atlanta, GA
Started: April 2005
NCT00102609
A phase I  study  of  Yolendis  and
Doxorubicin  in  patients  with  recurrent  or
persistent soft tissue sarcoma.
To determine:
1.  The  proper  dosage  of  both  drugs  when
combined, using three different test
concentrations.
Phase  II study  of  Et-743 in  patients  with
advanced ovarian cancer
USC,  Norris  Comprehensive  Cancer
Center, Los Angeles,  CA
NCT00050414
Phase II trial to study the effectiveness of
Et-743  in  patients  with  advanced  ovarian
cancer.
To determine;
1. The safety of the drug in patients.CHAPTER 1
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Ecteinascidin 743 in treating children with
refractory solid tumours
University of California San Diego Cancer
Center, La Jolla, CA
Started: October 2000
NCT00006463
Phase  I  study  to  determine  the
effectiveness  of  Et-743 in  children  with
refractory solid tumours.
To determine:
1.  The  maximum  tolerated  dosage  and  dose
limiting toxicity of the drug in patients.
2. The pharmacokinetics of the drug in patients
3. Any anti-tumour activity.
Ecteinascidin 743 in treating patients with
malignant mesothelioma
Dana-Farber Cancer Institute, Boston, MA
Started: July 2001
NCT00027508
Phase II trial studying the effectiveness of
administering  Et-743  to  patients  with
unresectable malignant mesothelioma.
To determine:
1. The response rate of drug in patients.
2. The toxicity levels of the drug.
3 The pharmacokinetics and pharmacodynamics
of the drug in patients.
4. Overall  survival  rate,  time  until  treatment
failure and the quality of life of patients treated.
Phase  II  study  of  Et-743  in  persistent  or
recurrent endometrial carcinoma
USC,  Norris  Comprehensive  Cancer
Center, LA, CA
NCT00050440
Phase  II  trial  to  determine  the  efficacy  of
Et-743  in  patients  with  persistent  or
recurrent endometrial carcinoma.
To determine:
1. The safety and efficacy of the drug in patients.
Et-743  in  patients  with  advanced  breast
cancer
Torrance,  CA
Started: November 2003
Ended: May 2004
NCT00050427
Phase  II  study  of  Et-743  in  patients  with
advanced breast cancer.
To determine:
1. The safety and efficacy of the drug in patients.CHAPTER 1
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Table 11. Clinical trials of Et-743 that are no longer recruiting patients.
(5)
Title, Location, Date Purpose Goals Set
The  effectiveness  of  combining  Doxil  and
Yondelis  to  Doxil  alone,  for  patients  with
ovarian cancer
Tucson,  AZ
Started: April 2005
End: November 2009
NCT00113607
A phase III  study  comparing  the
combination  of  Yolendis  and Doxil  to
Doxil  alone  in  patients  with  advanced
relapse ovarian cancer.
To determine:
1.  The  overall  survival  rate  in  patients  by
combining  both  drugs  in  comparison  to Doxil
alone.
A study of Et-743 in patients with advanced
liposarcoma or leiomyosarcoma
Started: April 2003
Ended: February 2008
NCT00060944
Phase II  trial  studying  the  efficacy  of
Trabectedin  in  patients  with  advanced
leiomyosarcoma or leiomyosarcoma.
To determine:
1.  The  safety  and  effectiveness  of  the  drug  in
patients.
Ecteinascidin  743  in  treating  patients  with
advanced soft tissue sarcoma
Ole  Steen  Nielsen,   Study  Chair,   EORTC
Soft  Tissue  and  Bone  Sarcoma Coop.
Group
NCT00003939
Phase  II trial  to  determine  the
effectiveness of administering Et-743 in
patients  with  advanced  soft  tissue
sarcoma.
To determine:
1. The response rate in patients.
2. Any acute side effects of the drug in patients.
3. The therapeutic activity of the drug in patients.
Ecteinascidin  743  in  treating  patients  with
previously treated metastatic osteosarcoma
Memorial Sloan-Kettering Cancer Center
NY
Started: December 1999
NCT00005625
Phase  II trial to  determine  the
effectiveness  of  Et-743  in  patients
previously  treated  for  metastatic
osteosarcoma.
To determine:
1. The response rate of patients treated.
2. The pharmacokinetics and pharmacodynamics
of the drug in patients.
3. The toxicity levels of the drug in patients.CHAPTER 1
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Ecteinascidin  743  in  treating  adults  with
advanced solid tumours
Newcastle  General  Hospital, Newcastle
upon Tyne, UK
Started: February 1996
NCT00002904
Phase  I  study  on  the  effectiveness  of
administering  Et-743  to  adults  with
advanced solid tumours.
To determine:
1. The pharmacokinetics of the drug in patients.
2. The maximum tolerated dosage of the drug in
patients.
3. Any anti-tumour effects.
4. The qualitative and quantitative toxicity effects
of the drug in patients.
Ecteinascidin  743  in  treating  patients  with
unresectable  advanced  or  metastatic  soft
tissue sarcoma
Memorial  Sloan-Kettering  Cancer
Center, NY
Started: February 2001
NCT00017030
A phase II  study  of  Et-743  given  to
patients with unresectable advanced or
metastatic soft tissue sarcoma.
To determine:
1. The overall survival rate of patients treated.
2. The pharmacokinetics and pharmacodynamics
of drug.
3. The toxicity level of drug in patients.CHAPTER 1
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1.3.3 Mechanism of action
Studies  have  shown  that  Et-743  binds  to  the  minor  groove  of
deoxyribonucleic  acid  (DNA),  alkylating  the  second  nitrogen  on  guanine, thus
bending the molecule towards the major groove formation.
(112,113) The proposed
mechanism for the binding of Et-743 to DNA, alkylating the second nitrogen on
guanine is shown in Fig. 36.
(114) It is also shown that Et-743 60b forms hydrogen
bonds with DNA as shown in Fig. 35.
(114) In this process, only two subunits of Et-
743  bind to  the  DNA  strand,  configuring  the  structure  in  the  minor groove,
resulting  in  interference  with  the  DNA  binding  factor  in  cells.
(115)  Et-743 also
inhibits the activity of NF-Y (nuclear transcription factor γ), which is activated by a
specific coding sequence (CCAAT). When these results where compared to cell
promoters lacking this CCAAT gene, no change in behaviour with Et-743 was
detected.
(116)
Fig. 35. Et-743 hydrogen binding sites to DNA. The arrows indicate the direction
of hydrogen bond donors and acceptors.
At  low  concentrations,  Et-743  inhibited  the  activity  of  topoisomerase  1
isomerases, which act on or change the topology of DNA.
(117) The effectiveness
of any anti-tumour activity of Et-743 is thus related to the transcription dependent
growth  arrest (at  a  concentration  of  1-10 nM),  as  well  as  the  transcription
independent apoptosis of cells when Et-743 is administered at a concentration of
10-100 nM.
(118)CHAPTER 1
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Fig. 36. The proposed mechanism of Et-743 alkylating the N2 of guanine 78. The 12NH of the carbinolamine 79 catalyzes the dehydration of
C21, yielding the iminium ion 80. Nucleophilic attack by GN2 on 80 results in the expulsion of the transiently bound H2O, which contains the
proton released by guanine N2 81. The resulting adduct 82 retains a protonated N12. Hydrogen bonds are depicted by dotted lines, and B
corresponds to a DNA base hydrogen bond acceptor.
(114)CHAPTER 1
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Recent studies were conducted to determine the DNA binding properties
of Et-743 and different analogues (Et-745 60c, Et-637 63 and Et-594 62). Results
from gel retardation assays showed the ranking of the compounds (from most to
least active, Fig. 28) as Et-743>Et-637>Et-594>Et-637-OBu 64 and finally Et-745.
Et-743  showed  extensive  binding  to  DNA  whereas  Et-745  did  not  bind  at  all,
suggesting no potency in configuring DNA in cancerous cells.
(119)
Studies have  also  been  conducted  in  order  to  further  understand  the
molecular  mechanism  of  Et-743 binding  to  DNA  and  the inhibition  of DNA
replication in cancerous cells. This investigation was conducted using yeast cells
to determine the cytotoxicity levels. Yeast cells contain both BER (base excision
repair)  and  NER  (nucleotide  excision  repair),  DNA  repair  mechanisms.  In  the
presence of Et-743 cell death occurred, but cells that did not contain these DNA
repair mechanisms showed resistance to Et-743.
(120) This suggested that NER
plays a pivotal role in targeting the drug in order to repair DNA. This prompted
another  study to  further  understand these  recombinant  repairs  in  yeast  and
mammalian  cells. The  ability of Et-743  to reconfigure  the  DNA  into  the minor
groove  is  referred  to  as  the  NER  pathway,  which  is  recognised  by  XPG  (a
specific protein involved in NER) within the NER system, hence cells that lack
NER are resistant to Et-743.
Fig.  37.  Dexamethasone  (C22H29FO5, 392.1993 g/mol)  used  to  decrease  the
hepatotoxicity of Et-743 in patients.
Recent clinical trials also showed that aside from Et-743’s efficacy, high
levels  of  the  drug can  lead to  liver  damage  in  patients.  For  this  reason,
dexamethasone 83 (DEX, Fig. 37) was given to patients, resulting in a significantCHAPTER 1
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decrease in hepatotoxicity.
(121) The effectiveness of DEX in reducing the toxicity
of  Et-743 in  patients was  mirrored  by a 75% reduction  in the level  of
hepatotoxicity in rats; an important consideration for further trials conducted in
vivo.
(122)
1.3.4 Problems with production
The problems facing on economic production of Et-743 are similar to those
of  bryostatin  1  (section  1.2.4).  Approximately 1  metric  ton  of Ecteinascidia
turbinata is needed to extract 1 g of the drug. Due to the high demand for the
marine organism, several alternative methods are being used for the production
of  Et-743.  PharmaMar  has  been  extracting  Et-743  from  sea  squirts using an
aquatic culturing system, ensuring continuous drug production.
(99) This method
does not reduce the amount of the organism needed to produce grams of the
drug. In 2000, a twenty one step semi-synthetic route was developed which is
used in conjunction with cyanosafracin B 74 (Fig. 33), resulting in the production
of Et-743.
(98,99,123)
Since the discovery of Et-743, it has progressed the furthest of all MNPs in
clinical studies against various cancers.
(5) Et-743 is still extracted from tunicates
found attached to rocks and mangrove roots in the Caribbean Sea, along the
Florida coast and in the West Indies. Aquaculture systems for farming of the sea
squirt are currently employed year round in order to provide the various clinical
trials with continued supplies of the drug,
(46) but the extraction process is a major
drawback, resulting in low percentage yields and expensive production costs for
the drug.CHAPTER 1
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1.4 Paclitaxel (Taxol)
The  pacific  yew  tree  (Taxus  brevifolia)  is found along  the  coast  of
California, stretching from as far north as Alaska to southern California, and also
in Idaho and Columbia. It is also found in Florida (Florida yew tree). The trees are
protected  under  wild-life regulations, as they  were  previously  extensively
collected for the isolation of the active compound paclitaxel (Taxol).
Despite the historical use of the tree, for medicinal purposes, it was in the
early 1960s that the anti-tumour compound, Taxol 84 (Fig. 38), was first identified
and in 1971 that the structure of the compound was determined.
(124,125) The total
synthesis was not achieved until the early 1990s by Nicolaou et al.,
(126) followed
by a four step semi-synthesis by Holton et al., in 1994 (Fig. 39).
(127) Other groups
have since modified the synthesis of Taxol in the hope of increasing the yield.
(128)
With  the  discovery  of Taxol from  the Pacific yew  tree,  hundreds  of  other
compounds such as Taxol C, taxane alkaloids, diterpenoids, lignans, and sugar
derivates, etc., have been isolated from different yew trees.
(129)
Fig. 38. Paclitaxel (Taxol), (C47H51NO14, 853.3304 g/mol), an anti-cancer agent
initially isolated from Pacific yew tree, Taxus brevifolia.CHAPTER 1
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Fig.  39. The four step semi-synthesis of Taxol, using 10-Deacetylbaccatin as a
precursor.
1.4.1 Clinical trials
Despite the initial identification and isolation of paclitaxel in the early 1970s
phase I clinical trials were not conducted until 1984, with phase II trials beginning
shortly  after (between  1984  and 1986).
(124) Since  then,  nearly one  thousand
clinical trials of paclitaxel have been conducted.
(5) The initial clinical trials were
first conducted using the drug as a sole agent against various cancers (ovarian,
breast), then  proceeding  to  synergistic administration  with  other  medicinal
agents.
(5) Many  trials  have already been  completed and achieved successful
results in vivo and Table 12 summarizes some of the many clinical trials that
have already been completed. Hundreds of trials are, however, still ongoing with
many still in their initial stages. The first public record of paclitaxel in clinical trials
became available in 1988 showing a 30% response rate in patients suffering from
ovarian cancer.
(130)
Recently, attempts have been made to modify the bioavailability of Taxol
in patients, which is problematic due its large particle size (0.6-17 µm). The ability
to solvate the drug for administration is difficult hence the rate of absorption in theCHAPTER 1
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intestine  is  very  low. The  drug  was  placed  under  supercritical  conditions  with
salicylic acid to reduce the particle size, thus facilitating the bioavailability of the
drug in patients. Utilising this method led to a substantial reduction in the particle
size of Taxol, from 0.6-17 µm to 0.3-1.7 µm.
(131)
Other experiments in relation to the level of unbound and bound Taxol
have also been recently reported, involving quantitative analysis of unbound and
bound Taxol found  in  the  plasma  of  patients  after  Abraxane  (ABI-007)  was
administered.  Results  showed  that  paclitaxel  had 88.8%  efficacy  in  cells  with
merely 5% of the drug unbound to the plasma protein in patients.
(132) Abraxane
uses  albumin,  a  human  protein,  to  deliver Taxol  into  cells  more  readily  than
cremophor, a solvent used to aid in the administration of Taxol into patients.
(133)
Taxol has recently been used to stabilize microtubules in rats to restore facial
nerves, allowing the movement of whiskers using only 10 µg/mL of Taxol.
(134)CHAPTER 1
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Table 12. A few completed clinical trials of paclitaxel as a sole agent and in combination with other natural products.
(20)
Topic, Location, Date Title Goals set
Paclitaxel  in  (AIDS-KS):  A phase II  trial
conducted by Baker Norton Pharmaceuticals
Massachusetts  General  Hospital, AIDS
Oncology Research, Boston, MA
Started: Nov. 2
nd, 1999
Ended: June 23
rd, 2005
NCT00002189
Phase II trial of paclitaxel to treatment of
patients  with  advanced  refractory
Kaposi's Sarcoma (AIDS-KS). (Related
studies)
(135)
To determine:
1. The response rate and tumour progression in
patients.
2.  Qualitative  and  quantitative  toxicity  levels  of
drug in patients.
Micellar paclitaxel for  the  treatment  of
severe psoriasis.
(136)
NCI Bethesda, MD
Started: September 2000
Ended: October 2002
NCT00006276
Phase II  trial  studying the  intravenous
administering  of  micellar  paclitaxel in
patients with severe psoriasis.
To determine:
1. The safety and effectiveness of using paclitaxel
to treat patients with psoriasis.
Flavopiridol  and paclitaxel administered  to
treat  patients with  locally  advanced  or
metastatic oesophageal cancer
Memorial  Sloan-Kettering  Cancer Center,
NY
Started: July 2000
NCT00006245
Phase  II trial studying  the efficacy of
Flavopiridol  and paclitaxel in  patients
with refractory oesophageal cancer.
To determine:
1.  The  response  rate  and  toxicity  levels  of both
drugs in patients.
2. The quality of life of patients after treatment.
3. The pharmacokinetics of drug in patients.
Further study of giving ABI-007 and Taxol to
patients with metastatic breast cancer
Abraxis BioScience, Inc., Durham, NC
Started: June 2001
Ended: July 2006
NCT00046527
Phase III trial to study the use of ABI-
007 (a cremophor free, protein
stabilized, nanoparticle paclitaxel)  and
Taxol to patients with metastatic breast
cancer.
To determine:
1. The  maximum  tolerated  dosage  to  be
administered.
2. Any reduced  infusion  time  or  risks  of
hypersensitivity.
3. The pharmacokinetics of the drug in patients.CHAPTER 1
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Administering paclitaxel  with  and  without
gemcitabine to women with advanced breast
cancer
Haematology/Oncology Group, Santa Rose,
CA
Started: July 2000
NCT00006459
Phase  III trial  study of administering
gemcitabine  with paclitaxel in
comparison  to paclitaxel alone,  to
patients  with  unresectable,  locally
recurrent or metastatic breast cancer.
To determine:
1. The overall survival rate of patients treated.
Carboplatin  and paclitaxel administered
with, and, without ISIS-3521 to treat patients
with NSCLC
ISIS Pharmaceuticals Inc., Carlsbad, CA
Started: October 2000
NCT00017407
Phase  III  trial to  study  the  therapeutic
combination  of  administering
carboplatin  and paclitaxel,  in
comparison  to  carboplatin, paclitaxel
and  ISIS-3521  to  treat  patients  with
advanced, previously untreated NSCLC.
To determine:
1. The overall survival rate and response rate of
drugs in patients.
2. The safety and duration of response in patients
treated.
A pilot study of paclitaxel and  radiation
therapy for the treatment of locally advanced
head and neck cancer
National Cancer Institute Bethesda, MD
Started: July 1995
Ended: June 2004
NCT00001442
 Phase  I trial  studying  the  use  of
paclitaxel with radiation therapy to treat
patients with locally advanced head and
neck cancer.
To determine:
1. The toxicity level of drug in patients.
Paclitaxel, UFT and leucovorin administered
to  patients for  the  treatment  of  advanced
gastric cancer
Department  of  Oncology,  National  Taiwan
University Hospital, Taipei, TWN
Started: March 2003
Ended: June 2005
NCT00154778
Phase II trial studying the effectiveness
and  safety  of  administering paclitaxel,
UFT and leucovorin  to  treat  patients
with advanced gastric cancer.
To determine:
1. The response rate and safety level of drugs in
patients.
2. The time of progression in patients.CHAPTER 1
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1.4.2 Mechanism of action
Paclitaxel interferes with the normal function of microtubules by binding to
the β subunit tubulin, hence locking the microtubule and increasing stability. This
prevents the mitosis of cells since the chain formation of microtubules is needed
for the transportation of the cellular components for cell replication.
(137) In doing
so, Taxol effectively depletes the cell’s present and triggers apoptosis. Due to
Taxol’s insolubility in water it is generally administered to patients in a formulation
of a vehicle cremophor el micelles (a non-ionic surfactant used to equilibrate the
emulsion of non-polar compounds into aqueous solutions).
(138) In 1996, Han et
al., conducted a study, indicating that Taxol binds to β-tubulin using the binding
site  as  shown  by  the  arrow (Fig.  40).  This  was  determined  by  developing  a
fluorescent derivative of Taxol 88 (2-AB Taxol), to aid in detecting the binding site
of the derivative to the β-tubulin. The results from this study showed that the C2
position as shown below is associated with the binding of taxol to β-tubulin.
(139)
Fig. 40. The benzoyl group as shown binds to the β-tubulin.
(139)
An  increase  in  the  dosage reaching  the  site  of  action is  achieved  by
modifying Taxol or by formulating a complex method to allow the drug to reach its
active site.
(140,141,142) Bovine serum albumin (BSA), a proteinaceous microsphere,
has been investigated for the potential transport of macromolecules within the
bloodstream to the delivery site. With this in mind, a study was conducted to
determine the  delivery, release  rate  and  anti-tumour activity of  a Taxol-BSACHAPTER 1
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complex, in comparison to administering Taxol alone, to mouse multiple myeloma
cells (MPC-11). The number of dead cells from each formulation was the same
but the greater the concentration of Taxol in the microspheres the more effective
the drug was against the myeloma cells. The reported success for the Taxol-BSA
complex was attributed to the presence of mesitylene (an organic solvent) used
in the preparation process.
(142)
Using  DNA  electrochemical  investigations,  the  mechanism  of  the  DNA-
drug  interaction for Taxol  was  studied. Results  from  the  electrochemical
investigation showed a decrease of guanine in DNA as the concentration of Taxol
increased, eventually reaching a level of saturation (2.3x10
7 M
-1). This decrease
can be related to the binding of Taxol to the groove on the DNA strand.
(143)
1.4.3 Production of Taxol
The isolation of Taxol from the bark of the Pacific yew tree resulted in a
great demand for the drug. This caused many problems as the only means of
isolation was by extracting the bark, where the highest concentration of the drug
is found. In 1969, 1.20 ton of bark was collected; producing 10 g of pure Taxol
and this  was  merely  the  beginning, with  thousands  of  trees being felled for
extraction purposes. Between 1977 and 1987 2.95 ton of bark was collected and
used for clinical trials about to begin.
(124) The yield from isolating Taxol from the
bark of the yew tree is approximately 0.01% dry weight of bark. The vast number
of trees that were sacrificed for in vitro and in vivo testing of paclitaxel caused
major  concerns  for  the  protection  and sustainability  of  the  yew  trees,
(124) and
protection orders  forced  the  development  of  other  methods  to  produce Taxol
efficiently, on an economical level.
Other  methods  of purifying  and  isolating Taxol were  subsequently
investigated, resulting in higher percent yields.
(144) In the 1990s the synthesis ofCHAPTER 1
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the  drug was achieved, but the large  number  of  steps  made  it  very  time
consuming and the percentage yields were still low. A major breakthrough was
achieved with a four step synthesis producing Taxol in an 80% yield.
(127) Since
then,  other  methods have  been  employed  to  produce Taxol.  Currently  Bristol
Myers Squibb uses plant cell fermentation to grow the drug by cell culturing,
(145)
and in 2000 it was reported that the annual sales of Taxol was approximately 1.6
billion dollars.
Modification  methods  have  been  applied  to  the  fermentation  of  cell
culturing  to  produce Taxol.
(146,147,148) A  recent  study  showed that salicylic  acid
induced the production of Taxol in cultured cells of Taxus chinensis (Chinese yew
tree).  Results  showed  that high concentrations  of  salicylic  acid  induced  the
production  of Taxol and  resulted  in  it killing  the  cell  cultures.  However,
quantitative studies showed that 20 g/mL of salicylic acid was enough to promote
the production of Taxol to 1.626 mg/g dry weight, causing little or no damage to
the cell cultures.
(149)
It is now known that the production of Taxol is due to a fungus living in the
yew tree.
(150) Taxol has also been isolated from fungus collected from Cupressus
spp.,  Citrus  medica  and Taxus  celebica  (Chinese  yew  tree).
(151,152,153)
Understanding the origin of Taxol may help devise a novel production method
using an artificial  method  and  techniques  that  have  been  devised  for  the
production of the bryostatins and Et-743.
1.5 Work conducted
In order to understand the importance of finding an efficient method for the
production of such complex natural drugs, it is imperative to first review studies
that have already been conducted in order to identify the many problems that are
currently affecting the isolation of MNPs. The numerous synthetic steps requiredCHAPTER 1
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for the preparation of drugs such as bryostatin 1 and Et-743, resulting in low
percentage yield of products, and the environmental consequences of harvesting
marine  organisms  for  the  isolation  of MNPs  are  two  examples  of  the  many
problems affecting the availability of such drugs.
Subsequent chapters describe innovative and practical methods that have
been  developed  in  order  to  overcome  the  problems  facing  the  availability  of
MNPs. This work is focused on two marine organisms, Bugula neritina, a marine
bryozoan  which  produces  the  bryostatins,  and Ecteinascidia  turbinata,  a  sea
squirt, which produces the ecteinascidin compounds, but some preliminary work
has been started on the production of Taxol. Taxol as mentioned, is a terrestrial
NP, however recent studies have shown that the production of Taxol is due to a
fungus found at the root of the yew trees. For this reason, attempts have been
started to apply the procedures used for the production of the bryostatins and Et-
743 to that of Taxol, by modifying the properties to attract the fungi responsible
for the production of the drug. This is important as it would provide an alternative
method  of  producing  the  drug, and  illustrate  the  efficacy  of  our  method  as  a
universal tool for the application of other NPs, both terrestrial and marine. The
work  related  to  the  production  of Taxol is mostly  discussed  in  the  suggested
future works section of this thesis.
Detailed  analysis  of  the  environment  (sediment),  where  these  NPs  are
found,  was  necessary  in  order  to  identify  and  understand  the  conditions  that
promote the survival of these marine organisms and their ability to produce the
compounds isolated from them. Results from this study instigated the application
of a new technique of applying a chemical composition to an artificial surface to
encourage the production of these NPs. It is suggested that this method could
easily be applied to the production of other NPs, both terrestrial and marine, by
simply modifying its constituents. Based on this proposition, several experimentsCHAPTER 1
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are currently being conducted, using this method, for the production of Taxol.
Preliminary results are showing some success, suggesting the viability of these
treated  artificial  surfaces  as  a  means  of  cultivating  and  isolating  Taxol  as  an
alternative to synthetic methods alone. Taxol is currently produced in a four step
synthesis process and is manufactured fairly efficiently by this method. Results
regarding  the  production  of  any  bryostatin  compounds  and  ecteinascidin
compounds are mentioned in their respective chapters.
As  an  adjunct  to  this,  experiments  involving  the trans-esterification  of
bryostatin 1 were carried out to determine the effects of the drug under various
conditions  (37°C,  ambient  condition,  and UV light),  giving  insight  into  its
behaviour  in  the  environment and  in  the  body,  respectively. Results  from  this
showed that the compound does degrade to form m/z < 927 and compounds with
m/z > 927. Two computational experiments were also conducted, involving the
binding of the bryostatins and other MNPs to Fe
3+, resulting in the formation of a
siderophore complex. From the results collected in this study, the data suggests
that  many  of  the  compounds  can  form  siderophore  complexes  and  act  as
possible medicinal agents, as many appeared to have high dipole moment to
surface volume (D/V) ratios similar to polar solvents; suggesting their ability to act
as polar or non-polar agents when bound to Fe
3+.
With the computational study suggesting the ability of bryostatin 1-Fe
3+ to
act as a possible medicinal agent, cell line tests were conducted to determine its
efficacy in comparison to bryostatin 1 alone. This new bryostatin-Fe
3+ (fer-mer)
compound was investigated against chronic myeloid leukaemia and human lung
carcinoma cells in order to determine its effectiveness in comparison to bryostatin
1  alone.  Data  from  both  computational  experiments  was  used  to  support  the
initial  theoretical  hypotheses  that  the  fer-mer  compound  may  act  as  a  better
medicinal agent than bryostatin 1 alone.CHAPTER 1
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The subsequent chapters will focus on understanding the chemical and
ecological  environment  within,  and  surrounding, Bugula  neritina  and
Ecteinascidia turbinata, giving  insight  into  the  impact  of  the  structure  of  the
bryostatins  and  Et-743.
(154,155,156,157)  The  development  of  a  novel  and  efficient
technique to collect the NPs from their host organism and surrounding sediment
has been explored and an innovative method is proposed for the efficient and
economical production of bryostatin, Et-743 and Taxol which could subsequently
be adapted to other plant based or MNPs.CHAPTER 1
68
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for the production of the bryostatinsCHAPTER 2
81
2.1 Introduction
Within recent decades, the ocean has become an increased target for the
identification and isolation of new compounds with possible medicinal activity.
(1,2)
The isolation of numerous NPs has shown much success in clinical trials against
various  cancers,  such  as  prostate,  kidney,  ovarian,  leukemia, etc..
(3) Further
studies  of  these NPs  and  others have  been  limited  due  to: 1) environmental
concerns of collecting marine organisms; 2) their seasonal availability; 3) the time
consuming process; and/or, 4) labor intensive isolation techniques currently used.
Alternative methods, such as synthetic techniques, have been determined and
aquaculture farming of marine organisms has been conducted, in the hope of
developing a feasible method to produce economically these natural products.
Despite continuous efforts, no practical method has so far materialized for the
feasible production of any bryostatin compounds.
Agar  is  a  type  of  gel  designed  to  support  the  growth  of  bacteria  in  a
controlled  environment.
(4) Many  different  agars  are  used  for  the  production  of
bacteria, each depending on the bacteria of interest.
(5) For example, mannitol salt
agar is a growth medium which contains high concentrations of sodium chloride,
used specifically for the growth of Staphylococci spp.. By using this agar, the
growth of other bacteria are inhibited due to the high concentrations of sodium
chloride present.
(6) Another example is the production of a potato carrot agar, a
semi-selective medium, for the isolation of Alternaria spp., Epicoccum spp., and
Phoma spp. from soil and plant samples. The medium consisted of 10 g/L of
potato  and  carrot as  a  base  and  manganese(II)  chloride,  which  was  used  to
isolate selectively the bacteria of interest by inhibiting the growth of other species
of bacteria in the soil and plant samples.
(7)
Nutrient agars containing peptone, amino acids and carbon sources, are
also used for the production of microorganisms. Despite this remarkable tool toCHAPTER 2
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aid in the growth of bacteria, many bacteria are still unable or impossible to grow
under  controlled  conditions. With  recent  developments  by  other  groups,  new
speculations regarding the true source of marine organisms have suggested the
correlation of marine bacteria to marine organism containing MNP’s.
(8,9,10,11) For
this reason, the concept of an agar medium, was applied to the production of
marine bacteria, using a chemical compilation developed.
In order to develop the chemical composition that was subsequently used,
initial analysis of the environment of these marine organisms was conducted in
order to understand the conditions in which these marine organisms live and the
properties of the environment that can aid in the production of such compounds.
In this regard, initial studies for developing a novel method for the economical
production  of the bryostatins  was instigated by  first  understanding  the
environment  of its  host organism. This involved a  thorough  investigation and
chemical  analysis of  the  marine  environment  where Bugula  is  found.
(12,13,14,15)
Based on results from these studies, a composition of chemicals was used to
develop an artificial growth medium, in an attempt to mimic the composition of the
host marine organism. This artificial growth medium would serve as an artificial
surface  to  cultivate  and  isolate  the  marine  bacterium  responsible  for  the
production of the bryostatins. Previous studies have shown traces of bryostatin 1
in several marine organisms other than Bugula, further supporting the postulate
that a marine bacterium is responsible for the production of the bryostatins.
(12-15)
Bugula neritina has also reportedly been found in areas along the coast of
England  and  for  this  reason a  small  scale  experiment  was  conducted off  the
coast of Sunderland, UK, using the same artificial medium. The artificial growth
medium (as tablets) was placed in three designated locations for an allocated
time to  initiate  the broth assessment. The  purpose  of  this  experiment  was  to
determine  if any bacterial  growth  along  the  coast  of  England  would showCHAPTER 2
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prominence for the production of any bryostatin compounds. Successful results
showing the production of different bryostatin compounds from either US or UK
locations would revolutionize  the  availability  and  reproducibility  of  natural
products for pharmaceutical industries and companies demanding such products.
2.2 Experimental Section
In  each  experiment,  the  chemical composition was applied either as  a
paste or  packed  into  a  tablet  form.  Sample  extracts  collected  from each
experiment were compared to bryostatin 1 standard. Samples were analyzed in
positive mode by a LC-MS system, with a gradient solvent system consisting of
0.1% formic acid and methanol, in a 95:5 ratio, respectively, with a run time of 30
min and a flow rate of 1 mL/min. A C18 Luna column (Sigma Aldrich, 250 mm by
4.6 mm,  5 µm)  was  used  to  analyze  all  samples. Some  samples  were  also
analyzed using the MALDI-TOF-MS (Matrix assisted laser desorption ionization,
time of flight mass spectrometry) at the University of Georgia Mass Spectrometry
Facility  (Athens,  Georgia,  USA). A  matrix  consisting  of  50:50  water  and
acetonitrile with 0.1% TFA (trifluoroacetic acid) was used to run the samples in
this  study. All  samples  analyzed via  LC-MS were conducted  at chemiSpec,
University  of  Sunderland (Sunderland, UK) and  at  the  USDA  (United  States
Department of Agriculture, Tifton, Georgia, USA), respectively. High resolution
mass  spectrometry  (HRMS)  data were  collected  by  the  University  of Warwick
(Warwick,  UK).  The  samples  analyzed  by  HRMS were  conducted using  a
nanoLC-ESI-MS with  the  NanoAcquity/Q-ToF  instrumentation  (Waters). The
reference  compound  used  was  the  [Glu
1]-Fibrinopeptide B  (human
F3261, Sigma),  infused  at  0.5  µL/min  sampled  for  1  s  each  minute  of  data
collection.CHAPTER 2
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2.2.1 Mineral paste, Gulf of México (February 2006)
The chemicals (Table 1) were combined and applied as a paste to both
sides  of  two  artificial  surfaces  (grids).  Each  surface  contained a  strip  of zinc
sandwiched between two strips of copper (Fig. 1). The grids were placed in the
water on February 11
th 2006, at 10:00 a.m., and removed after 6 hr in the water.
The grids were air dried, then stored at 4
°C before being placed at Alligator Point,
Florida (25° 36' 0" N, 81° 14' 28" W). Each grid was positioned inside a PVC
tube, with holes drilled in each side to allow water to flow freely. Each end of the
tube was covered with a screen to prevent anything from entering: each set of
traps (a total of 2) were tightly secured to a weighted support as shown in Fig 2.
After immersion for 6 hr, the grids from each trap were removed and placed into
two large pails containing salt water.
One pail was placed at RT (room temperature, 23°C) and the other was
stored at 4°C. On May 8
th 2006, at 9:00 a.m., 12 wk after the grids were placed at
4°C, a white film was removed from the surface of the water and extracted into 30
mL of ethanol (Fisher Scientific) then stored at 4°C. After 24 hr, the ethanol was
placed under vacuum to dryness. A second extraction of the white film into 30 mL
of methanol (Fisher Scientific) was carried out, then placed at 4
°C. After 48 hr the
methanol was placed under vacuum to dryness.
Fig 1. The reassembled grid after placing strips of copper on each side.CHAPTER 2
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Fig 2. The trap design of the grids inside the PVC pipes before being placed in
the water.
Table 1. The chemical composition used to produce the tablets.
Chemicals Amount used (g) Company Product code
Calcium carbonate 100.004 Fisher Scientific S71922
Iron (III) chloride 3.000 Fisher Scientific FL-01-0784
Iron (np)
a 0.05 Nanophase 0800
CuO (np) 0.01 Nanophase EXP0502
CuCl2 0.123 Sigma-Aldrich 221783-500G
Instant ocean 1.000 Marine Labs SS3-50
Marine buffer 0.500 SeaChem UPC#
000116034708
Sodium acetate 0.400 Fisher Scientific S210-500
Squalene 0.500 (10 drops) Sigma-Aldrich S3626-100 mL
Peptone 1.000 Fisher Scientific BP1420-100
Glycerine 1.003 Fisher Scientific G33-500
Stearic acid 0.400 Aldrich 175366-1Kg
Octanoic acid 0.215 (10 drops) Acros Organics 167261000
Docosanoic acid 0.799 Aldrich 216941-5G
Amino acid tablets 1.411 (1 tablet) GNC 750612
Sugar 1.000 Pure Cane
Dixie Crystals
S133E06A-PA
Chitin
b 4.09 Gulf of México N/A
Sand 3.017 N/A I116-500
Distilled water 35 mL N/A N/A
a np – nano particle
b chitin - shrimp shells
A second experiment was later conducted using the method mentioned
above. However, a chemical (cement) was applied to adhere the paste to each
side of the grids. A total of 5 grids were prepared and placed at Alligator Point,
FL. The grids were placed under the exact conditions (location, time period in
water, and conditions  in the laboratory etc.)  as previously. Results  from the
experiments were analyzed as mentioned in section 2.2.CHAPTER 2
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2.2.2 Mineral paste, Gulf of México (May 2007)
On March 12
th 2007, at 10:00 a.m., another experiment was conducted
using the combined chemicals listed in Table 2; a modified composition of those
given  in  Table  1. Dry combinations  of  chemicals  (20  g)  were packed  into  15
plastic vials with a hole in the top of each vial to allow the passage of water. All
15 vials were placed in a bacterial chamber filled with calcium carbonate pellets
and iron chloride (Fig. 3), then submerged at Alligator Point, Florida. On March
31
st 2007, at 12:00 p.m., the container was removed from the water at Alligator
Point, Fl. The water from each vial was replaced with 30 mL of methanol-DTPA
(diethylene triaminepentaacetic acid) solution before vials were stored at RT.
Table 2. The chemical composition used to produce the tablets.
Chemical Amt used Company Product code
CaCO3 500 g Fisher Scientific S71922
FeCl36H2O 10 g Fisher Scientific FL-01-0784
Marine Buffer 2 g Sea Chem UPC# 000116034708
Instant Ocean 2 g Marine Labs SS3-50
Sodium acetate 2 g Fisher scientific S210-500
Sodium nitrate 2g Fisher scientific
Sodium sulfate 1 g Fisher scientific AC21875-0250
Peptone 2 g Fisher scientific BP1420-100
Amino Acid 10 tablets Fisher Scientific S71922
Fish Oil 10 tablets GNC 750612
Multi-Vitamin 10 capsules Equate N/A
Vitamin A & D 10 capsules Spring Valley N/A
Vitamin C 10 tablets Spring Valley N/A
Sugar 20 g Pure Cane Dixie
Crystals
S133E06A-PA
Glycerin 2 mL Fisher scientific G33-500
Stearic acid 1 g Sigma Aldrich 175366-1Kg
Squalene 2 mL Fisher scientific AC20747-1000
Octanoic acid 2 mL Fisher scientific 167261000CHAPTER 2
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Fig. 3. A 2-dimensional image of the chamber (section 2.2.2).
2.2.3 Mineral paste, Gulf of México (June 2008)
On June 15
th 2008, at 12:00 p.m., the combined chemicals listed in Table
2 were compressed into tablets (average weight of 10 g), and then placed into 50
mL plastic vials with two holes in each vial for water to flow through. A total of 10
vials, each containing 4 tablets, were placed at Alligator Point, Florida, for 1 wk
and removed on June 22
nd 2008, at 12:00 p.m.. Vials were then transferred into
containers  with  water  from  Alligator  Point and  placed  at  4°C  for  48 hr,  then
moved to RT for 4 ½ wk of the broth assessment. The broth was checked twice a
week; which entailed the removal of a white film from the surface of the water that
was extracted into 80 mL of anhydrous methanol (Fisher Scientific), followed by
the addition of 10 g of mineral paste compilation (Table 2) to the container. The
methanol extract was filtered using 5 µm filter paper and placed into a vacuum to
dryness.  Total  dry  weight  of  crystals  collected (1.85  g) was  later  analyzed
(section 2.2).
2.2.4 Mineral paste, UK coast (November 2006)
On November 3
rd 2006, at 5:00 p.m., three locations off the North East
coast (Sunderland Marina (54º 55'N, 01º 22' W), Hartlepool Marina (54º 41' N,
7-10ft
under
water
Bacterial
chamber
Mineral vial
Channel
marker Rope 4ft
Rope 5ft
Water passage in/out
of chamberCHAPTER 2
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01º  11' W)  and  Hartlepool  Fish  Quay  (54° 41′ 26.56″ N,  1° 12′ 39.79″ W)  were
selected for this study. Tablets were prepared (section 2.2.1). A total of 6 vials,
each containing 2 tablets, were placed at each location for 1 wk. Samples were
collected on November 11
th 2006, at 10:00 a.m., then collected in pails of sea
water  and stored  at  RT (18
ºC)  for  4 wk  to  determine  cultivation  of  bacterial
growth. The film produced after 4 wk was collected from the surface of the water
and was extracted into anhydrous methanol. The sample was analyzed by LC-
MS at chemiSpec.
2.3 Results
All the results collected were compared to the LC-MS and MALDI-MS of
a bryostatin  1 reference standard  (Figs.  4  and  5)  respectively. Due  to  low
detection  limitations  for  each  peak  from  the  samples  in  this  study,  no  further
evidence could be obtained to conclusively support or disprove the correlation of
the peaks identified with their possible bryostatin representations.
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Fig. 4. LC-MS of bryostatin 1 standard (C47H68NaO17, m/z 927, retention time
18.46 min).CHAPTER 2
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Fig 5. MALDI-MS of bryostatin 1 standard (10 µg) in 5 mL anhydrous methanol.
Bryostatin 1 (M+Na)
+
(C47H68O17Na, 927.4349 g/mol)
Bryostatin 11 + (Na-2H)
+
(C39H56O15Na, 787.3511 g/mol)
(M+H)
+Bryostatin 2
(C45H67O16, 863.4423g/mol)
(M+H)
+Bryophan ring
(C37H53O13, 705.3480 g/mol)CHAPTER 2
90
The  above  illustration  shows  how  bryostatin  1  fragments  in  the  mass
spectrometer  to  give  the  peaks  as  shown. There  are  twenty  bryostatin
compounds  that  have  been  isolated  from Bugula  neritina,  each  bryostatin
compound differs by the R1 and R2 group positions as shown above. Bryostatin
1+ Na
+ adduct 9b (C47H68O17Na, 927.4349 g/mol) loses C2H3O
. ion with a m/z of
863.826 (M+H)
+. This peak can therefore be correlated to bryostatin 2 (M+H)
+ 89,
which has a formula of (C45H67O16, 863.4423 g/mol). Due to the intensity of this
peak, it is suggested that only a fraction of the bryostatin 1 molecule loses acetyl
to show the formation of the peak as shown.
In much of the MALDI-MS data that has been conducted for bryostatin 1,
consistent fragment is always shown: the peak with a m/z of 789 (M+Na)
+ 90
sometimes seen as 787 (M-2H+Na)
+ peak. As shown above, the species of mass
789 can be formed by the loss of the carboxylate group (R2 group), which can be
correlated to the bryostatin 11+Na
+ adduct (C39H58O15Na, 789.3668 g/mol).
The basic structure for all of the bryostatin compounds is the bryophan
ring (M+H)
+ 91 (C37H53O13, 705.3481 g/mol). The loss of the R1 and R2 groups
gives  the  basic  structure  of  the  bryophan  ring  (i.e.  the  acetate  group  at  R1
position and the C8 chain at the R2 position). The formation of this ring gives a
stable  product,  as  many  of  the  ester  groups are susceptible  to  hydrolysis  or
degradation. As shown above, bryostatin 1 fragments to give a m/z of 705.715,
which could correlate  to  the  bryophan  ring  (M+H)
+.  Of  all  the  bryostatin
compounds  that  have  been  isolated  from Bugula,  bryostatin  1  has  the  most
potency as a medicinal agent. The fragments of bryostatin 1 shown in Fig. 5 are
used as a reference to support further the postulated species, identified by their
m/z, found for the samples in this study, and to allow correlation to the bryostatin
compounds they might represent.CHAPTER 2
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2.3.1 Mineral paste, Gulf of México (February 2006)
The purpose of this study was to develop an artificial medium that would
attract  marine  bacteria presumed  to  be responsible  for  the  production  of  any
bryostatin  compounds  in  the Bugula  ecosystem. Observations  from  the  pail
containing grids at 4
°C noted the formation of a white film on the surface of the
water. The pail placed at RT (23
°C) showed no sign of a white film and was
therefore deemed unsuccessful. Having compared the results from pails stored at
RT with those at 4
°C, it is suggested that marine bacteria are responsible for the
production of the white film collected from the pail at 4
°C and that they are likely
to grow and live longer in a colder environment as opposed to 23
°C. In general,
bacteria  tend  to  initially  grow  and  reproduce  rapidly,  but  eventually  die  in  the
environment. This is due to many factors, such as 1) lack of a food source or
nutrients; 2) too many toxins produced by the bacteria; 3) temperature (some
bacteria prefer colder temperatures while others prefer warmer conditions); and,
4) oxygen concentrations, to name only a few.
(16) The thick, white film collected
off the surface from the water after 12 wk was extracted in ethanol and dried in a
vacuum  for  analysis.  The  crystals  collected  are  shown  in Fig.  6  and  mass
spectral data of the ethanol extract from the white film (Fig. 7). None of the peaks
shown in Fig. 7 can be correlated to any bryostatin compound.
Fig. 6. Crystal collected from the extraction of white film produced from the broth
at 4
°C.CHAPTER 2
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Fig. 7. Mass spectral data of crystal collected from the small scale growth.
2.3.2 Mineral paste, Gulf of México (May 2007)
In this study, the chemicals from Table 1 were modified as shown in Table
2 in order to improve the cultivation and continuous growth of marine bacteria
isolated from the ocean. Food sources (amino acids, multi vitamins, and fish oil,
etc.) were added as growth factors to attract and maintain the marine bacteria on
the surfaces while placed in the water. After the 3 wk period, the mineral paste,
calcium  carbonate  pellets  and  water in  the  bucket appeared  black  in  color,
emitting a pungent odor. The solvent extracted from each vial appeared golden
yellow in color and after 48 hr all the vial contents were combined and analyzed
by LC-MS (Fig. 8). The m/z of 927 shown below shows the presence of bryostatin
1, despite the shift in retention time from 18.45 min to 17.52 min, which can be
due  to  a  change  in  temperature  or  other  properties  when  the  sample  was
analyzed.CHAPTER 2
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Fig 8. LC-MS of mineral paste extracted into methanol.
Fig. 9. Structure of DTPA (C14H23N3O10, 393.1378 g/mol)
DTPA 92 (Fig. 9.) is a chelating agent used as a soil extractant to remove
metals,  such  as Fe
3+,  Na
+,  Ca
2+, and Zn
2+, etc.,  from the sediment.
(17) In  the
extraction process, DTPA was used as a means of extracting the compounds
O O
O O
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O
O
O
OH
HO
O
HO
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H
H H
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Na+
Bryostatin 1 + Na
+ (C47H68O17Na,
927.4348 g/mol)CHAPTER 2
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easier. Bryostatin 1 was used as a control in the mass spectrometry studies and
is  almost  exclusively  observed  as  a  Na
+  adduct  Typically  the  bryostatins  are
observed  as  Na
+  adducts,  unless  an  aminocarboxylate  such  as  EDTA
(ethylenediaminetetraacetic acid)  or DTPA is utilized in the extraction.
2.3.3 Mineral paste, Gulf of México (June 2008)
After 1 wk in the water, most of the tablets appeared black in color and
after 2 days at RT, the tablets were completely black. A gelatinous film seen on
the surface of the water after 5 day at RT was removed and extracted into 80 mL
of anhydrous methanol during the 4 ½ wk broth assessment. The dry weight of
crystals (1.72 g) was analyzed by HRMS as shown in Fig. 10 and 11.
Fig 10. The extract ion chromatogram for peaks identified from the white film.CHAPTER 2
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Fig. 11. High resolution mass spectra of the extract ions shown in Fig. 10.
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Based on the data collected from the white film, Fig. 11 shows three peaks
that may be correlated to three different bryostatin compounds. These peak are:
a) m/z at 902.9849 (M+Na)
+, which may be Bryostatin 8 + Na
+ 93 (C45H68O17Na,
903.4348  g/mol), b) m/z  at  895.4370  (M+H)
+,  which  may  be  bryostatin  4 94
(C46H71O17, 895.4685 g/mol), and c) m/z at 935.4685 (M+2H)
+, which may be
bryostatin 12 95 (C49H75O17, 935.4998  g/mol). Based  on  the  HRMS  data
collected, the peaks (Fig. 11) each showed an error of approximately 30 ppm
when compared to the possible bryostatin compounds that each could represent.
For example, the calculated mass accuracy of bryostatin 4 is (895.4685, M+H)
+
and bryostatin 12 is (935.4998, M+2H)
+. The acceptable marginal difference is 10
ppm.  In  the  mass  spectrometer,  different  radicals  can form to  give  different
masses (M+H)
+ (M+2H)
+, (M-H)
+ and (M-2H)
+.
(18) These radicals occur naturally
in the mass spectrometer and can therefore be accounted for in relation to the
peaks shown above. Aside from the bryostatin compound that the peak at m/z of
903 might represent, it was observed that the m/z at 903 shown in Fig. 11 splits
by a m/z of 0.5, which suggests the possibility that the compound with a m/z of
903 may be a dimer bound together by a Na
+ adduct.
2.3.4 Mineral paste, UK coast (November 2006)
After 1 wk in seawater, only tablets from the vials placed at Hartlepool
Marina were black in colour, suggesting the presence of bacterial growth. After 2
wk at RT, the formation of a thin gelatinous surface film was noticeable in the
containers with samples from Hartlepool Marina and Hartlepool Fish Quay. By
the 4
th wk, a white gelatinous film completely covered the surface of the sample
pails  from  Hartlepool  Marina  and  the  Fish  Quay,  each  was  removed  and
extracted into 20 mL anhydrous methanol (Fisher Scientific). Further purifications
were conducted by TLC (thin layer chromatography, 5.08cmX1.27cm, silica gelCHAPTER 2
97
60) plates, using a 30/70 mixture of petroleum ether and ethyl acetate as the
mobile phase. This separation technique showed two distinct bands, under uv
light, which were removed from the silica plate and placed in methanol. All the
results  from  this  experiment  were  unsuccessful in detecting any  bryostatin
compounds from the samples collected at each location.
2.4 Discussion
Many marine organisms are believed to produce these biologically active
compounds 1) as a chemical defense mechanism (prey, predator or compete for
territory due to the overgrowth of species), 2) as a secondary method for survival,
or 3) as  secondary  metabolites.
(19,20,21,22) Secondary  metabolites  are organic
compounds produced by marine organisms that have no effect on the growth,
development and reproduction of marine organisms. However, many secondary
metabolites are believed to be created by modified primary metabolite enzymes
or  by  using  substrates  of  primary  metabolite  origin.  Primary  metabolites  in
contrast to secondary metabolites, are important for the growth, development and
reproduction of organisms.
(23) For example, okadic acid 1, a NP originally isolated
from sponges, Halichondria okadai and Halichondria melanodocia, is responsible
for  most diarrheic  shellfish  poisoning  related  illnesses  in  humans. The
significance  of  okadic  acid  is  unclear in the  sponges  from  which  it  has  been
isolated; however, it has been shown to help the marine sponge, Lubomirskia
baicalensis, tolerate extremely cold conditions.
(19)
Many of  the  marine  organisms  that  have  shown activity  as  medicinal
agents are filter feeders (e.g. Ecteinascidia turbinata and Bugula neritina) and
therefore contain high levels of marine viruses and bacteria, (suspected to be the
primary source in the production of marine natural products). Attempts have been
made to determine which particular bacterium is responsible for the production ofCHAPTER 2
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the bryostatins  and  the  ecteinascidin  compounds; however  no  conclusive
evidence has yet been established.
(8-11) Nonetheless, some groups have shown
that  the  production  of  these  drugs  can  be  correlated  to  the  presence  of
photosymbiont in the marine organisms, which can be cultured to produce the
drugs more efficiently.
(24,25)
.
Fig. 12. A 2-dimensional image showing the ubiquity of bacteria within the marine
ecosystem.
Previous  work  by  this  group  has  shown  that  natural  products  (e.g.
bryostatins)  are  ubiquitous  in  the  ecosystem  in  which  the  marine  organism  is
found.
(12-14)  From  this  study  and  others  (e.g.  environmental  study),  it  can  be
concluded that these marine organisms filter in the bacteria that are responsible
for  the  production  of  these  natural  products  (Fig.  12).  The  specificity  and
uniqueness of any particular marine organism is believed to be dependent upon
the environmental preferences of a particular bacterium, as it selects a suitable
host to live in and produce such compounds.
The chemicals  used  in the assessment  of  this study were based  on
detailed analysis of the marine organism, Bugula neritina, and the ecosystem in
which it is found.
(12-14) The importance of the chemicals can be placed into four
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categories. Firstly, the surface of Bugula has shown to contain high levels of
calcium  carbonate  and  extraction  of  the  marine  organism has  shown  high
concentration  of nano  particles  (Fe, CuO);  indicating  that  the  bacteria  found
within the organism thrives on these components. The ecosystem of the marine
organism has a high deposit of limestone (approximately 40%) as well, which
accounts  for  the  main  component  of  our  chemical composition to  be  calcium
carbonate. These  chemicals  were  therefore  used  as  a  means  to  attract  the
bacteria,  due  to the  perceived high  affinity  for  the compounds.  The
concentrations shown in Tables 1 and 2 were based on previous study showing
the concentration values of iron, copper an calcium in the marine ecosystem.
(14)
Concentration levels of iron and copper found in Bugula are higher than any other
living creature can tolerate.
Secondly, to cultivate and isolate the bacteria, it is necessary to replicate
the contents of the ocean in efforts to mimic the environment of the bacteria. For
this reason marine buffer and Instant Ocean were used. Marine buffer consists of
a combination of different salts of magnesium, sodium, and potassium, etc., in
the form of carbonates, chlorides, sulfates, and borates, etc., which are important
to maintain the pH (8.3) of the environment.
(26) Instant Ocean contains synthetic
sea salts which contain traces of the elements needed for natural sea water, as
found in the marine environment, necessary for animal growth.
(27) Many of these
salts  are  important  for  bacteria,  for  example,  potassium  salts  function  as  a
cofactor  for  certain  enzymes  and  magnesium  salts  function  as  a  cofactor  for
certain enzymatic reactions etc..
(28) The addition of sodium acetate, sulfate and
nitrate was rationalized as additional salts that are important for bacterial growth.
The  total  percentage  of  salts  used  only  accounts  for  approximately  0.8%  dry
weight of the chemical composition.CHAPTER 2
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Thirdly, the vitamins, amino acids, fish oil, peptone, sugar, and glycerin
were  all used as  a form  of food  source and  nutrients  to  promote  growth  and
development  of  the  bacteria. Peptone  is  used  in  agars  (nutrient  agars)  to
stimulate  the  growth  of  bacteria.  Sugar  and  glycerin  are used  as  forms  of
carbohydrate  as  an  energy  source  for  bacteria. Vitamins  are  important  as
bacteria need the organic molecules (containing C, H, O, N, S, and P, etc.) and
vitamins in order for enzymes to function.
(28, 29) For example, vitamin B12 was a
coenzyme,  methyl  form cobalamine, and  vitamin  K  is  a  coenzyme  form.
(28,29)
Amino acids are the building blocks of proteins, important for metabolism and
nutrition. Proteins are important for cell signaling and the cell cycle. These are
important as the plasma membrane of bacteria consists of a protein lipid bi-layer,
and the cell wall is made of peptidoglycan, which is a polysaccharide chain with
cross-links peptide with D-amino acids.
(28,29)The concentration values of vitamins,
and amino acids, etc., used were based on the necessity of those chemicals for
bacterial growth. For example, a total of 6 grams of peptone is generally used as
a source of amino acids, nitrogen, sulfur and phosphorus.
(28,29) In this study, 2
grams of peptone were used and the 4 grams in correspondence included the
amino acid tablets that were used to give a total of 6 gram; which accounts for a
total of 1.2% dry weight of the chemical composition.
Fourthly,  chemicals  such  as  squalene,  stearic  acid,  octanoic  acid,  and
docosanoic acid are all carboxylic acids used due to their earlier observation in a
sediment  study  that  was  conducted  of  the  marine  environment.
(13,14) The
importance of these carboxylic acids and hydrocarbons to marine bacteria is still
being determined; however, properties of squalene and stearic acid, important to
bacteria, have been determined. Squalene is a natural organic compound, found
in shark liver oil, which is used as a biosynthetic precursor for steroid and bile
acid synthesis in bacteria and sea squirts among other functions.
(30) Stearic acidCHAPTER 2
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is  a  saturated  fatty  acid  found  naturally  in  animal,  fat  and  vegetable  oil.  It  is
important for cell culturing for the bio-manufacture of protein, important for the
cell structure of the cell wall in bacteria.
(31) The concentrations of the acids used
are in proximity to values found in a previous study.
(14) The total percentage of
squalene and stearic acid used accounts for approximately 0.6% dry weight of
the  chemical  compilation. Together,  the  chemical  compilation  served  as an
appropriate medium to cultivate the bacteria, as these chemicals are naturally
found in the ecosystem of Bugula.
(14)
Data collected from Alligator Point strongly suggest success in capturing
marine bacteria from  the  ecosystem  of  the  marine  organism.  With promising
preliminary results from using this method in the Gulf of México, the technique
was also implemented off the coast of Sunderland. Bugula neritina has previously
been found off the coast of England, and for this reason three trial locations with
high  levels  of  heavy  metals were  chosen. Two  of these  sites  showed
encouraging, but inconclusive, results.
(32)
Bugula neritina is a seasonal marine organism, found between the months
of  October  to  April,  and  is  temperature  dependent  (18-22°C);  however,  the
marine organism has been found during the summer time in the Gulf of México. It
is important to note that the data collected from the three experiments conducted
at  Alligator  Point,  Florida  varied,  which  may be  due  to  the  change  in  water
temperature  when  each experiment  was  conducted.  For  example,  the
temperature of the water in February (section 2.3.1) was 17°C and the peaks
shown in Fig. 7 suggest no correlation to any bryostatin compounds. However,
the average water temperature for samples placed in March (section 2.3.2) was
23°C and results collected from this sample show a m/z of 927 (Fig. 8), which
suggest  the  isolation  of  bryostatin  1. The  average  water  temperature  for  the
samples placed in June (section 2.3.3) was 25°C with results from the artificialCHAPTER 2
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medium showing two peaks at m/z of 903 and 895 (Fig. 11) which could correlate
to bryostatin 8+Na
+ and bryostatin 4 respectively, as mentioned earlier. It should
also be noted that Bugula was also found attached to the containers which were
placed in the water in section 2.2.3.
Since the artificial mediums from the studies conducted (section 2.2.1 -
2.2.3) were all placed at the same location, it is suggested that there are two
factors  that  account  for the  variation  in  the data  collected,  which  are:  1) the
temperature of the water when the samples were placed, and 2) how long the
artificial medium was placed in the water. For this reason, it is suggested that
such  factors  may  also  explain  the  presence  of  the  twenty  different  bryostatin
compounds that have been isolated from the marine organism. Other factors for
the identification of these 20 compounds are believed to be dependent on the
geographical location of the marine organism, season and depth of collection.
(33)
For example, bryostatin 4 is extracted from Bugula found in the Gulf of México,
Gulf of California and Gulf of Sagami.
(33) Bryostatin 12 and 13 are extracted from
Bugula  collected off  the  Eastern  Pacific Ocean.
(34)  Bryostatin  14  and 15  were
extracted from Bugula found in the Gulf of México and Eastern Pacific Ocean
(California).
(35) Bryostatins 16-18 are extracted from Bugula found in the Gulf of
México.
(36)
This study clearly shows that the origin of production of these compounds
is related to bacteria found in the marine organism. Sufficient evidence showing
the likely production of the essential bacteria in the laboratory demonstrates the
relevance of bacterial growth enough to explore further using this technique for
producing these compounds on a large scale.CHAPTER 2
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2.5 Conclusion
In conclusions it can be stated:
1) The chemical composition in comparison to agar media, posed much success
in  isolating  marine  bacteria  from  the Bugula’s  ecosystem,  consistent  with  the
seasonal availability of the marine organism in the area.
2) Despite inconclusive evidence to determine the production of any bryostatin
compounds using this method, results showing the production of marine bacteria
in the broths strongly suggest that the bacteria merely looks for a host suitable for
survival and colonization.
3) Bugula was not seen or looked for at the three designated sites used in the
UK; nonetheless, the mineral paste compilation indicated a possible cultivation of
bacteria.
4) Both  experiments show  substantive  evidence  that  methods  other  than
synthetic techniques, aquaculture and genetic identification of bacteria can be
used in the production and isolation of NPs.
5) By modifying the technique used, this method can be useful in overcoming
problems currently affecting the production of MNPs.CHAPTER 2
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3.1 Introduction
The bryostatins are MNPs that were originally isolated from the bryozoa,
Bugula neritina. Since the isolation of bryostatin 1 in the 1980s, nineteen other
bryostatin compounds have been isolated from Bugula, which are found all over
the world. For example, bryostatin 4 is extracted from Bugula found in the Gulf of
México,  Gulf  of  California  and the Gulf  of  Sagami.
(1) It  takes  approximately
fourteen tons of Bugula to extract approximately eighteen grams of bryostatin 1,
while  the  current  method  of  production involves  a  65  step synthetic process.
Bryostatin  1  is  the  most studied  bryostatin  and  it is  currently  in a  number  of
clinical  trials  for  the  treatment  of  various  cancers  such  as  kidney,  prostate,
ovarian,  leukaemia  and  is also being  looked  at  as  a possible  treatment  for
Alzheimer’s disease.
(2) For this reason, it is essential that an economical method
is  developed  which  would facilitate  more  trials  and  the  treatment of  greater
numbers of patients.
It has been suggested that the true source of the NP is of bacteria found in
the marine organism.
(3,4,5) Studies conducted by Manning et al., have also shown
a ubiquitous component responsible for the compound as traces of bryostatins
have  been  found  in  various  marine  organisms  in  the Bugula  ecosystem.
(6,7,8)
Additional work has also been conducted, showing the chemical properties of the
ecosystem  where  the  marine  organism  is  found  and  the  marine  organism
itself.
(7,9) From  these  studies  the development  of  an  artificial medium for  the
production of the bryostatins was developed. The chemical composition of this
medium  is similar  to  that  of  the  ecosystem  and  the  marine  organism; this
replicating  the  components  of  the  ocean and  the  organism in  an  artificial
environment.
As  mentioned,  other  groups  have  suggested  the  presence  of  marine
bacteria as the source for the production of the bryostatins. In the laboratory,CHAPTER 3
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agar  media  are  usually  used  for  the  cultivation  of  bacteria  in  an  artificial
environment, with different media used for the cultivation of specific bacteria.
(10)
This chemical composition, based on the marine ecosystem of Bugula, serves as
an alternative to agar media. It has been reported that 99% of naturally occurring
microorganisms are almost impossible to cultivate in the laboratory and have yet
to be identified.
(11) For those that do grow in the laboratory, agar media are used
to aid in the growth and production of the bacteria. Different agar media are used
to provide nutrients, and the additional chemicals necessary for specific bacteria
to  grow.  The  chemical composition also  contains  the  necessary  nutrients and
chemicals which  have  been  identified  in  the  marine  environment in  which  the
marine organism resides.
Based  on  studies  (chapter  2) suggesting  the  efficacy  of  the  artificial
medium, this study was conducted to improve its efficacy for the isolation of the
bacteria  of  choice. The artificial  surfaces  used  were  coated (treated) with  the
chemical composition  in  order to  determine  the  overall  efficacy and  the  most
feasible artificial surface for  economical  production. The artificial  surfaces
(polyurethane, sawdust and cellulose sponge) used in this study were prepared
and  processed  as described  below. The  results  from  this  study  would  thus
provide  sufficient  means  to  isolate  and  produce the marine  natural  products
needed, as well as providing further proof of the real source of production for the
NP. Initial  results suggest  the production  of different bryostatin  compounds  in
most of the artificial surfaces used.
3.2 Experimental Section
The artificial  surfaces  were treated  using  the  chemical composition as
initially described in section 2.2.2. The surfaces were coated (treated) in a two
step process as shown in Tables 1 and 2. In both steps sponges (Dick Blick ArtCHAPTER 3
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Materials, 32901-0000), Bugula (provided by the Gulf Specimen Marine lab in
Panacea,  Fl.), and  sawdust  were  coated  by submerging  the  surfaces  in  each
solution for total of 4 hr, while polyurethane strips were coated by submerging the
strips  in  each  solution for  8 hr. After  the  allocated  time,  the  surfaces  were
removed and air dried, before coating them in the second solution. After both
coatings were applied, the surfaces were air dried at room temperature (RT) then
packed into bacterial amplification chambers (BACs) as shown in Fig. 1. Initial
traps consisted of 5 BACs: two for polyurethane; two for sponges; and a control
containing  both  a  strip  of  untreated  polyurethane  (1 ft)  and  two  untreated
sponges,  each  separated  by  a  strip  of  zinc  (Fig. 2). The  amount  of Bugula,
sawdust  and  chitin  used  in  this  study  were  not  quantified.  The  weight  of  the
artificial surface were not determined before and after coating with the chemical
composition used.
Fig. 1. An inside view of a bacterial amplification chamber.
Table 1.  Surfaces were first treated with the listed chemicals. A total of 4 strips of
polyurethane, and 2 strips of cellulose sponge were treated, as detailed below.
Chemicals Amount used Company Product code
Calcium carbonate 20 g Fisher Scientific S71922
Iron Chloride 10 g Fisher Scientific FL-01-0784
Instant Ocean 2 g Marine Labs SS3-50
Distilled Water 700 mL N/A N/A
Bacterial
Amplification
Chamber (2ft)
Floatation
device
Pores
Artificial
surface
Rope (1ft)
Weight
………
……….
……….
……….
……….
……….
……….
……….
……….
Support for
floatation
device
Spring
link ¼”CHAPTER 3
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Table 2. The chemicals used for the second coating of the artificial surfaces. A
total  of  32  strips  of  polyurethane and  16  strips  of  cellulose  sponge per  4  L
containers.
Fig. 2. A 2 dimensional design of the prototype used for the broth assessments:
BACs were placed at three designated locations in Florida.
The BACs  were  placed  in  Alligator  Point  Yacht  Basin,  Alligator  Point,
Florida (25° 36' 0" N, 81° 14' 28" W) and Turkey Point (29° 54' 0.9" N, 84° 30'
0.7" W), St. Teresa, Florida, USA. A total of 74 sponges and 60 polyurethane
strips  were  used  in  this  study.  The  traps  were  checked twice  a  month  to
determine that bacterial growth on the media was taking place. After the allocated
Chemical Amount used Company Product code
CaCO3 5 g Fisher Scientific S71922
FeCl36H2O 2 g Fisher Scientific FL-01-0784
Amino Acid 10 tablets Fisher Scientific S71922
Fish Oil 10 tablets GNC 750612
Multi-Vitamin 10 capsules Equate N/A
Vitamin A & D 10 capsules Spring Valley N/A
Vitamin C 10 tablets Spring Valley N/A
Sugar 15 g Pure Cane Dixie
Crystals
S133E06A-PA
Marine Buffer 2 g Sea Chem UPC# 000116034708
Sodium acetate 2 g Fisher scientific S210-500
Peptone 2 g Fisher scientific BP1420-100
Sodium sulfate 1 g Fisher scientific S421-1
Glycerin 2 mL Fisher scientific G33-500
Stearic acid 1 g Sigma Aldrich 175366-1Kg
Squalene 2 mL Fisher scientific AC20747-1000
Octanoic acid 2 mL Fisher scientific 167261000
Distilled water 4 L N/A N/A
Weight
 1.5 ft
 1 ft
Bacterial
Amplification
Chamber 2ft
Plywood
(2X4) 7ft
Channel
marker
7-10 ft
under
water
 6 in  9 in
Floatation
device
 6 in
….
….
….
….
….
….
….
….
….
.....
….
….
….
….
….
….
….
….
.....
….
….
….
….
….
….
….
….
.....
….
….
….
….
….
….
….
….
.....
….
….
….
….
….
….
….
….
Pores
Spring link
¼”
P
RopeCHAPTER 3
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time period (Table 3), the artificial surfaces were removed from the BACs and
placed  in  containers  filled  with  sea  water  from  their  respective  location.  The
containers  were  placed  at  4°C  for  48  hr  then  placed  at  RT  for the  broth
assessment.
The extraction procedures are mentioned in section 3.2.1-3.2.3. Samples
from  all  the  experiments  were analyzed by MALDI-TOF-MS  and  LC-MS  as
described in section 2.2. Samples from all the broths were collected, processed
and  analyzed (section  3.2.4) using a  Scanning  Electron  Microscope  (SEM),
Valdosta State University, Valdosta, GA (USA). Additional images for each broth
from each location, additional spectra for each broth assessment, and additional
SEM images can be found on the enclosed DVD.
3.2.1 Artificial surfaces
Table 3. The different artificial surfaces (AS) used, the cultivation period in the
water, and the assessment period of the broths at RT.
AS Location Year Water Broth
growth
1 Alligator
Point, Fl.
February 24
th, 2007 at 12:00 p.m. to May 17
th, 2007 at
10:00 a.m.)
11  ½
wk
12 wk
2 Alligator
Point, Fl.
May 17
th, 2007 at 10:00 a.m. to May 27
th, 2007 at 11:00
a.m.
10 day 10 wk
3 Alligator
Point, Fl.
May 27
th, 2007 at 1:30 p.m. to June 18
th, 2007 at 5:00
p.m.
3 wk 8 wk
4 Alligator
Point, Fl.
February 24
th, 2007 at 12:00 p.m. to May 17
th, 2007 at
10:00 a.m.)
11  ½
wk
12 wk
5 Alligator
Point, Fl.
June 18
th, 2007 at 5:00 p.m. to June 25
th, 2007 at 12:00
p.m.
1 wk 7 wk
6 Alligator
Point, Fl.
June 15
th, 2008 at 1:00 p.m. to June 22
nd, 2008 at 1:00
p.m.
1 wk 4 ½ wk
7 Panacea,
Fl.
June 15
th,2008 at 2:00 p.m. to June 22
nd, 2008 at 2:00
p.m.
1 wk 4 ½ wk
8 St.  Teresa,
Fl.
February  24
th,  2007  at  1:00  p.m.  to  May  17
th,  2007  at
11:00 a.m.)
11  ½
wk
12 wk
1. Two BACs containing treated sponges (4, 19.1cmx11.4cmx5.08cm) respectively.
2. Three BACs containing treated sponges (10, 7.62cmx2.54cmx2.54cm) and packed with chitin (shrimp
shells) as fillers respectively.
3.  One  BAC  containing  treated  sponges  (10, 7.62cmx2.54cmx2.54cm),  and  packed  with  the  marine
organism, Bugula neritina, (Gulf Specimen Marine Lab) as fillers.
4.  Six  BACs  containing  treated  polyurethane  strips  (10, 12.7cmx2.54cmx2.54cm)  respectively.  Two
chambers were placed at Alligator Point, two were placed at Panacea, Fl. and two at St. Teresa, Florida.
5. Four BACs, two containing treated sawdust and one containing sawdust and sponge and one containing
treated sawdust and sponge respectively. A total of (10, 7.62cmx2.54cmx2.54cm) sponges were placed in
the chamber containing sponge.
6. Three BACs containing treated sponges (total of 7, 19.1cmx11.4cmx5.08cm) respectively.
7. Three BACs containing treated sponges (total of 7, 19.1cmx11.4cmx5.08cm) respectively.
8. Two BACs containing treated sponges (total of 4, 19.1cmx11.4cmx5.08cm) respectively.CHAPTER 3
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3.2.2 Extraction of white film
Analysis of each container after 48 hr at RT showed the formation of a
white film on the surface of the water. This film was removed from each container
biweekly, extracted into 40 mL anhydrous methanol (Fisher Scientific) and then
stored at 4°C. Biweekly assessments of the broths were followed by the addition
of 10 g of mineral paste composition (section 2.2.2, Table 2) to each container.
After  the complete  assessment  (growth  assessment  of  bacteria  at  RT  as
mentioned in section 3.2, Table 3) of the surfaces at RT, the extracts collected
were filtered, using a 5 µm filter paper followed by a 0.2 µm filter paper.
3.2.3 Extraction of artificial surfaces
After the assessment period (time period for the grow-out of the broths at
RT, Table  3),  the  artificial  surfaces  from  each container  were  removed  and
prepared for extraction. Surfaces were air dried at RT for 24 hr, then placed in
100 mL of methanol containing 2 g of sodium sulfate for 48 hr. The extract was
filtered using a 5 µm filter paper then placed at 65°C for 72 hr to remove the
methanol. Crystals were  analyzed  and  correlated  with  the  white  film  extracts
collected from their respective containers.
3.2.4 Preparative procedure for SEM analysis
The white film collected from each broth assessed and the AS used in the
broths, as mentioned in section 3.2.1, were analyzed by SEM. Samples were
collected on July 16
th 2007, at 10:00 a.m., and prepared as mentioned below.
Samples were analyzed on the SEM, from July 17
th 2007 to July 25
th 2007.
Each sample (white film and AS) was removed from the broths and placed
directly into a chemical fixative consisting of 1% glutaraldehyde in 0.2 M sodium
cacodylate  buffer,  pH  7.2  for  4  hr. After  4  hr, the  samples  were  washed  byCHAPTER 3
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replacing  the  fixative  with  fresh  buffer  3  times  at  15  min  intervals, without
exposing the samples to air. The buffer was then replaced with deionized water
until the sample was immersed in 100% deionized water only. The samples were
then dehydrated using 95% ethanol. A 10% gradation series of ethanol (10, 20 to
90%) using 95% ethanol was used with each series added for 10 min, until the
samples were in 100% absolute ethanol respectively. This process was repeated
again, to replace samples in ethanol, with 100% acetone, necessary for critical
point drying.
Once  in  acetone,  the  samples  were  placed  in  plastic  containers  then
placed in a critical point drier. After critical point drying, samples were mounted
on a stub then coated with argon. The stubs were then placed in the vacuum
chamber  of  the SEM and  analyzed.  The  preparative  procedures  for  the  SEM
mentioned  above were  conducted  as indicated by  the  Biology  Department  at
Valdosta  State  University, Valdosta,  GA,  USA, where  the  samples  were
analyzed.
(12)
3.3 Results and Discussion
Artificial surfaces were checked twice a month to determine the timescale
of bacterial growth from the three designated locations. After 2 wk, surfaces from
all three locations showed no sign of bacterial growth. However, 4 wk after the
start date, samples from St. Teresa Bay and Alligator Point were black in color
and  reduced  in  size  when  compared  to  the  control sponges (untreated).
Untreated AS placed in both locations retained their original appearance after 12
½ wk, as shown in Fig. 3.
Most of the AS (sponge, sawdust and Bugula) that were used in this study
turned completely greenish black in colour, were reduced in size, slimy and gave
off a pungent odor, after being placed in the water. The BACs containing spongeCHAPTER 3
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and chitin (shrimp shells) showed no presence of chitin after 10 days in the water.
The sponges left in the container alone were greenish black in colour, reduced in
size, slimy and gave off a pungent odor. The Bugula placed in the BACs with the
treated  sponges  was  still  present  when  the  BACs  were  removed,  after  the
allocated time in the water. The Bugula was black in color; similar in appearance
to the sponges in the chamber. In all the BACs containing the controls, there was
no  change  in  appearance,  size,  colour  or  texture compared to  the  untreated
surfaces (sponge and polyurethane), as shown in Fig. 3.
Fig. 3. Sponges shown above were placed at St. Teresa Bay, Florida for 13 wk.
The  treated  sponge  (top)  appears  green/black  in  color  while  the  untreated
sponge (bottom) still retained its original appearance.
The strips of polyurethane were not as effective as the other AS used.
After 4 wk the surface of the polyurethane strips appeared partially black on the
surface, however the bacterial growth was not as pronounced as shown on the
other surfaces. After 13 wk the appearance of the polyurethane strips in all three
locations was consistent, showing limited bacteria growth. After 2 wk at RT, the
surfaces still remained the same, and the water was clear and odourless (Fig. 4).
Despite  the  partial  black  appearance  on  sections  of  the  polyurethane,  this
artificial surface was not successful in collecting any marine bacteria from either
location, as opposed to the other artificial surfaces used, while in the laboratory,CHAPTER 3
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for the broth assessment at RT, no indication of bacterial growth was seen. The
white  film formed  on the  surface  of  the  other  containers  was  not  seen  in the
container  containing  the  polyurethane  strips  collected  from  each  location,  as
shown below.
Fig. 4. Treated polyurethane strips placed at Panacea, Fl. for 13 wk.
The three surfaces used were selected in order to establish which would
serve  as  the  most  successful surface,  when  coated  with  the artificial  media.
Previous work by Yasumoto-Hirose et al., showed that polyurethane treated with
various agar media and placed in seawater was successful in cultivating marine
bacteria.
(13)Applying this concept to the chemical composition used by this group,
polyurethane strips were treated then placed in the stated locations. Throughout
the  13  wk  period,  bimonthly  analysis  of  traps  showed  no  signs  of  bacterial
growth, especially in comparison to the other two artificial supports. Results from
the polyurethane blocks left at RT for 12 ½ wk were also unsuccessful.
These  results questioned  the  credibility  of  using  polyurethane  as  a
potential  artificial  surface  as  the  other  two  artificial  surfaces  showed  more
promise in  cultivating the bacteria from Bugula ecosystem. This  suggestion  isCHAPTER 3
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based upon the success of the other surfaces that we used in this study; of which
all showed the presence of bacterial growth when analyzed by SEM (Fig. 14).
After 48 hr of placing all the containers at RT, a white film covered the
water layer in each container and areas of the sponges protruding above the
water layer as shown in Fig. 5. This white film was seen on the surface of the
water,  in  each  container,  and  was  continuously  present  throughout  the  broth
assessment. These results were consistent for the artificial surfaces placed at all
three locations.
Fig. 5. White film  is shown  after  48 hr  at RT from a  broth  containing  treated
sawdust placed at Alligator Point, Florida for 1 wk.
The chemicals used in this study were based on detailed analysis of the
marine organism, Bugula neritina, and the ecosystem in which it is found.
(8,9) As
mentioned earlier, this chemical composition was developed to replace the use of
agar media which is normally used for the cultivation of bacteria in the laboratory.
As previously stated, approximately 99.9% of bacteria are almost impossible to
grow in the laboratory using agar media.
(11) Being based on the properties of the
ecosystem,  the  chemical composition would  serve  as  a  replica  of  that
environment and therefore aid in the cultivation and isolation of marine bacteria.CHAPTER 3
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For example, the surface of Bugula has been shown to contain high levels
of  calcium  carbonate,  and  extraction  of  the  marine  organism has  shown  high
concentration  of  nano  particles  (Fe, CuO); suggesting that  the  bacteria  found
within the organism thrive on these components.
(9) The ecosystem of the marine
organism also  has a  high  deposit  of  limestone  (approximately  40%),  which
accounts  for  the  main  component  of  our  chemical composition  being  calcium
carbonate.
Secondly, to cultivate and isolate the bacteria, it is necessary to replicate
the contents of the ocean in an attempt to mimic the environment of the bacteria.
For this reason, marine buffer and Instant Ocean were used. Many of these salts
are important for bacteria. For example, potassium salts function as a cofactor for
certain  enzymes,  and  magnesium  salts  function  as  a cofactor  for  certain
enzymatic reactions etc..
(14)
The vitamins, amino acids, fish oil, peptone, sugar, and glycerin were all
used  as nutrients  in  order  to  promote  the  growth  and  development  of  the
bacteria. Vitamins are important as bacteria need the organic molecules in order
for enzymes to function.
(14,15,16)For example, vitamin B12 was a coenzyme, methyl
form cobalamine, and vitamin K is a coenzyme form.
(14)
Next,  chemicals  such  as  squalene,  stearic  acid,  octanoic  acid,  and
docosanoic acid are all carboxylic acids used due to the initial findings in a study
that was conducted by Manning et al., of the marine environment.
(8,9) Stearic acid
is  a  saturated  fatty  acid  found  naturally  in  animal,  fat  and  vegetable  oil.  It  is
important for cell culturing for the bio-manufacture of protein, and important for
the cell structure of the cell wall in bacteria.
(17)
The purpose of analyzing the surfaces in the broths, aside from the white
film collected was to compare the data to that from the white film extracted from
the  surface  of  the  water in each  container,  and  to  determine whether theCHAPTER 3
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compounds of interest were actually in the white film, or in the artificial surfaces.
Based on the data collected both the surfaces and the white film gives peaks that
can  be  correlated  to  different  bryostatin  compounds.  As  shown  in  the  tables
below, many of the peaks can be seen in more than one broth. This is important
as it shows a consistency in the data from the different surfaces placed in the
same location, and that the surfaces used are promising and all are efficient for
use as artificial surfaces. The main difference between the artificial surfaces was
the percentage of bacteria cultivated, for example, increasing the surface area
from blocks of cellulose sponge to using strands of sawdust, increased the yield
of the bacteria collected.
Tables 4 and 5 both show a summary of the peaks from the MALDI-MS
and LC-MS analysis of each sample. The structures shown next to the tables are
suggestive structures for the peaks that could correlate to the different bryostatin
compounds. Examples of MALDI-MS data are shown in Fig. 6-11. Spectral peaks
from  samples  collected  were  compared  to  a  bryostatin  1  standard
12  (Fig. 6).
Based on the fragmentation pattern of bryostatin 1, structural formulae for the
dominant peaks were postulated with reference to data collected in chapter 6.
The twenty bryostatin compounds that have been isolated each differ only by the
R1 and R2 groups, as shown in Fig. 6.CHAPTER 3
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Table 4. The artificial surfaces which produced a white film over a 9 wk period in the laboratory. Spectral peaks, both MALDI-MS and LC-MS,
are shown. The highlighted m/z values have been used to suggest the bryostatin compounds each might represent.
Peaks
(m/z)
Container
1 Container
2 Container
3 Container
4 Container
5 Container
6
705
714
733
743
752
761
789
798
805
874
889
895
903
912
925
959
998
1. Sponges from Alligator Point.
2. Sponges from St. Teresa Bay.
3. Sponges and chitin from Alligator Point.
4. Sponges and Bugula neritina from Alligator Point (Fig. 11).
5. Sponges and sawdust from Alligator Point (Fig. 10).
6. Sawdust from Alligator Point.
(M+H)
+Bryostatin 4
(C46H71O17, 895.4685 g/mol)
(M+Na)
+Bryostatin 8+Na
+
(C45H68O17Na m/z 903.4348 g/mol)CHAPTER 3
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Table 5. Spectral peaks from extracts collected from artificial surfaces heated to 65°C, from both MALDI-MS and LC-MS analysis. The
highlighted m/z values have been used to suggest the bryostatin compounds each might represent.
Peaks
(m/z)
Container
7 Container
8 Container
9 Container
10 Container
11 Sample
12
705
713
733
755
761
789
808
851
875
889
928
943
962
998
7. Sponges from Alligator Point (Fig. 8).
8.   Sponges from St. Teresa Bay
9.   Sponges and chitin from Alligator Point.
10. Sponges and Bugula neritina from Alligator Point (Fig. 7).
11. Sponges and sawdust from Alligator Point.
12. Control sample was bryostatin 1 standard in methanol (Fig. 6)
O O
O O
HO
O
O
O
HO
OH O
O
O
H
H H
91
(M+H)
+Bryophan ring
(C37H53O13, 705.3480 g/mol)
Bryostatin 11 + (Na – 2H)
+
(C39H56O15Na, 787.3511 g/mol)CHAPTER 3
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Fig. 6 MALDI-MS of bryostatin 1 standard in anhydrous methanol. Bryostatin 1+
Na
+  adduct  (C47H68O17Na,  927.4348  g/mol).  The  structures  shown  below
correlate to the m/z peaks shown in Fig. 6.
(M+Na)
+Bryostatin 1+Na
+
(C47H68O17Na, 927.4348 g/mol)
O O
O O
HO
O
O
O
HO
OH O
O
O
H
H H
91
(M+H)
+Bryophan ring
(C37H53O13, 705.3481 g/mol)
(M+Na)
+Bryostatin 11+Na
+
(C39H58O15Na, 789.3668 g/mol)
(M+H)
+Bryostatin 2
(C45H67O16, 863.4423 g/mol)CHAPTER 3
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The  above  illustration  shows  how  bryostatin  1  fragments  in  the  mass
spectrometer can give  the  peaks  shown  above. There  are  twenty  bryostatin
compounds  that  have  been  isolated  from Bugula  neritina,  each  bryostatin
compound differs by the R1 and R2 group positions as shown above. Bryosatin 1+
Na
+ adduct 9b (C47H68O17Na, 927.4348 g/mol) loses (C2H3O
.)
. radical at the R1
position to give an m/z of 863.826 (M+H)
+. This peak can therefore be correlated
to bryostatin 2 89 (M+H)
+ which has a formula of (C45H67O16, 863.4423 g/mol).
In many of the MALDI-MS data that has been obtained for bryostatin 1, a
consistent fragment that is always shown, is the peak with a m/z of 789 (M+Na)
+.
As shown above the mass at 789 is formed by the loss of the carboxylate group
(R2 group) which can be correlated to bryostatin 11+Na
+ adduct 90 (C39H58O15Na,
789.3668 g/mol).
The basic structure for all the bryostatin compounds is the bryophan ring
91 (M
+: C37H52O13, 704.4302 g/mol). The loss of the R1 and R2 groups gives the
basic structure of the bryophan ring (e.g. the acetate group at R1 position and the
C8 chain at the R2 position). As shown above, bryostatin 1 fragments to give an
m/z of 705.715 which suggests the bryophan ring (M+H)
+. Of all the bryostatin
compounds that have been isolated from Bugula bryostatin 1 has the greatest
potency as a medicinal agent. The fragments of bryostatin 1 shown in Fig. 6 are
used as a reference to further support the postulations of the m/z values found for
the samples in this study.
Studies by Pettit et al., have shown that the exposure of bryostatin 1 to
various conditions can lead to the degradation of bryostatin 1.
(18) Some of the
mass peaks found within the samples suggested different bryostatin compounds
or other related compounds found in Bugula neritina. The peaks shown in Fig. 6
can also be correlated to the fragmentation pattern of the bryostatin 1. It shouldCHAPTER 3
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also be  noted,  however,  the  compounds  shown could also  be biosynthetic
precursors for the production of bryostatin 1.
(19,20)
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Fig. 7. MALDI-MS of sponge extract removed from the broth containing Bugula
and sponge. The extract was heated at 65°C for 72 hr.
(a) (b)
Bryostatin 11+Na
+ Bryophan ring (M+H)
+
(C39H58O15Na, 789.3668 g/mol) (C37H53O13, 705.3480 g/mol)
As shown  in  Fig. 7,  the  peak  at m/z  705.715  (M+H)
+ suggests  the
bryophan  ring 91 of  the  bryostatins  (M
+: C37H52O13,  704.3402  g/mol). The
bryophan ring form the basic structure of all the bryostatin compounds, for this
reason the isolation of the bryophan ring can be a precursor to the production of
bryostatin 1.
(21)CHAPTER 3
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Fig. 8. The extract ion chromatogram of a peak analyzed by HRMS. The sample
is a sponge extract at RT for artificial surfaces placed at Alligator Point, Fl. in
June 2008.
The extract was divided equally into two containers; one was placed at
65°C while the other was placed at RT to dry. A dry weight of crystal extracts
(1.12 g) was collected from white film over 4 wk period. A total of 21 sponges
were extracted into 1L of methanol. The dry weight of crystals collected from the
heated sponge extract was 25.23 g with 24.79 g from the extract placed at RT.
Results from HRMS (Fig. 8) show the extract ion chromatogram at m/z of 895.4,
a peak consistent with results cited in chapter 2. The peak at m/z 895 (M+H)
+ can
be correlated to bryostatin 4 94 (M
+: C46H70O17, 894.4607 g/mol). The margin of
error for the peak in correlation to bryostatin 4 is 34 ppm, with the acceptable
error  usually  being  10 ppm.  This  may  be  due  to  the  instrument  not  being
calibrated properly.
(M+H)
+Bryostatin 4
(C46H71O17, 895.4685 g/mol)CHAPTER 3
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Fig. 9. LC-MS of white film collected from the surface of water, in the container containing sawdust and sponge placed at Alligator Point, Fl.CHAPTER 3
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Fig. 10. LC-MS of white film collected from the surface of water, in the container containing Bugula and sponge placed at Alligator Point, Fl.CHAPTER 3
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In Figs. 9 and 10 below, one peak at an m/z of 903 (M+Na)
+ is seen in
both  samples  at  a  RT  of  17.74  minutes.  It  is  suggested  that  this  peak  may
correlate to bryostatin 8 + Na
+ 93 (C45H68O17Na, 903.4348 g/mol) as shown in
Fig. 11. The LC-MS data from both samples correlate to two different treated AS,
(sawdust and sponge; Bugula and sponge), that were used in the study, with both
placed at Alligator Point, Florida.
Fig. 11. Bryostatin 8 + Na
+ adduct (C45H68O17Na, 903.4348 g/mol)
Both  surfaces  were  placed  at  different  times  in  the  water;  chambers
containing Bugula and sponge were placed in the water from May 27
th 2007, at
1:30 p.m. to June 18
th 2007, at 5:00 p.m., and the chambers containing sawdust
and sponge were placed in the water from June 18
th 2007, at 5:00 p.m. to June
25
th 2007, at 12:00 p.m.. This strongly suggests a ubiquitous component that was
isolated  during  that  time  period  in  which  the  treated  surfaces  were in situ.
Analysis of the surfaces from both locations, by SEM, shows the presence of
numerous bacteria as shown in Fig. 14.CHAPTER 3
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Fig. 12. Artificial surfaces where checked on April 14
th 2007 at 2:00 p.m., the
presence of Bugula was seen on the PVC pipes containing the treated surfaces.
Bugula is a seasonal and temperature dependent marine organism. It is
generally  found  attached  to  boats  and  other  substrates  during  the  months  of
October  to  April  (18-22°C);  however, Bugula  was  found  attached  to  the  PVC
pipes which were used to store the AS while the surfaces were placed at Alligator
Point, Fl. Bugula was seen attached to the PVC pipes during the months of April
to June 2007, and June 2008, while the surfaces were placed in the water (Fig.
12). The presence of Bugula suggests that the bacteria isolated from the marine
environment  may  have  also  been present  in  the Bugula  attached  to  the  PVC
pipes; however this was never verified as the Bugula attached to the PVC pipes
were not analyzed. From the graph shown in Fig. 13 below, it is clearly seen that
the change in water temperature which may be correlated to the data collected
(Tables 4 and 5). In Tables 4 and 5, a peak with an m/z of 789 is seen in many of
the different AS that were placed at Alligator Point, Fl. at different time periods.
This peak with an m/z of 789 may correlate to bryostatin 11+ Na
+ as mentioned
earlier. However, many of the other peaks vary in the times the surfaces were
placed in the water. For example, in June 2008, the AS placed at Alligator Point,
Fl., showed a peak at an m/z of 895 which may correlate to bryostatin 4; a peak
which was not seen in the other surfaces used at the allocated times shown in
Table 3.CHAPTER 3
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Fig. 13. Daily recorded water temperature of Alligator Point, Florida where the
surfaces were placed from February to June.
It is important to note that, since the artificial mediums from the studies
conducted (section 3.2.1) were all placed at the same location, it is suggested
that there are three factors that account for the variation in the data collected,
which are: 1) the temperature of the water when the samples were placed, 2)
how long the treated artificial surfaces were placed in the water, and 3) the broth
assessment period of the surfaces at RT. It is also suggested that such factors
may also account for the presence of the twenty different bryostatin compounds
that have been isolated from the marine organism.
3.4 Symbiont bacteria
Results from all the bacterial broths in this study showed that with the right
medium and the optimum conditions, the desired bacterium can be cultivated.
Despite the  lack  of any  further  analysis  to  determine  the  specific  bacteria
responsible  for bryostatin production,  SEM  images  from  each  broth  were
collected.  Surfaces  and  white  film  from  each  container  were  processed  and
viewed under the microscope, showing vast numbers of bacteria in each (Fig.CHAPTER 3
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14).  Most  of  the  bacteria  in  Fig.  14  are  bacilli  (rod-shaped),  which  are
approximately two micron in size. However, cocci (spherical) bacteria are also
seen, which are approximately one micron in size.
(16)
Fig. 14. An SEM image of the white film collected from BACs containing treated
artificial surfaces placed at St. Teresa Bay, Fl.
As shown in Fig. 14 most of the bacteria are found in clusters, which is
also known as a biofilm. A biofilm is a structured community of microorganisms
encapsulated within a self-developed polymeric matrix and adherent to a living or
inert surface.
(22) Single-celled organisms generally exhibit two distinct modes of
behaviour. One type of biofilm is the familiar free floating, or planktonic, form in
which  single  cells  float  or  swim  independently  in  some  liquid  medium.  The
formation of a biofilm begins with the attachment of free-floating microorganisms
to a surface.
(23) These first colonies adhere to the surface initially through weak,
reversible van der Waals forces. If the colonies are not immediately separated
from  the  surface,  they  can  anchor  themselves  more  permanently  using cell
adhesion structures such as pili.
(23) Bacteria living in biofilms display a complex
arrangement of cells and extracellular components, forming secondary structuresCHAPTER 3
132
such as micro-colonies, through which there are networks of channels to enable
better diffusion of nutrients.
(24)
3.5 Conclusion
Despite  significant  improvements  in  finding  a  cost  efficient  method  to
produce this NP, some inconsistencies in the cultivation of the marine bacteria
were apparent, resulting  in  inconclusive  evidence for  the  support for  the
production of any bryostatin compounds.
In summary, results from the artificial surfaces used showed that:
1. The chemical composition used was successful in capturing marine bacteria
from Bugula’s ecosystem.
2. Despite the very close comparability of certain m/z values (34 ppm), the HRMS
data for the samples fell above the accepted error limit of 10 ppm for absolute
identification.
3. Low detection levels also presented problems for further studies; hence the
spectral  data cannot  support  or  disprove irrefutably the  production  of  the
bryostatin compounds that the masses could represent.CHAPTER 3
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Artificial surfaces treated with a composition of
chemicals for the production of Et-743CHAPTER 4
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4.1 Introduction
The  anti-tumour  drug  Ecteinascidin  743 60b (Fig. 1),  also  known  as
Yolendis or Trabectedin, is a MNP extracted from the sea squirt, Ecteinascidia
turbinata.
(1,2,3) Since the isolation of the compound from the marine organisms in
the 1970s, Et-743 has become by far the most advanced compound in late stage
phase  II clinical  trials  and  has  already  entered  phase  III  clinical  trials  for  the
treatment  of  various  cancers  such  as  soft  tissue  sarcoma,  osteosarcoma,
melanoma, and prostate cancer, etc..
(4)
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Fig. 1. The structure of Et-743 (C39H43N3SO11, 761.2613 g/mol).
Despite the efficacy of Et-743 as a potential anti-tumour agent, the overall
success of the drug is restricted due to its limited supply. For this reason, the
need  for  an  economical  method  to  produce  compounds  such  as  Et-743  is
imperative. A 45 step synthesis of the compound was achieved in 1996 by Corey
et al., however the numerous steps are time consuming and the overall yields are
low.
(5) Other attempts, such as aqua-culturing of the marine organism has been
developed as an alternative method for the production of the drug, however the
percentage yields from this, are again still low.
(6) The synthesis of a synthetic
analogue of  Et-743, Phthlascidin  650 67 (Fig.  2),  has  also  been achieved by
Corey et al., and this shows similar cytotoxic effects as Et-743.
(7)CHAPTER 4
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Fig. 2. Phthlascidin 650 (C36H34N4O8, 650.2371 g/mol), a synthetic analogue of
Et-743, with anti-tumour properties.
Since the discovery of Et-743, other ecteinascidin compounds have been
identified, along with the synthesis of different analogues of the drug, with some
having greater activity than others. However, Et-743 is still the most potent.
(8,9)
Recently, Safracin B 74 (Fig. 3) was isolated from the bacteria, Pseudomonas
fluorescens,  and  this  is  now  used  to prepare Et-743  in  a  21  step  semi-
synthesis,
(10,11,12,13) but the overall percentage yields of Et-743 by this method are
still low.
N
N
O
HO
O
O
O
R
H
H
H
H
NH
NH2
O 74
Fig. 3. Safracin  B  (C28H36N4O7,  540.2578 g/mol),  a  compound  produced  by
Pseudomonas fluorescens used for the production of Et-743.
(12)
Despite several alternative methods that have been used in an attempt to
improve the overall yields for the production of the compound, no method has
thus far proved valuable. Previous work has shown that Et-743 is not only found
in the sea squirt, but the active compound is also ubiquitous in the environment
where the organism resides.
(14,15) Since then, the original source of the drug hasCHAPTER 4
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been  continuously  questioned. From  the  ubiquity  of  the  compound  in  the
ecosystem of the marine organism, it has been suggested that marine bacteria
could  be responsible  for  the  production  of  the  marine  organism.  Marine
organisms such as sea squirts are filter feeders and can easily ingest marine
bacteria. It has also been suggested that many marine organisms use marine
bacteria to produce primary and secondary metabolites for various reasons that
are still being determined.
(16,17,18,19)
In the laboratory, the primary method for the isolation and cultivating of
marine bacteria uses an agar medium. Agar is a gel medium which contains all
the  necessary  growth  factors  needed  for  bacteria  to  grow.
(20,21) Despite the
innovation of the use of agar media, many bacteria are still impossible to grow in
an artificial setting, unless the properties necessary for the bacteria growth are
determined. In this study, the concept of using an agar medium was implemented
into  the  development  of  a  chemical  composition,  which  consisted  of the
chemicals and growth factors similar to those in an agar medium, but without the
use  of  any  agar.  The  chemicals  were  selected  based  on  previous  studies
conducted which analyzed the sediment and properties of the ecosystem of the
organism, in order to determine the conditions in which the sea squirts resides.
(15)
This  chemical composition,  was  applied  to  the artificial  surfaces  (as
detailed in section 3.2) by coating the surface with the chemicals, then placing
the surfaces in locations where the sea squirt is present, in order to determine if
the  production  of  Et-743  from  its  ecosystem  would  be  possible.  The  treated
surfaces, having been coating with a composition of chemicals, have properties
similar to that of the ecosystem and the marine organism. This may therefore be
a beneficial tool to mimic the host organism and a suitable means for the isolation
of the source responsible for the production of Et-743.CHAPTER 4
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With previous work, as mentioned, showing the compound present in the
marine  environment; BACs containing  treated AS (sponges)  were  placed  in
Panacea, Florida and Lido Key, Florida where the sea squirt is found. Aside from
placing the AS at these locations, sediment and sea squirt from Panacea was
also collected to investigate the presence of any ecteinascidin compounds in the
Gulf of México. Mass spectral results from both locations strongly suggest peaks
corresponding  to two ecteinascidin  compounds,  however  low  detection  levels
could not give a definite mass accuracy to conclusively support the correlation of
the data sets.
4.2 Experimental Section
All the samples in this study were analyzed as mentioned earlier (section
2.2). Et-743 standard was donated by the NCI (Bethesda, Maryland). Artificial
surfaces  (sponges)  were  treated  as  previously (section  3.2).  Extraction
procedures are detailed in sections 3.2.1-3.2.3. Additional SEM images of the
white film collected from each broth and images of the surfaces initially removed
from the water can be found on the enclosed DVD. Preparative procedures for
the contents analyzed by SEM are as given in section 3.3.4. Tables 1 and 2 show
the correlation of the different R groups for the different ecteinascidin compounds
that have been isolated from the sea squirt.
4.2.1 Extraction (Panacea and Lido Key, Fl., 2007)
The broths were assessed at RT (room temperature) for a total of 4 wk
(Lido Key sponges) and 12 ½ wk (Panacea sponges). Sponges were treated and
packed into three BACs which were placed in Lido Key, Florida (27° 18' 2.7648"
ºN, -82°  34'  5.5302" W) and Panacea,  Florida  (30°  1'  44"  N,  84°  23'  56"W)
respectively. The cultivation period for traps placed at Lido Key for 5 days (JulyCHAPTER 4
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2
nd 2007, at 10:00 a.m. to July 7
th 2007, at 11:00 a.m.) and at Panacea 13 wk
(February 24
th 2007, at 11:00 a.m. to May 17
th 2007, at 9:00 a.m.). After the
allocated  time  period,  the  surfaces  were  transported  to  the  laboratory  in
containers of sea water from each respective location.
4.2.2 Extraction (Panacea, Fl., 2008)
On June 15
th 2008, at 2:00 p.m., the sponges prepared as mentioned in
section 3.2 were placed in the Gulf of México at Panacea, Fl. The sponges (21,
19.1cmx11.4cmx5.08cm)  were  packed  into  three  chambers  and placed  at
Panacea, Florida for 1 wk and removed on June 22
nd 2008, at 2:00 p.m.. The
surfaces were then transported to the laboratory, containing water from the same
location. The broth assessment  was carried  out  for  a  total  of  4  ½ wk as
mentioned in sections 3.2.2 and 3.2.3. The solvent extracts from both and the
surfaces  were  placed  in  a  vacuum until  dry. The  crystals  collected  from  both
extracts (white film and surfaces) were extracted into anhydrous methanol (Fisher
Scientific) and analyzed as mentioned in section 2.2.
4.2.3 Sea squirt extraction (Panacea, Fl., 2008)
Sea squirt was collect from crab traps at Panacea on June 2006 and June
2008. Sea squirts collected on June 17
th 2006, at 11:00 a.m. were air dried at RT
then placed in 30 mL of anhydrous methanol. The sample extract was filtered
using a 0.2 µm filter then analyzed. Sea squirt (600 g wet weight) collected on
June 22
nd 2008, at 2:00 p.m. from the same location was air dried at RT, then
extracted into 300 mL anhydrous methanol. The sample extract was filtered using
a 5 µm filter paper followed by a 0.2 µm filter then analyzed as mentioned in
section 2.2.CHAPTER 4
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4.3 Results and Discussion
After 4 wk in the water, the treated surfaces (Panacea, Florida; section
4.2.1) appeared partially black in colour, reduced in size and gave off a strong
pungent odor suggesting bacterial growth. The untreated surfaces retained their
original appearance (Fig. 4). At RT, containers from both locations showed the
formation of a white film visible on the surface of the water after 2 days (Fig. 5).
Results from all the extracts collected in this study, were compared to the Et-743
standard (Figs. 6 and 8).
Fig. 4. Treated and  untreated  sponges  shown  above  were  both placed  at
Panacea, Florida (section 4.2.1). Images of both sponges were taken at the 8 wk
mark during the 14 wk period in the water.
Fig. 5. The formation of the white film on the surface of the water during the broth
assessment at RT (8 wk).
According to Rinehart et al., the molecular weight of Et-743 60b is (M
+:
C39H43N3SO11, 761.2613 g/mol,),however, when dehydrated the compound has a
mass  of (M
+: C39H41N3SO10, 743.2507 g/mol,).
(3,22,23) This  explains  why  theCHAPTER 4
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standard shows peak with m/z of 744 97 and a smaller peak with an m/z of 762.
The  peak  at  m/z  776  (M+H)
+ 60g correlates  to  the  dioxyecteinascidin  743
extracted naturally in the standard (Fig. 8).
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Fig. 6. MALDI-MS of an Et-743 standard in 2-propanol. Et-743 (Fig. 8) has a
mass of 762.2613 g/mol (M+H)
+. When dehydrated (Fig. 7), it has a mass of
744.2585 g/mol 97 ([M+H-H2O]
+, C39H42N3SO10).
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Fig. 7.  Et-743  (M
+: C39H43N3O11S,  761.2613 g/mol,  when  dehydrated M
+:
C39H41N3O10S, 743.2507 g/mol).CHAPTER 4
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Fig. 8 LC-MS  of  Et-743  (M+H-H2O)
+  standard 60b. As  shown, peaks  with m/z  at  744  (M+H-H2O)
+ 97,  762  (M+H)
+  and  776
[dioxyexteinascidin 743, (M+H)
+] 60g at a retention time of 9.5 to 10.4 min.
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There are eight known ecteinascidin compounds that have been extracted
from the sea squirt and four synthetic compounds that have been prepared as
shown in Tables 1 and 2.
(22,23) The difference between each is defined by their R
groups, as shown in Tables 1 and 2. Et-743 is primarily extracted from the sea
squirt, Ecteinascidia turbinata.
(1-3)
Table 1. Ecteinascidin compounds  characterized  by  different  R  groups.  The
numbers shown in brackets represent the different structures for each compound
shown below.
(23) Molecular formula (M+H-H2O)
+ determined by HRFABMS.
Et- compounds Molecular
formula
Molecular ion
formula
R1 R2
Et-729 (60a) C38H41N3SO11 C38H39N3SO10 H OH
Et-722 (59) C39H40N4O9S C39H38N4SO8 H OH
Et-736 (59) C40H42N4O9S C40H40N4SO8 CH3 OH
Et-743 (60b) C39H43N3O11S C39H41N3SO10 CH3 OH
Et-745 (60c) C39H45N3SO11 C39H43N3SO10 CH3 H2
Et-759A (60d) C39H43N3O12S C39H41N3SO11 CH3 OH
Et-759B (60e) C39H43N3O12S C39H41N3SO11 CH3 OH
Et-770 (60f) C40H42N4SO10 C40H42N4SO10 CH3 CN
Et776 (60g) C40H45O11N3S C40H46O11N3S CH3 OMe
* Et-759A/B: S=oxide
(a) (b)
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Table 2. Ecteinascidin compounds  characterized  by  different  R  groups.  The
numbers shown in brackets represent the different structures for each compound
shown below.
(23) Molecular formula (M+H-H2O)
+ determined by HRFABMS.
Et compounds Molecular
formula
Molecular ion
formula
R1 R2 X Y
Et-583 (61c) C29H33N3SO8 C29H33N3SO8 H OH OCH3 OH
Et-597 (61c) C30H35N3SO8 C30H35N3SO8 CH3 OH OCH3 OH
Et-594 (62d) C30H30N2SO9 C30H30N2SO9 CH3 OH XY: O-CH2-O-
Et-596 (62d) C30H32N2SO9 C30H32N2SO9 CH3 OH OCH3 OH
Et-637 (63e1) C30H35N3SO9 C30H35N3SO9 CH3 OH XY: O-CH2-O-
Et-637-OBu (64e2) C34H40N2SO11 C34H40N2SO11 CH3 OH XY: O-CH2-O-CHAPTER 4
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(A1: R = H; A2: R = CH3) (B1 – XY(C-CH2-O); B2 – X = OCH3; Y - OH)
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Fig. 28. The structures for the ecteinascidin analogues in Table 8.
In  the  Et-743  standard  other  peaks  related  to  different ecteinascidin
compounds  were  identified  which could  arise  due  to  impurities  the  extraction
process. For example, in Fig. 9 the peak with m/z of 771 (M+H)
+ 60f, corresponds
to Et-770 (M
+: C40H42N4SO10, 770.2616 g/mol).CHAPTER 4
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Fig. 9. LC-MS of Et-743 standard showing impurities within sample.
4.3.1 Treated surfaces (Panacea, Fl., 2007)
The white film (Fig. 10) from samples collected every 48 hr over an 8 wk
period and extracted as mentioned in section 3.2.2. The MALDI-MS data from the
extracted sponges heated to 65°C for 72 hr is shown in Fig. 11. In Fig. 10, an m/z
of 760.859 (M+H)
+ is shown which could correspond to Et-759 A/B 60d/e with a
molecular  formula  of C39H41N3O11S, 759.2456 g/mol. Results  from  Panacea,
Florida showed  some  consistency  with  mass  spectral  peaks  collected  from
artificial surfaces placed in Lido Key, Florida (Fig. 12). Sea squirts collected from
Panacea (Fig. 13) also gave a peak with an m/z of 760 (M+H)
+ consistent with
the data from bacterial growth collected from the artificial surfaces and the Et-743
standard (Fig. 6 and 8).
(M+H)
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(C40H43N4O10S, 771.2694 g/mol)CHAPTER 4
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Fig. 10. MALDI-MS of the white film collected over a 12 ½ wk period from treated
surfaces placed at Panacea, Florida.
Data obtained from the extracts heated to 65°C and those not heated were
similar. The consistent correlations between the two data sets were helpful in
understanding the effects of temperature, if any, on the NP. Firstly, the stability of
the  compound  prevented  the  molecule  from  degrading  when  the  extract  was
heated to 65°C. Secondly, the structure does not have a bryophan ring, therefore
the stability of the compound is greater than bryostatin 1, whose bryophan ring
has many ester bonds that can be easily broken.
(24)
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Fig. 11. MALDI-MS of sponge extract heated to 65°C for 72 hr.
4.3.2 Treated surfaces (Lido Key, Fl., 2007)
After 1 wk, all treated surfaces appeared black in colour and after 1 wk at
RT a white film was visible on the surface of the water. Data analysis of the film
was taken after 6 wk of production (Fig. 12). As shown in Fig. 12, the peak with
an m/z of 760. 882 correspond to Et-759 A/B 60d/e with a molecular formula of
C39H41N3O11S, 759.2456 g/mol. This peak is also seen in samples collected from
Panacea, Florida [Fig. 10, 760.859 (M+H)
+] and is also present in the sea squirt
(original  source  of  the ecteinascidin  compounds)  as  shown  in  Fig. 13.  This
correlation strongly suggests the isolation of Et-759A/B from the ecosystem of the
marine organism.
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Fig. 12. MALDI-MS of the white film collected over a 4 wk period from surfaces
placed at Lido Key, Florida.
4.3.3 Treated surfaces (Panacea, Fl., 2008)
After 1 wk in the water, the treated surfaces were black in colour, reduced
in size and gave off a pungent smell, similar to the surfaces mentioned in section
4.3.1. The  dry  weight  of  crystals  collected  in  section 3.2.2 was 0.76 g.  Dry
weights of crystals collected from sponge extract heated and not heated were
25.41 g  and  22.57  g  respectively.  Analysis  of  all  the  extracts  showed  no
indication of any ecteinascidin compounds in any of the extracts collected.
4.3.4 Sea squirt extraction (Panacea, Fl., 2008)
Ecteinascidia turbinata, originally found in the West Indies, was shown to
contain Et-743, however other locations where the sea squirt is found have also
showed levels of the NP to be present.
(25) Previous work has shown that Et-743 is
ubiquitous in the ecosystem of the sea squirt, with traces of Et-743 having been
found in red mangroves in the Florida Keys.
(14) Sea squirt collected in June 2006
was analyzed by MALDI-MS. Results showed no significant correlation to any
(M+H)
+Et-759 A/B
(C39H42N3O11S, 760.2534 g/mol)CHAPTER 4
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ecteinascidin compounds.  Sea  squirt  extract collected in  June  2008  was  first
analyzed by LC-MS (Fig. 13) and then analyzed by HRMS as shown in Fig. 14
and 15.
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Fig. 13. Extract of Ecteinascidin turbinata collected from Panacea, in June 2008.
The sea squirt extract as shown in Fig. 13 shows two peaks at a m/z of
744  (M+H)
+ 97 and  760  (M+H)
+ 60d/e.  This  correlation  is  important  as  the
compound was initially isolated from the sea squirt collected in the West Indies.
Detection  levels  for  the m/z  at  744.3  (Fig. 13)  was  too  low  to  obtain  a mass
accuracy. However, the peak at m/z of 760.3 as mentioned is suggested to be Et-
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759A/B. The HRMS for Et-759A/B 60d/e as shown below is is (M
+: 759.2698
g/mol) however the correlation of the peak in Fig. 14 to Et-759 A/B has a HRMS
value of (M
+: 759.2456 g/mol), showing an error of 21 ppm, with the acceptable
error limit being 10 ppm.
Fig. 14. HRMS of sea squirt extract as mentioned in Fig. 13.
An LC-MS (uv-vis) comparison of the extract and the Et-743 standard (Fig.
15) shows an overlap of the peak at a retention time of 10 minutes. The presence
of  this  peak  in  both  samples  strongly  suggests  the  possibility  of  it  being  Et-
759A/B.  The other  peaks  in  the  standard,  other  than  Et-743 are mostly  likely
impurities of the compound collected during the isolation of the sea squirt. An
additional study was conducted by injecting equal volumes of both the Et-743
standard and the sea squirt extract as a mixture and analyzed by LC-MS shown
in Fig. 15. This mixture was then compared to Et-743 standard alone to show a
more distinct overlap of the peaks in support of the correlation of the peak to Et-
(M+H)
+Et-759  A/B
(C39H42N3O11S, 760.2534 g/mol)CHAPTER 4
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759A/B 60d/e. In The MALDI-MS it is natural for ions to occur in the form of
(M+H)
+, (M+2H)
+, (M-H)
+ and (M-2H)
+.
(26)
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Fig. 15 LC-MS of Et-743 standard and sea squirt extract injected as a mixture.
The green  peak represents  the  sea  squirt  extract  and the  red represents  the
standard.
4.3.5 Symbiont bacteria
There  is  no  conclusive proof  of  the  primary  source  responsible  for  the
production  of  Et-743,  however  evidence  suggests  that  the  marine  symbiont,
Candidatus endoecteinascidia frumentensis type 1 strain is a strong candidate as
it is the only bacterium found to be associated with the sea squirt found in both
the Mediterranean Sea and the West Indies.
(27,28) Direct sequencing of the gene
from  the  type  1  strain after  PCR  (polymerase  chain  reaction)  amplification  to
obtain DNA data, indicated the importance of the marine symbiont in the sea
squirt found in both locations.
(28)
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In an artificial environment, it is hard to grow bacteria. Less than 1% of
bacteria that have been identified are either impossible or very hard to grow.
(29)
The broths that were accessed from both locations suggest that marine bacteria
can grow in the laboratory however it is important to know the conditions at which
they thrive in order to aid in their continuous production. No attempts were made
to determine whether the chemical composition, developed for the broths, could
also be useful for the cultivation of the bacterium Candidatus endoecteinascidia
frumentensis. In agreement with the work of other groups, based on SEM images
collected  from  the  broths  placed  in  both  locations,  it  is  proposed  that  marine
bacteria are responsible for the production of Et-743 and this claim is supported
by the ubiquity of the compound in the locations mentioned. No conclusive data
on the specific bacterium has yet been obtained.
Data analysis of bacterial broths from the artificial surfaces placed in both
locations suggests that the chemical composition used to treat the surfaces has
met with some success in capturing marine bacteria. It is tentatively suggested
that  the  bacterium  captured  and  cultivated from  the  artificial  surfaces may  be
Candidatus endoecteinascidia  frumentensis.
(28) The  identification  of the  same
bacterial strains in the different stages of the sea squirt provides some correlation
between the presence of the bacteria in the ecteinascidin compounds and the
ecosystem of the marine organism.
(28)
Despite the fact that marine bacteria cultivated from the artificial surfaces
were not studied further to determine the specific bacterial strain, SEM images
from both broths at RT showed much evidence of bacteria in the white film, as
well as on the surfaces themselves. Most of the bacteria, Fig. 16, are bacilli (rod-
shaped) and are approximately two microns in size. However, some filamentous
(thread-like)  and  cocci  (spherical)  bacteria  are  also  seen,  which  are
approximately five microns  and one  microns  in  size,  respectively. BacterialCHAPTER 4
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filamentation  is  a  defect  in  the completion  of replication  and  is  observed  in
bacteria responding to various stresses. This may happen, for example, while
responding  to  extensive DNA  damage  through  the SOS  response  system.
Nutritional change may also cause bacterial filamentation. Shapes of bacteria in
SEM image bacillus (rod) coccus (round) filamentous (thread like).
(21,30)
Fig. 16.  SEM  image of  sponge  removed from  the  broth  at  RT  over  the 4  wk
assessment period. Sponges were located at Lido Key, Fl for 1 wk.
As shown in Fig. 16 most of the bacteria seen under the SEM are found in
clusters also  known  as  a  biofilm,  which is  a  structured  community  of
microorganisms enclosed within a polymeric matrix, found either adherent to a
living or inert surface.
(31) One type of biofilm which is suggested to be present in
the broths is familiar free floating, or planktonic biofilm, which form as single cells
that float or swim independently in some liquid medium.
(32) The SEM images of
the white film, could be biofilms of bacteria clustered together (Fig. 16), which
was  collected from the  surface  of  the  water  from  the  broths  assessed  in  this
study. Biofilms are formed by the attachment of free-floating microorganisms to a
surface,  or  liquid  surface. For  the  attachment  to  take  place,  colonies initially
adhere to the surface by weak, reversible van der Waals forces; those that areCHAPTER 4
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not immediately separated from the surface more permanently by pili, which are
cell  adhesion  structures.
(33) Micro-colonies  are  formed  when  bacteria form
complex  arrangements  of  cells  and  extracellular  components  while living  in
biofilms. This  is  done through  networks  of  channels which  allow  for  better
diffusion of nutrients.
(33)
In  relation  to  this  suggestion, MALDI-MS  and  LC-MS  data  from the
extracts  collected  from  the  artificial  surfaces  were  compared  to an Et-743
standard, with preliminary results suggesting correlations  to ecteinascidin
compounds. The  two  locations  used are  both  prominent  sites  where  the  sea
squirt  is  found.  Despite  the  geographical  assumption  and  seasonality  of  the
marine  organism, Ecteinascidia  turbinata  is  known  to  contain  levels  of  Et-743
only in sea squirts found in the Caribbean, Mediterranean and along the Southern
Coast of Florida.
4.4 Conclusion
The use  of artificial  surfaces  was  successful  in  capturing  the  marine
bacteria from both locations where the sea squirt is found. Preliminary results
showed the reliability of this technique for the production of other NPs, which
could be achieved by merely modifying the chemical composition necessary for
the cultivation of the specific bacterium of choice. Since the current method of
producing the drug is neither appropriate nor sustainable, this novel technique
could prove a promising cost effective and economical solution for the production
of Et-743. Despite the mass spectra showing the possible production of different
ecteinascidin compounds, low detection levels prevented further mass accuracy
determination to either support or disprove the identifications of Et-743 and its
analogues.CHAPTER 4
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5.1 Introduction
Alternative  sources  for NP from  the sea have been  an  increasingly
important investment over the past fifty years. However, many problems, such as
harvesting marine organisms, isolating drugs and tedious synthetic steps, all limit
the  production  of NPs  for the pharmaceutical  industry.  For  this  reason, other
alternative methods have since been attempted to overcome such problems. For
many  years,  diverse  groups (industrial, and agricultural, etc.) have  conducted
studies  on sediment from the environment, focusing on a  variety  of research
areas for diverse reasons.
(1,2,3,4) For  example,  a  recent  study  conducted  by
Giltrap et  al.,  focused  on  chemical  properties  of  marine  sediment at three
locations in Ireland. Results from this study, showed the concentration of metals
such as copper, lead, nickel, and zinc, etc., and organic contaminants such as
anthracene, dichlorodiphenyltrichloroethane,  naphthalene  and,  endosulphan  A,
etc., were  detected  in  the sediment; indicating  the  toxicity  levels  of  these
compounds in the water.
(5)
There are many different types of microorganisms found in sediment and
the  ocean with  beneficial  functions  such  as:  1) the capability to  produce
predominant populations of actinomycetes, which are believed to be responsible
for the production of marine natural products isolated from marine invertebrates;
2)  the  presence  of  nitrobacteria,  to  remove  nitrogen  ions  from  water;  3)  the
presence of non toxic gamma positive bacteria, ubiquitous in the environment,
with bioactive properties;  and  4)  the  presence  of lactobacteria  such  as
Lactobacillus  acidophilus,  used  to  disintegrate  lignin  and  cellulose,  which  are
generally difficult to decompose. The microorganisms mentioned above are a few
examples of the different types of marine organisms found in sediment and water,
each with a specific function.
(6)CHAPTER 5
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For this reason, there has been an increasing interest in studying sediment
for the isolation of NPs or marine bacteria with medicinal potential.
(7,8,9) A study
was conducted by Adesina et al., on the composition of soil bacteria in various
countries in Europe, to determine any in vitro activity. This showed that 18.3% of
the bacteria had in vitro properties as anti-fungal agents.
(8)
A recent study conducted by Cetecioğlu et al., showed that the diversity of
marine bacteria in sediment, collected from different locations in the Marmara
Sea,  is  significantly  based  on  the  depth at  which  the  sediment samples  were
collected and of chemicals such as sulfur, iron, and manganese. Results also
showed that the archaeal communities (52 archaeal species), were more diverse
than bacterial diversity (48 bacteria species) in all the sites that were used in the
study.
(10) Studies conducted by Manning et al., analyzing sediment samples from
the Gulf of México, have also shown high concentrations of different metals.
(11)
This data was also correlated to marine bryozoa in the area and marine bacteria
within Bugula neritina, in order to further understand the conditions the organism
resides in and the environment where it is collected.
With  many investigations  showing  the  ubiquity  of  marine  bacteria  in
sediment and correlation of the production of natural products to marine bacteria,
a new study was conducted primarily focusing on sediment in the ecosystem of
Bugula  neritina. This  was  designed to  test the  viability of isolating bryostatin
compounds from Bugula’s natural environment. Detailed analyses of sediment in
the Bugula locality  have  previously detected traces  of  various  bryostatin
compounds. This  prompted four separate studies, concentrating  on sediment
from Alligator Point, Florida. Successful extraction of compounds of interest from
the  sediment  would  support  the  idea that one ubiquitous  component  (e.g. a
marine bacterium) is responsible for the production of the NPs. Results from this
study would hopefully support and correlate to the findings discussed in previousCHAPTER 5
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chapters; designing  and  developing  artificial  surfaces in  combination with  the
mineral paste composition, to attract marine bacteria in the ecosystem of Bugula
neritina.
5.2 Experimental section
5.2.1 Sediment extraction (March 2006)
February 2
nd 2006, at 9.00 a.m., sediment (wet  mass 506.41  g) from
Alligator Point Marina, Florida was collected and stored at 4°C. On March 8
th
2006, at 9.00 a.m., the sediment was processed and extracted as described. A 1
L solution of 0.06 M HNO3 (Fisher Scientific) was slowly added to the sediment;
the  extract  was  stirred and left  to  settle.  After  3  hr  the  top  layer  (water)  was
discarded and replaced with an equal volume of water in the sediment container,
along with 50 mL of 0.1 M NaOH (Fisher Scientific). The sample was stirred and
left to settle. After 0.50 hr, the top layer (water) was discarded and a 1 L solution
of 0.005 M EDTA (ethylenediaminetetraacetic acid, Fisher Scientific) was added
to the sediment and stirred for 48 hr.
After 48  hr,  the  sediment  was  filtered then  placed under  vacuum  to
dryness (dry  weight of 203.49 g). To the dried sediment, 150 mL of pentanol
(Fisher Scientific) was added and at 2 day intervals replaced with another 150 mL
of pentanol until a total of 1.5 L of pentanol was used. The extract collected was
filtered,  using  a  5  µm  filter  paper, followed  by  a  0.2  µm  filter. The  pentanol
extracts from each interval were combined and the sediment in the container was
filtered and dried producing a dry weight of 141.16 g (Table 1).
A 1 L solution of 0.01 M EDTA adjusted to pH of 2-3 with 0.1 M HCL
(Fisher Scientific) was added to 1 L of the pentanol extract and stirred (Fig. 1).
After 48  hr,  the  foam  between  both  layers  was  removed and  placed under
vacuum to dryness. The pentanol layer was added to a 1 L solution of 2.30 g ofCHAPTER 5
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FeCl3  (Fisher  Scientific),  44  mL  of  0.1  M  NaOH, plus  an additional  0.55  g  of
NaOH pellets. This pentanol-iron (III) chloride solution was stirred for 48 hr. The
foam  layer  between  the  pentanol-iron  (III)  chloride  mixture  was  removed  by
centrifugation and dried.
Fig. 1. Mixtures of 1L of pentanol extract and 1L of EDTA solution resulted in the
formation of a foam suspension between both layers.
5.2.2 Sediment extraction (May 2006)
On May 9
th 2006, at 9.00 a.m., a wet weight of 1.17 kg of sediment was
used for a second extraction of sediment collected from Alligator Point, Florida.
This  sediment  was  removed  from  the  same  container  containing  sediment  as
used in section 5.2.1. Volumes of acid and base were used, as in section 5.2.1.
The total dry weight of the sediment before extracting into 1.5 L of pentanol was
369.63 g. The total mass of the dry sediment after extracting into pentanol was
271.74 g. A total of 0.66 g of white powder (foam) was collected, as in section
5.2.1, from this extraction process.
FoamCHAPTER 5
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5.2.3 Sediment extraction (June 2006)
On June 19
th 2006, at 9.00 a.m., a total of 5.5 L of pentanol was used to
extract approximately 9.611 kg of sediment collected from Alligator Point, Florida.
Three litres of 0.16 M HCL was periodically added to the sediment over a 5 day
period,  after  which  the  top  layer  (water)  was  removed  and  a  4 L  solution of
0.03125 M  NaOH  was  added  to  the  sediment. A total  of  2  L of  the  pentanol
extract-EDTA solution was used to isolate white powder (foam) for analysis. The
detailed amount of pentanol added and removed over the course of the extraction
procedure is given in Table 4. The purification procedures (sections 5.2.4) were
used for the remaining 2 L of extract collected.
5.2.4 Purification of sediment extract
Two techniques, detailed below, were used to determine the most suitable
purification method using the sediment extraction collected (section 5.2.3). The
primary goal was to isolate any compounds that could signify the presence of any
bryostatin compounds.
5.2.4.1 Column Chromatography
Silica (Fluka) was packed into a 10" column then flushed using 75 mL of
petroleum  ether  (Aldrich),  followed  by  20  mL  of  the  pentanol  extract. The
pentanol  extract was  then  flushed  with  petroleum  ether  (200  mL  of  40/60)
followed by 150 mL of methanol (Sigma Aldrich), which was used to separate the
different bands.  The  first fractions collected  were  the  excess petroleum and
remaining pentanol from the column. Finally the methanol fraction was collected,
which  was  evaporated  to  dryness.  The  second,  third  and  final  fractions  were
analyzed by LC-MS to determine the success of separating the components from
the pentanol extract.CHAPTER 5
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A second modified column was prepared using basic alumina oxide (BDH
Laboratory Supplies) instead of silica, and hexane (Sigma) instead of petroleum
ether. The 10" column was initially flushed with 150 mL of hexane, followed by 20
mL the pentanol extract. The pentanol extract on the column was then flushed
with  100  mL  of  hexane  followed  by  90  mL  of  methanol.  Each  fraction  was
collected separately and analyzed by LC-MS.
Attempts were made to prepare an iron bonded 8-hydroxyquinoline silica
column.
(12,13)In the process of preparing the 8-hydroxyquinoline silica column, the
compound did not bind to the silica to form a siderophore medium for the isolation
of the bryostatins. This method was not pursued further.
5.2.4.2 Ionic liquids
Ionic  liquids  are  liquids  comprised  of  99.9%  ions,  often  referred  to  as
molten salts such as ammonium, imidazolium, etc., with melting points less than
100
ºC. In a liquid-liquid extraction using ionic liquids, these solvents ideally bind
the compound of interest by changing its polarity.
(14)
5.2.4.2.1 1-Butyl-2,3-dimethylimidazolium hexafluorophosphate
Ionic  liquid,  1-butyl-2,3-dimethylimidazolium hexafluorophosphate 101
(Sigma Aldrich), was heated at 34
ºC to melt the salt. The molten salt (1 g) was
added to 5 mL of the pentanol extract, placed in a water bath (34
ºC) for 10 min
and sonicated for 30 min at 30°C. The top layer (pentanol extract) was removed
and 5 mL of deionized water was added to the ionic liquid (lower layer) and the
mixture was sonicated again for 15 min. The water was removed and 5 mL of
methanol was added to the ionic liquid. The sample was placed in a cold bath (-
86
ºC)  for  30  min.  The  crystal  formed  (dry  weight  0.0035 g)  was  removed  byCHAPTER 5
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suction filtration using a 5 µm filter paper. The methanol-ionic liquid mixture was
evaporated to dryness.
5.2.4.2.2 N, N-Dimethylethanolammonium propionate
The Ionic liquid method using N,N-dimethylethanolammonium propionate
100 (Bioniqs)  was  used with  a  few  adjustments.  The  ionic  liquid  (5  mL)  was
added to 5 mL of pentanol extract and sonicated for 30 min. The bottom layer
(ionic liquid) was placed in 5 mL of deionized water and sonicated again for 20
min. After sonication, the two layers collected were analyzed by LC-MS.
5.2.5 Sediment extraction (June 2008)
On June  15
th 2008,  at 12.00 p.m., two collections  of  sediment from
Alligator Point, Florida, were assessed. The first collection (600 g) was processed
using  experimental  procedures given  in section  5.2.1; however, anhydrous
methanol (Fisher Scientific) was substituted for pentanol and once the methanol
extracts  were  collected  and filtered,  the  sample  was  placed under  vacuum to
dryness.
The  second  collection was  a  raw  extraction,  collected  by  filtering  the
sediment  to  dryness  (dry  weight 600 g) and extracting  into 1 L anhydrous
methanol. Crystal extracts, collected from both samples, after solvent removal,
were analysed by LC-MS. Sediment collected was stored at 4°C until June 16
th
2008, at 9:00 a.m., when the processing of the sediment extracts for each batch
(600 g of dry sediment for processed and 600 g dry sediment for non processed)
began.CHAPTER 5
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5.3 Results and Discussion
All extractions collected were compared to a bryostatin 1 standard (Fig. 2)
donated by the NCI in Bethesda, Maryland. All the samples were analyzed as in
section 2.2. Bryostatin 1 has two absorbance values at 233 nm and 262 nm. The
absorbance value at 262 nm was used to analyze all extracts conducted in this
study,  as  well  as the absorbance  value  of  660  nm  for  any  indication  of
chlorophyll. An ultraviolet-visible spectroscopy (uv-vis) was used to determine the
absorbance values of the extracts at the wavelengths mentioned above.
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Fig. 2. Bryostatin 1 standard with Na
+ adduct (C47H68O17Na, 927.4349 g/mol).
Having  extracted  sediment from  Alligator  Point,  Fl. at  different  time
periods, findings strongly suggested that the bacterium producing the NP can be
(M+Na)
+ Bryostatin 1+Na
+
(C47H68O17Na, 927.4349 g/mol)
(M+Na)
+ Bryostatin 11+Na
+
(C39H58O15Na, 789.8724 g/mol)CHAPTER 5
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found in the Bugula environment all year round; with higher concentrations from
October  to  May.  However,  this  also  showed  that  different  compounds  were
detected at different times in the year. Concentrations in the collections made
during the summer season are not as pronounced. For example, in Fig. 11 there
does  not  seem  to  be any  peaks  that  could  be  correlated  to  any  bryostatin
compounds. One  reason  for  this  would  be  that  the  bacteria  are  temperature
dependent and thrive better in colder conditions; when the water is approximately
18-22°C. Based on this, it can be construed that the marine organism is merely
used as a host for the bacterium, which would explain the seasonal availability of
the drug. Another family of NPs, macrolactin a-f, has been isolated from sediment
collected in their host environment.
(15, 16)
The use of pentanol in the study, adversely affected further analyses due
to the high viscosity of the solvent. For this reason, several separating techniques
were evaluated to determine the best method of isolating the compounds from
the solvent; however, no method proved practical. The four sediment extractions
showed preliminary success in isolating compounds that could be correlated to
different bryostatin compounds but no conclusive evidence could be obtained due
to low detection levels
5.3.1 Sediment extraction (March 2006)
A total of 10 collections from the sediment sample were made. Table 1
shows the amount of pentanol collected from each extraction over a 3 wk period.
The white foam collected from the pentanol-EDTA layer had dry weight of 2.31 g
(Fig. 3). The  pentanol  extract  (Fig. 4)  shows  several  peaks  consistent  with
previous  results  from  the  artificial  mediums  and  surfaces  analyses.  Table  1
shows the amount of pentanol added and removed at every 2 day interval.CHAPTER 5
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Table 1. Pentanol collected and uv-vis data for each sample extraction.
Pentanol
(mL)
Amt retrieved (mL) Absorbance
(263 nm)
Absorbance
(660 nm)
150 36 1.525 0.0488
300 209 (inc. 36) 0.90 0.0308
450 330 ( inc. 209) 0.59 0.0490
600 503 (inc. 330) 0.46 0.0203
750 619.50 (inc. 503 0.52 0.0395
900 778 (inc. 619.50) 0.35 0.0382
1050 905.50 (inc. 778) 0.376 0.0315
1200 1020.50 (inc. 905.50) 0.280 0.0271
1350 1160.50 (inc. 1020.50) 0.164 0.0198
1500 1290 (inc. 1160.50) 0.110 0.010
From the 150 mL of pentanol that was added in the initial addition only 36
mL was collected. This may be due to the absorption of the pentanol into the
sediment. From the 1.5 L of pentanol used in the extraction process, only 1290
mL was collected from the sediment; an indication of how much was absorbed
into the sediment. Despite the fact that the sediment was filtered to dryness, to
remove any additional pentanol added during the extraction process, at least 210
mL was unaccounted for due to absorption into the sediment. Bryostatin 1 has a
characteristic uv-vis absorbance at 262 nm and chlorophyll at 660 nm. Table 1
shows the gradual decrease at both absorbance values, suggesting the removal
of components of interest at these wavelengths.
Table 2. Solubility test of white powder (0.02 g) in various solvents
Solvents Results
Hexane Clear solution – powder settled at the bottom of the test-tube.
Pentanol Solution turned cloudy – powder settled at the bottom of t-tube
Ethanol Solution turned cloudy – powder settled at the bottom
Water Solution turned cloudy – powder settled at the bottom
0.1M HCL Solution turned cloudy – powder suspended in the acid
0.1M NaOH Solution clear – powder completely dissolved in the baseCHAPTER 5
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Fig. 3. Image of the dried white foam collected from the pentanol-EDTA mixture.
In the pentanol-EDTA mixture, EDTA was used as a surfactant to remove
any  organic  compounds bound  to any  metals  present in  the pentanol  extract.
Surfactants reduce the surface tensions of systems resulting in the foam (white
powder) that was collected between both solvent layers (Fig. 1). A solubility test
of the white powder from the pentanol-EDTA mixture was also carried out using
various  solvents  (Table  2). The appearance  of  the  white  powder  in  hexane
suggests that it has properties consistent with polar compounds; since hexane is
non-polar,  polar  compounds are  insoluble  in  non-polar  solvents. In  water  and
ethanol, two polar solvents, the powder formed a suspension making the solvent
cloudy, suggesting polar properties; the non-polar components of the compound
settled at the bottom of the test-tube. The solubility of the white powder in 0.1 M
NaOH  indicated  that  components  of  the  powder  could  contain  a  mixture  of
carboxylic acids or compounds with carboxylic acid side chains.
The mass spectrum of the pentanol extract (Fig. 4) was compared to the
powder (Fig. 5). The method shows the successful isolation of the compounds of
interest. Further analysis to determine the mass accuracy for the peaks shown in
(Fig. 5) proved difficult as the powder contained too many ions.CHAPTER 5
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Pentanol Extract
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Fig, 4. Mass spectrum of the pentanol extract.
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+
(C49H75O17, 935.4998 g/mol)CHAPTER 5
172
8
7
9
.
2
1
8
8
6
5
.
2
1
1
895.199
8
5
1
.
2
1
8
9
3
3
.
1
6
1
9
1
7
.
2
3
1 709.104
0
1000
2000
3000
4000
5000
6000
700 750 800 850 900 950 1000 m/z
i
n
t
e
n
s
i
t
y
Fig. 5. Mass spectrum of the white powder in a positive ion test in TFA (trifluoroacetic acid).
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(C37H57O13, 709.3793 g/mol)CHAPTER 5
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Fig. 4 shows a peak at m/z 935 (M+2H)
+, and Fig. 5 shows two peaks at
m/z  709  (M+H)
+  and m/z  895  (M+H)
+,  all  of  which  could  suggestively  be
correlated to the bryostatin 12 95 (M
+: C49H72O17, 933.1032 g/mol), bryophan ring
98 (M
+: C37H56O13, 708.3715 g/mol) of the compound and bryostatin 4 94 (M
+:
C46H70O17, 894.4607 g/mol), respectively. In Fig. 4 the peak at m/z 935 can be
correlated  to  an  (M+2H)
+  as  this  can  generally  occurs  within  the  mass
spectrometer.
(17) This peak could therefore similarly correlate to bryostatin 12, as
mentioned above. This suggests that the white powder may also contain organic
compounds.
5.3.2 Sediment extraction (May 2006)
Data  relating  to  the 10  fractions  collected  over  a  3  wk  period (section
5.3.1) is shown in Table 3. The pentanol extraction collected was analyzed (Fig.
6) and compared to the results of the white powder (Fig. 7).
Table 3. Pentanol collected and uv-vis data for each sample extraction.
Pentanol (mL) Amt retrieved (mL) Absorbance at 262 nm
150 38 0.8452
300 148 (inc. 33) 0.6050
450 289 ( inc. 148) 0.4213
600 413 (inc. 289) 0.3713
750 558 (inc. 413) 0.2169
900 693 (inc. 558) 0.1941
1050 827 (inc. 693) 0.1386
1200 965.50 (inc. 827) 0.1259
1350 1088.50 (inc. 965.50) 0.0743
1500 1264 (inc. 1088.50) 0.0846CHAPTER 5
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Fig. 6. MALDI-MS of pentanol extract (section 5.2.2).
(M+Na)
+ Bryostatin 16/17+Na
+
(C42H62O14Na, 813.4032 g/mol)CHAPTER 5
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Fig. 7. LC-MS data of white powder from the sediment extraction (section 5.2.2).CHAPTER 5
176
The initial volume of pentanol seemed to be substantially absorbed by the
dry  sediment,  with  only  38  mL  of  pentanol  removed  after  adding  150  mL
originally. From the 1.5 L of pentanol added in total, 236 mL was absorbed into
the  sediment.  Despite  filtering  to  remove  any  additional  pentanol,  it  was  still
retained within the sediment. The uv-vis absorbance values at 262 nm showed a
decrease over time which suggests almost complete extraction from the sediment
over the 3 wk period.
The peak at m/z 813 (Fig. 6), could be correlated to bryostatin 16/17+Na
+
99 (C42H62O14Na, 813.4032  g/mol).  Aside  from  the  possible  bryostatin
compounds shown in the data, Fig. 7 shows the presence of a polymer in the LC-
MS with a consecutive loss of 44 g/mol. Polymers are large molecules consisting
of repeated units. The consecutive loss of a species with m/z 44 correlates to the
loss  of  a  repeating  unit  from  the  polymer. It  is  suggested  that  the  source  of
polymer  found  in  the  sediment  extraction  is  due  to  specific  bacteria  in  the
sediment degrading polymer sources in the ocean, as shown by Pan et al..
(18)
5.3.3 Sediment extraction (June 2006)
Table 4 shows the amount of pentanol that was added to the sediment,
how much was collected, how often the extractions were taken and the uv-vis
absorbance values suggestive of bryostatin 1. The white powder collected from
the pentanol-EDTA layer in this extraction had dry weight of 5.41 g. Analysis of
the pentanol extract (Fig. 8) shows two peaks at m/z 812.943 (M+Na)
+, m/z 903
(M+Na)
+ and m/z 787.486 (M+Na)
+ that  could  be  correlated  to  bryostatin
16/17+Na
+ 99 (C42H62O14Na,  813.4032  g/mol), bryostatin  8+Na
+ 94
(C45H68O17Na,  903.4348  g/mol) and  Bryostatin  11+Na
+-2H
+ 91 (C39H56O15Na,
787.5311 g/mol) respectively.CHAPTER 5
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Table 4. Data relating to the large scale pentanol extraction.
Date
added
Pentanol added
(mL)
Date
removed
Amt retrieved
(mL)
Uv-vis Abs.
260 nm
30/6/06 2000 4/7/06 1350 0.96906
4/7/06 1350 17/7/06 1125 1.5382
17/7/06 1125 6/8/06 1000 0.8198
6/8/06 1000 14/8/06 700 0.67905
A total of 5.5 L of pentanol was used in the extraction process and only
4.174 L was collected. A loss of 1.325 L is unaccounted for due to absorption into
the  sediment.  Despite  efforts  to  dry  the  sediment  to  remove  any  additional
pentanol, only what is accounted for was collected. The final extraction showed
an absorbance value of 0.6790 which did indicate that more pentanol could have
been  used  to  remove  any  additional  components  being  absorbed  during  the
extraction process. Bryostatin 1 has a distinctive uv-vis absorbance of 262 nm,
and these results demonstrate a possibility of isolation. Many organic compounds
have absorbance values similar to that of bryostatin; the absorbance value at 262
nm  was  merely  used as  a suggestive  tool  to  show  the  isolation  of  organic
compound(s) from the sediment.CHAPTER 5
178
8
8
7
.
8
8
5
9
0
3
728.576
954.483
870.908
812.943
1011.44
7
8
7
.
4
8
6
0
200
400
600
800
1000
1200
1400
1600
1800
2000
700 775 850 925 1000 1075 1150 m/z
i
n
te
n
s
i
ty
Fig. 8. MALDI-MS of sediment extract collected.
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5.3.3.1 Column chromatography
Results from both column chromatography techniques were unsuccessful
in isolating the compounds from the liquid extract due to the high viscosity of the
pentanol solvent. Despite the considerable volumes of solvent used to flush the
column, traces of pentanol were always present in the final fraction collection.
The  separating  methods  (basic alumina  oxide  and  silica  column
chromatography) were efficient at separating the chlorophyll from the pentanol
extract. However, due to the particulates and traces of pentanol still present in
the  final  collections, alternative techniques  were  sought  to establish  a better
method of extracting the compounds for further analysis.
The purpose of adding iron(III) chloride to the sediment extract collected
(section  5.2.1),  was  to test  whether  compounds  in  the  solvent  would  bind  to
iron(III), thus facilitating  a separation from the  solvent. Sodium hydroxide  was
used to make the solution basic, as a basic pH is needed for organic compounds
to  bind  Fe
3+.  Computational  data  to  support  this  postulation  is  described  in
chapter 7.
Data from previous work has shown that bryostatin 1 has the capability to
act as a siderophore by binding Fe
3+, forming a hexavalent complex. Taking into
account the ability for this to occur, this method was expected to be a viable
prospect  for  removing  any  possible  bryostatin  compounds  from the pentanol
solution.  The  extraction  of  doxorubicin  using  Fe
3+  loaded  8-hydroxyquinoline
bonded silica has been shown to be a suitable method for recovering the NP.
(19)
However, this promising method could not be used due to difficulties in preparing
the column; hence, the formation of a bryostatin-Fe
3+ complex, and subsequent
separation, was not possible.CHAPTER 5
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.5.3.3.2 Ionic liquids
Neither ionic liquid (Fig. 9 and 10) tested was shown to be suitable for the
isolation of the bryostatins from the pentanol extract. The crystals formed when
the ionic liquid-methanol mixture was cooled to -86
ºC were not analyzed, as high
pressure liquid chromatography (HPLC) data showed that the compounds were
still present when compared to the original pentanol solution.
Fig.  9.  The  structure of the  ionic  liquid N-N-dimethylethanolammonium
propionate.
(20)
Fig.  10. The  structure of the  ionic  liquid 1-butyl-2,3-dimethylimidazolium
hexafluorophosphate.
(20)
Ionic liquids are a relatively new method for substituting solvents with high
volatility and immiscibility in water, etc.. The purpose of using ionic liquids in this
work was  to modify  the charge  of  the  compounds  in  the  pentanol  extract,
resulting  in  a  change  in  polarity.  The  most  common  ionic  liquid,  1-butyl-2,3-
dimethylimidazolium hexafluorophosphate 101 (Fig. 10), was used in an attempt
to remove the organic compounds from the pentanol solution. The addition of
water would make the compound hydrophobic, hence, facilitating collection via
precipitation of the sample into the water layer, due to the change in polarity.
However, the hydrophobic effect of the initial ionic liquid used was unsuccessful.
An alternative ionic liquid was chosen that would be immiscible in water,
but not pentanol, and hence would allow easier removal of the bryostatin from theCHAPTER 5
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sample. Using ionic liquids for natural product extraction has been shown to be a
useful method when used for the extraction of artemisinin.
(21,22) The extraction of
artemisinin  using  hexane  was  compared  to  the  ionic  liquids bis
(methoxyethyl)ammonium bst (bistrifluoromethylsulfonamide) and
dimethylethanol ammonium octanoate. The ionic liquid method was shown to be
four times better than hexane for the extraction of artemisinin.
(21)
As  this technique  proved  successful for  artemisinin, its application  was
also  considered;  however,  the  results  realized  minor  flaws.  The  second  ionic
liquid was  also  unsuccessful  in  removing the  compounds  from  the  pentanol
extract. The major disadvantage of using ionic liquids is that each ionic liquid is
specific towards particular compounds, therefore determining the most suitable
salt for liquid-liquid isolation of compounds in the pentanol extract would be both
time  consuming  and  costly. In  effect,  the  most  suitable salt  could  only  be
determined if the supply company themselves conducted the study.
(20)
5.3.4 Sediment extraction (June 2008)
The ecosystem of Bugula contains high levels limestone, hence acid (0.1
M HCL) was added to the sediment to remove any excess calcium carbonate.
Previous study by Manning et al.,
(23) noted the presence of numerous carboxylic
acids in the ecosystem where Bugula is found; 0.1 M NaOH was therefore used
to  remove  any  carboxylic  acids  in  the  sediment. The  use  of  EDTA 102 for
processing  the samples was  to  remove  any  metals present.  EDTA  is  an  iron
chelating agent used to complex metals such as Ca
2+, Zn
2+ and Fe
3+ (Fig. 11).
(24)
The crystals collected from the raw extraction had a dry mass of 14.28 g and the
crystals collected from the processed extraction had a dry mass of 3.95 g. Mass
spectral results from both extractions are shown in Fig. 12.CHAPTER 5
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Fig. 11. The iron chelating agent EDTA bound to Fe
3+ion.
Despite the fact that the concentration of acid, used as a preparative step,
was not high, it is difficult to state whether the addition of acid did impact the
compound, e.g.  by subsequently reducing  the  percentage of  bryostatin
compounds extracted  from  the  sediment fractions.  It  is  impossible  to  fully
disprove that the addition of HNO3 had any effect on instigating the degradation
of bryostatin  compounds  present  in  the  samples. The  lack  of  any  bryostatin
compounds  in  either batches  of  sediment precludes  any  evidence  of  samples
being  compromised. However, comparison  of the  peaks  shown  in  the  uv-vis
chromatogram of both sediment samples (Fig. 12a) shows the overlap of three
different peaks at retention times of 15.7 to 16.3 min, 18.4 to 19.3 min and 19.4 to
19.9 min, respectively.
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Fig. 12a. LC-MS. chromatograms demonstrating correlation between processed
(blue) and raw (pink) sediment extracts from Alligator Point, Fl.
The overlapping peak at a RT of 15.7-16.3 min (Fig. 12a) shows the same
mass correlation (Fig. 12b), suggesting that the addition of acid for the processed
extraction of the sediment did not compromise that particular compound.CHAPTER 5
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Fig. 12b. Mass spectra of the peak at RT 15.7 to 16.3 min (Fig. 12a). The first
mass spectrum shows processed sediment extract the second mass spectrum
shows the raw sediment extract.
The overlap of the peak at a RT of 18.9 to 19.3 min implies the presence
of polymers in the sample, showing the consecutive loss of m/z of 44 g/mol. Both
mass spectral peaks (Fig. 12c) show a correlation in the polymers present. The
presence of polymers in the sediment can be expected due to the degradation of
polymer based material in the ocean by bacteria.
(19) However, a slight difference
between both spectra, due to the presence of other peaks that are only seen in
the processed sample versus the raw sediment extract (Fig. 12c). In Fig. 12c the
peaks  at m/z of 763,  786, 899 and  907  are  all observed  in  the  processed
sediment but not seen in the raw extraction process; however, none of the peaks
have any correlation to any of the bryostatins.CHAPTER 5
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Fig. 12c. Mass spectra of the peak at RT of 18.9 -19.3 min (Fig. 12a). The first
mass spectrum shows processed sediment extract the second mass spectrum
shows the raw sediment extract.
Fig. 12d points to the presence of polymers in both sediment samples,
showing  the  consecutive  loss  of m/z  of  44  g/mol.  Other  peaks  seen  in  both
samples  were  not  analyzed,  as  none  suggested  the  presence  of  bryostatin
compounds. The presence of these peaks in the processed sample and not the
raw  sediment  may be  due  to  the  formation  of  by-product  compounds.  This
suggests that the processing of the sediment may indeed have some impact on
other unidentified compounds in the sediment.
The broad peak, between 20-23 min in the uv-vis chromatogram in Fig.
12a,  suggests  the  presence  of  various  compounds  in  the  extracts  as  shown
below, including the peak at m/z of 803; while the processed sediment shows a
distinct peak with a m/z of 803 while the (Fig. 12e).CHAPTER 5
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Fig. 12d. Mass spectra for peak at RT of 19.4-19.9 min, (Fig. 12a). The first mass
spectrum shows processed sediment extract the second mass spectrum shows
the raw sediment extract.
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Fig. 126. Mass spectra for peak at RT of 20-23 min, (Fig. 12a). The first mass
spectrum shows processed sediment extract the second mass spectrum shows
the raw sediment extract.CHAPTER 5
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The results from all the extractions were optimistic in demonstrating that
sediment  found  in  the Bugula environment  could  be  an  alternative  source  for
obtaining bryostatin compounds economically in larger quantities. The extractions
collected, and white powder removed, from the extracts all showed peaks that
are  possible  correlations  to  several  bryostatin  compounds. The result  from
extraction of sediment for the isolation of other NPs has also been successful in
other published studies.  This  method  can  be optimised  to provide another
innovative and efficient means of obtaining marine natural products.
5.4 Conclusion
In conclusion it can be stated that:
1)  The  sediment  extractions  showed a strong  indication of  the  isolation  of
compounds that could be correlated to various bryostatin compounds. However,
due to low detection levels, no conclusive evidence could be obtained to support
or disprove the postulations.
2) Many of the mass spectral peaks identified in the sediment extraction were
also seen when artificial media and surfaces for the isolation of such compounds
from the ecosystem of Bugula neritina were investigated. (described in previous
chapters).
3) The consistency in data from all the analyses carried out strongly suggests
some  correlation  between  the  marine organisms  collected  in  the environment
where Bugula is found, and the marine bacterium believed to be responsible for
the production of the bryostatins.CHAPTER 5
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Naturally occurring esterification reactions and
hydrolysis of bryostatin 1CHAPTER 6
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6.1 Introduction
Since the isolation of bryostatin 1 9a in the 1980s, nineteen other bryostatin
compounds have been isolated from the marine organism, as shown by Manning et
al.,  believed  to  be  responsible  for  the  production  of  the  natural  product.
(1) Each
bryostatin compound differs by the different R1 and R2 groups as shown in (Fig. 1).
Many of the bryostatin compounds have been found in specific locations around the
world. For  example,  bryostatin  4  is  extracted  from Bugula  found  in  the  Gulf  of
Mexico, Gulf of California and Gulf of Sagami.
(2) Bryostatin 12 and 13 are extracted
from Bugula collected off the Eastern Pacific Ocean.
(3)
Fig.  1.  Bryostatin  1  (C47H68O17, 904.4451 g/mol)  has two variable groups  on the
bryophan ring, an acetate group at R1 and a C8 group at R2, which distinguishes the
twenty bryostatin compounds that have been isolated from Bugula.
Several studies by Haygood et al., have collected data suggesting the true
source of the NP to a specific bacterium found in the marine organism.
(4,5,6,7) This
group has also suggested that the different types of bryostatins are suggestively
related to the different types of bacterial genetics found in the marine organism.
(6)
From all the bryostatins that have been isolated, bryostatin 1 has shown to be the
most  efficient  medicinal  agent. Bryostatin  has  been in  over  thirty phase  I  and II
clinical  trials  for  various  cancers  such  as  kidney,  prostate,  breast  and  ovarian
cancer; and it is currently being looked at as a possible treatment for Alzheimer’sCHAPTER 6
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Disease.
(8) Bryostatin  1  has  shown much  efficacy  as  a  medicinal  agent in  vitro;
however, it fails slightly as an efficient agent in vivo.
In this study, it is suggested that the different bryostatin compounds can be
derived  by  naturally  occurring  esterification  reactions  rather  than  species
dependency  or  bacterial  genetics.  Many  carboxylic  acids,  such  as  octanoic  acid
(OA),  exist  in  the  marine  environment; for  this  reason, OA  was  selected.
(9) The
esterification or reverse ester reactions of bryostatin 1 (C47H68O17) and OA (C8H16O2)
as  reactants,  were  used  to  determine the  possible derivatization of  different
bryostatin  compounds.
(10) Results  suggested  that larger  compounds  ([bryo]-
(C8H16O2)x where x = 1, 2, 3 etc.) can form by reacting OA with bryostatin 1, under
various conditions.
Due to the different configurations possible as a result of the esterification and
reverse reactions, the hydrolysis of bryostatin 1 was also analysed. Different media
were  prepared to  determine  the  impact  of  hydrolysis  on  the  ester  bonds  on  the
bryophan ring. This determination is vital, first since bryostatin 1 is extracted from an
aquatic  environment  and  second  due  to  its  potential in  vivo.  This may help with
understanding and determining the  impacts  of bryostatin  1  when  administered in
vivo; and whether or not the concentration of bryostatin compounds would be initially
higher  than  currently  measured,  due  to  prolonged  exposure  to  water  after  the
organism is harvested.
(9)
6.2 Experimental
6.2.1 Hydrolysis of bryostatin 1
The hydrolysis of bryostatin 1 was conducted using uv-vis, to determine the
kinetics of the mixture, by measuring the absorbance values over a designated timeCHAPTER 6
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period. Bryostatin 1 (20 µg, B-7431, Boston, Massachusetts) was dissolved in 1.5
mL of pentanol (Fisher Scientific) and, over a two day period, the uv-vis absorption
was measured 3 times a day. On the third day, 50 µL of RO (reverse osmosis) water
was  added  to  the  pentanol  sample. Absorbance  values of the mixture  were
measured every 3 min for 4 hr, after which it was measured every 5 min for 1 hr,
then  every  10  min  for  another  hour.  After  a  total  of  6  hr,  the absorbance was
measured every 3-5 hr to ensure that the reaction had gone to completion.
6.2.2 Esterification of bryostatin 1
Bryostatin 1 (10 µg, B-7431, Boston, Massachusetts) stored at 4
°C was later
diluted in 20 mL anhydrous ethanol (A405-20, Fisher Scientific). Different samples
were  prepared  containing OA  (167261000, Acros  Organics  stock),  0.1 M  NaOH
(SS276-1, Fisher Scientific), 0.1 M HCL (SA45-1, Fisher Scientific), FeCl36H2O (I-88,
Fisher Scientific) and 18 Mohm RO water.
Six sets of samples containing bryostatin 1 were prepared, three containing
Fe
3+ and three without Fe
3+. Each set contained six samples: 1). octanoic acid and
bryostatin, 2). OA, a base and bryostatin 1, 3). OA, an acid and bryostatin 1, 4).
bryostatin 1 only, 5). a base and bryostatin 1, 6). an acid and bryostatin 1. With the
first batch of three sets; the first set was placed in the dark at ambient conditions
(22-24
°C) for 96 hr, the second set was placed under an ultraviolet lamp for 24 hr
and the third set of samples was placed in an oven at 37
°C for 48 hr. The same
conditions outlined above were used for the second batch of three sets of samples
containing iron(III) chloride respectively. All samples were stored at 4
°C after the
experiments were conducted, until they could be analyzed.CHAPTER 6
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Analysis  was achieved by  MALDI TOF-MS, University  of  Georgia  Mass
Spectrometry Facility (Athens, Georgia, USA). LC-MS data was obtained from the
US Dept. of Agriculture,  Tifton  (GA,  USA)  and  the  University  of  Sunderland
(Sunderland, UK).
6.3 Results and Discussion
6.3.1 Hydrolysis of bryostatin 1
After two day in pentanol, no change in the absorbance measurements was
observed. However,  after  50  µL  of  water  was  added,  the  characteristic  spectral
feature for bryostatin 1 (wavelength = 262 nm) started to decrease at a constant
rate, with most of the change occurring during the first couple of hours. This constant
decrease for the first hr is shown in (Fig. 2). This decomposition or reduction in the
concentration of the bryostatin 1 can be correlated to mass spectral data (Tables 1-
4). The concentration and absorbance intensity of the hydrolysis of bryostatin, is
expressed as a function of the initial concentration of bryostatin 1, over the three day
period, is shown (Fig. 2).
(10)
y = -1E-08x + 2E-05
R
2 = 0.9697
0.000023
0.0000231
0.0000232
0.0000233
0.0000234
0.0000235
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Fig. 2.  The uv-vis absorbance of bryostatin 1 showing its hydrolysis in aqueous
pentanol.CHAPTER 6
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The purpose of looking at these substitutions was to show that bryostatin 1
does  break  down  in  its  marine  environment  and/or  in  the  body,  resulting  in the
smaller, more stable bryophan structure, which could explain its performance in vivo.
The use  of  water as part  of  the  solvent,  as  shown  in  Table  1,  resulted  in  the
increased  degradation  of  the  compound  into  several  smaller  molecular  weight
species 927 g/mol as shown below. For example, the loss of the carboxylate group
(C8H15OO
.) results in the m/z of 787 (M+Na-2H)
+ 90 as shown in Table 1. The peak
at m/z  867  (M+H)
+ 104,  suggests  the  displacement  of  the  acetate  group  with  a
hydroxyl group at the R1 position and the hydrogenation of the carboxylate group at
the  R2  position  on  bryostatin  1. The  peak  at m/z  of  909 (M+Na-H2O)
+ 105, as
suggested is the loss of H2O from bryostatin 1+Na
+ adduct 9b (927-H2O, 909 g/mol).
Table 1. LC-MS analysis of bryostatin 1 standard, in different matrices, at a retention
time of 18.5 min. (± 0.1 min). The letters in superscript represent the structure that
correlates with the highlighted peaks as shown in Fig. 3 below.
Sample Solvent Additional
additives
Peaks observed
 m/z
Standard Methanol/formic acid - 851, 867
(b), 909
(d), 927
(c)
1 95% ethanol, 5%
water
- 581, 637, 659, 695, 727,
752, 768, 787
(a), 809, 865,
867
(b), 896, 927
(c), 978
2 32% ethanol, 68%
water
0.0075 M HCl 581, 637, 659, 729, 753,
867
(b), 909
(d), 949, 985
3 32% ethanol, 68%
water
0.1%  Instant
Ocean
581, 637, 659, 727, 787
(a),
867
(b), 909
(d), 927
(c), 978,
993
4 32% ethanol, 68%
water
0.1 % FeCl3 581, 637, 659, 727, 787
(a),
814, 829, 867
(b), 869,
909
(d), 927
(c), 957
(e), 978
5 32% ethanol, 67%
pentanol, 1% water
0.1% Instant
Ocean
581, 637, 659, 727, 779.
787
(a), 867
(b), 909
(d), 927
(c),
957
(e), 979
6 32% ethanol, 36%
water, 32% pentanol
Small piece of
Bugula neritina
(calcified
surface)
581, 637, 659, 727, 779.
787
(a), 867
(b), 909
(d), 927
(c),
957
(e), 979CHAPTER 6
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(a) (b)
O O
O O
HO
O
O
O
HO
OH
OH
O
O
O
O
Na+
H
H H
90
O O
O O
OH O
O
O
OH
HO
O
HO
O
OH
H
H H
H
O
O
104
Bryostatin 11+Na (M+Na-2H)
+ (M+H)
+
 (C39H56O15Na, 787.3511 g/mol) (C45H71O16, 867.4736 g/mol)
(c) (d)
O O
O O
O
O
O
O
O
OH
HO
O
HO
O
OH
H
H H
H
O
O
9b
Na+
O O
O O
O
O
O
O
O
HO
O
HO
O
OH
H
H H
H
O
O
105
Bryostatin 1 (M+Na)
+ Bryostatin 1 (M+Na-H2O)
+
(C47H68O17Na, 927.4348 g/mol) (C47H66O16Na, 909.4243 g/mol)
(e)
O O
O O
O
O
O
O
O
OH
HO
O
HO
O
OH
H
H H
H
O
O
106
Na+
(M+Na+2H)
+
 (C49H74O17Na, 957.4818 g/mol)
Fig. 3 a-e. The degradation of bryostatin 1 dissolved in different solvents correlating
with consistent peaks within each. The formation of larger molecular specie is also
shown in 3e.CHAPTER 6
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This impact on bryostatin 1 as a medicinal agent is emphasized considering
that the human body consists of approximately 70% water. The half-life of the drug in
the blood stream (0.81 hr) should be considered a critical measurement to better
understand its potential in the body.
(11,12) The decrease in absorbance appeared to
be proportional to the decrease in the concentration values of bryostatin 1.
An additional experiment, using bryostatin 1 standard exposed to water was
conducted under various conditions, (pH and ionic strength) and then analyzed by
LC-MS  (Table  1).  A  number  of smaller molecular  species  were  observed  in  all
samples, suggesting that ester bonds may be a key element in the hydrolysis, or
reverse esterification reactions, of bryostatin compounds when placed in water or
hydrophilic  solutions.  These  observations  could  be  significant  for  medicinal  and
harvesting/extraction applications.
(9,10) For example, bryostatins have been identified
in  marine  sediment  from  the Bugula  ecosystem  located  in  the Gulf  of  México,
suggesting  that  the  marine  bacteria  that  produce  the  bryostatins  reside  there.
(1)
Molecular species measured from this environment,
(1) show some consistency with
the m/z masses outlined in Table 2.
6.3.2 Esterification of bryostatin 1
The tables below summarize the peaks identified in all the samples that were
analyzed. Additional spectra of the samples analyzed can be found on the enclosed
DVD. Bryostatin  1  (Fig. 4)  has  numerous  ester  bonds,  making  the  compounds
unstable and prone to degradation or hydrolysis reactions. This makes the molecule
susceptible to cleavage under various conditions and the possibility of esterification
reactions to occur.
(13) For most samples (Tables 2-5), the mass spectral featuresCHAPTER 6
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show both a degradation of bryostatin 1 to smaller species (m/z < 927) and the
formation of larger species.
O O
O O
O
O
O
O
O
OH
HO
O
HO
O
OH
H
H H
H
O
O
9b
Na+
Fig. 4. Bryostatin 1 + Na
+ adduct 9b (C47H68O17Na, 927.4348 g/mol). R represents
the possible sites where substitution reactions may occur in the presence of OA,
forming ester bonds.
Fig. 5.  Multiple  substitution  of  the  bryophan  ring  by  OA  produces  much  larger
molecular species, for example (Table 2, 3(a, b) (M+Na)
+ C69H112NaO19, 1267.7690
g/mol) 107.
R3
R2
R4 R1
R6
R5CHAPTER 6
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Table 2.  Values (m/z) for bryostatin without Fe
3+. The numbers in brackets after the masses (e.g. 789(1)) correspond to peak
numbers in Tables 4 and 5.
(10)Examples of suggestive structures for the highlighted peaks shown in below.
Condition Sample
(a)
(m/z)
Sample
(b)
(m/z)
Sample
(c)
(m/z)
Sample
(d)
(m/z)
Sample
(e)
(m/z)
Sample
(f)
(m/z)
1. No light 789(2),
809(4),
847(7),
978(16),
998(18),
1196(24),
1267(26)
789(2),
809(4),
927(11),
978(16),
998(18),
1267(26)
789(2),
796 (3),
909(10),
972 (15)
998(18),
1007(19),
1057(21),
1196 (24)
789(2),
809(4),
998(17),
1057(21)
789(2),
809(4),
847(7),
978(16),
1057(21),
1267(26)
909 (10),
927(11),
956(14),
1007(19),
1026(20)
2. UV
lamp
789(2),
796 (3),
809(4),
927(11),
998(18),
1007(19),
1196(24)
789(2),
796 (3),
874 (8)
932(12),
1007(19)
789(2),
927(11),
978(16),
1007(19),
1026(20),
1233(25),
1141(23)
789(2),
809(4),
824(5),
847(7),
889(9),
927(11),
978(16),
998(18)
789(2),
809 (4),
927(11),
998(18),
1267 (26)
727(1)
847(7),
889(9),
927(11),
1141(23)
3. 37
°C 789(2),
809(4),
847(7),
927(11),
998(18),
1057(21),
1267(26)
789(2),
847(7),
982(17),
998(18),
1196(24),
1267(26)
796 (3),
809 (4),
889(9)
927(11),
789(2),
847(7),
927(11),
978(16),
998(18),
1007(19)
1057 (21)
789(2),
874 (8)
932(12),
978(16),
1141(23)
789(2),
825(5),
927(11),
978(16),
1026(20),
1057(21)
(a)5.52*10
-7M bryostatin 1, 1.53*10
-4M OA.
(b)5.52*10
-7M bryostatin 1, 2.38*10
-3M HCl, 1.5*10
-4M OA.
(c)5.52*10
-7M bryostatin 1, 2.38*10
-3M NaOH, 1.5*10
-4M OA.
(d) 5.52*10
-7M of bryostatin 1.
(e)5.52*10
-7M bryostatin and 2.44*10
-3M  HCl.
(f) 5.52*10
-7M bryostatin and 2.44*10
-3M  NaOH.
Bryostatin 11 + Na
+
(C39H58O15Na, 789.3667 g/mol)
O O
O O
HO
O
O
O
HO
OH
O
O
O
H H
H
O
HO
O
108
 (M+H)
+
(C41H61O16, 809.3954 g/mol)
O O
O O
HO
O
O
O
HO
OH
O
O
H H
H
OH
O
O
109
(M+2H)
+
(C41H64O15, 796.4239 g/mol)CHAPTER 6
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The degradation of bryostatin 1 (Fig. 6a) can result from reverse esterification
by: (6b)  the  hydrolysis  of  the carboxylate  at  the  R2  position  (C7H15COO-R2 →
C7H15COO
- + HO-R2), (6c) the reduction of the hyxdroxyl group at the R2 position
(ROH→ R-H), or by (6d) dehydration (R1-CHOH-C-R2 → R1-CH=CH-R2 + H2O).
(10)
The synthesis to form larger species (m/z > 927) can result from (e) esterification (R-
OH + OA → R –OOC-C7H15) or (f) hydration reactions (R1-CH=CH-R2 + H2O →  R1-
CHOHCH-R2).
(10) Even though the exact structures cannot be determined from the
mass  spectral  data  alone,  many  empirical formulae shown  in  the  tables  above
strongly  suggest  the  possible  existence  of  some  of  the  products.  Figures 7-9
represent  the  mass  spectra  for  different  samples,  respectively,  as  mentioned  in
Tables 2 and 3.
Spectral characteristics  showing  the  gain  or  loss  of 2H shown  in Fig. 7
illustrates a single peak at 927, but also shows other spectral features. The (M-2H)
+
is a frequent attribute resulting in the  m/z 787 (789-2H
+) 90. In the MALDI-MS, it is
normal for radical to be formed giving different masses [(M+H)
+, (M+2H)
+, (M-H)
+
and (M-2H)
+] as shown in the samples above.
(14) The MALDI-MS process itself had
no significant effect on the formation of peaks obtained from samples. If this had
been the case bryostatin 1 standard would have the identical spectral peak profile to
that of the samples analysed.
Results  from  previous  experiments  show  the  degradation  of  bryostatin
consistent with data collected from this study, illustrating that bryostatin 1 can react
with  its  own  components  under  various  conditions.
(7)  It  is  also  suggested  that
reverse esterification can result in the loss of a C8 group from one bryophan ring,
which  can esterify  a  position  on  another  bryophan  ring  to  form  a  larger  species
(Table 4), with the possibility of other large species, as shown in Tables 2-5.CHAPTER 6
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(a)
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.
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HO HO
OH
OH
O
O
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H
H H
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(c)
O O
O O
HO
O
O
O
HO
OH
OH
O
O
O
O
Na+
H
H H
90
(d)
O O
O O
O
O
O
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O
HO
O
HO
O
OH
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H H
H
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(e)
(f)
O
O O
O O
O O
O
O
OH
HO
O
HO
O
OH
H
H H
H
Na+
O
112
O
OH
Fig. 6.  (a) Bryostatin  1+Na
+  adduct 9b (C47H68O17Na,  927.4348  g/mol). (b) the
hydrolysis of the carboxylate group from bryostatin 1 gives a structure with a mass of
(C39H58NaO16, 805.3617 g/mol) 110. (c) the reduction of the hyxdroxyl group gives a
structure of  (C39H58NaO15, 789.3667 g/mol) 90. (d) The  dehydration of bryostatin
1+Na
+ adduct (C47H68O17Na, 927.4348 g/mol) resulting in the formation of m/z 909
(M+Na)
+ 105 (C47H66O16Na, 909.4243 g/mol), (e) The OA molecule can undergo an
ester reaction with one of the bryophan’s R-OH groups resulting in a m/z of 1057
111 (C55H86NaO18, 1057.5706 g/mol), (f) The hydration of bryostatin 1+Na
+ resulting
in the formation of m/z at 945 112 (C47H70NaO18, 945.4454 g/mol).
(10)CHAPTER 6
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Fig. 7. The reaction involving sample 3d shows the parent ion (m/z of 927) as well as a number of degradation products (<927) and
larger structures that can be attributed to the attachment of OA attaching (Fig. 4). The structures shown are suggestive correlations
to some of the peaks in the above mass spec.
(M+Na)
+Bryostatin 7+Na
+
(C41H60O17Na, 847.3722 g/mol)
(M+Na)
+Bryostatin 1+Na
+
(C47H68O17Na, 927.4348 g/mol)
(M+Na)
+Bryostatin 11+Na
+
(C39H58O15Na, 789.3668 g/mol)
(M+H)
+Bryostatin 11
(C39H59O15, 767.3848 g/mol)
 (M+Na)
+
(C55H86O18Na, 1057.5706 g/mol)
O
O O
O O
O
O
O
O
HO
O
HO
O
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H
H H
H
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O
115
(M+Na+H)
+
(C53H83O16Na, 998.5573 g/mol)CHAPTER 6
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Fig. 8. Mass spectrum of sample 1d (Table 2).
(M+Na)
+ Bryostatin 11+Na
+
(C39H58O15Na, 789.3668 g/mol)
(M+Na+H)
+
(C53H83O16Na, 998.5573 g/mol)
O O
O O
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O
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HO
OH
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O
O
O
O
H
H H
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(M+H)
+ Bryostatin 11
(C39H59O15, 767.3848 g/mol)
 (M+H)
+
(C41H61O16, 809.3954 g/mol)CHAPTER 6
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Fig. 9. Mass spectrum of sample 2e (Table 2).
(M+Na+H)
+
(C53H83O16Na, 998.5573 g/mol)
(M+H)
+ Bryostatin 11
(C39H59O15, 767.3848 g/mol)
(M+Na)
+ Bryostatin 11+Na
+
(C39H58O15Na, 789.3668 g/mol)
O O
O O
O
O
O
O
HO
O
O
O
OH
H
H H
H
O
O
O
O
O
Na+
O
107
(M+Na)
+
(C69H112O19Na, 1267.7690 g/mol)
 (M+H)
+
(C41H61O16, 809.3954 g/mol)CHAPTER 6
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Table 3. Values (m/z) for bryostatin samples that contain Fe
3+. The numbers in brackets after the masses (e.g. 789(1)) correspond
to empirical formulae in Tables 4 and 5.
(10)Examples of suggestive structures for the highlighted peaks are shown below.
Condition Sample
(g)
(m/z)
Sample
(h)
(m/z)
Sample
(i)
(m/z)
Sample
(j)
(m/z)
Sample
(k)
(m/z)
Sample
(l)
(m/z)
4. No light 789(2),
809(4),
978(16),
998(18),
1057(21)
789(2),
809(4),
824(5),
998(18),
1102(22),
1389(34)
789(2),
809(4),
978(16),
998(18),
1114(29)
789(2),
809(4),
927(11),
998(18),
1026(20)
789(2),
809(4),
889(9),
1026(20),
1102(22),
1227(32)
789(2),
809(4),
909 (10),
927(11),
941(13),
1141(30)
5. UV 789(2),
809(4),
927(11),
998(18),
1026(20)
789(2),
809(4),
956(14),
998(18),
1026(20)
789(2),
809(4),
941(13)
789(2),
809(4),
941(13),
998(18),
1007(19),
1114(29)
789(2),
927(11),
962(27),
1057(21)
789(2),
847(7),
927(11),
1057(21),
1302(33)
6. 37
°C 789(2),
809(4),
956(14),
962(27),
998(18)
789(2),
809(4),
847(7),
941(13),
998(18)
831(6), 789(2),
809(4),
927(11),
985(28),
1141(23,
30)
1205(31)
909 (6),
927 (11),
1102(22),
1205(31)
789(2),
809(4),
927(11).
998(18),
1196 (24)
(g) 5.52*10
-7M bryostatin 1, 1.50*10
-4M OA, 1.19*10
-4M Fe
3+ solutions.
(h) 5.52*10
-7M bryostatin 1, 1.46*10
-4M OA, 1.17*10
-4M Fe
3+, 2.32*10
-4M HCl.
(i) 5.52*10
-7M bryostatin 1, 1.46*10
-4M OA, 1.17*10
-4M Fe
3+, 2.32*10
-4M NaOH.
(j)5.52*10
-7M bryostatin 1, 1.22*10
-4M Fe
3+.
(k) 5.52*10
-7M bryostatin 1, 1.19*10
-4M Fe
3+, 2.38*10
-3M HCl.
(l) 5.52*10
-7M bryostatin 1, 1.19*10
-4M Fe
3+, 2.38*10
-3M NaOH
(M+Na)
+ (C45H70O16Na, 889.4556 g/mol)
(M+Na)
+C61H98O18Na, 1141.6645 g/mol)CHAPTER 6
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Table 4. Values (m/z) corresponding to bonds formed with octanoic acid and at the various sites as showed in Fig. 4. The peak
numbers below correlate with each (m/z) value that can be identified in different experimental conditions as shown in Tables 2 and
3.
(10) Structures for the highlighted peaks are as shown.
Peak R1 R2 R3 R4 R5 m/z Emp Formula
1 OH H 727 C37H56O14
2 C2H3O2 H 789 C39H58NaO15
3 CH3COO H 796 C41H64O15
4 CH3COO OH 809 C41H61O16
5 C2H3O2 C2H3O2 825 C41H61O17
6 CH3COO OH 831 C41H60NaO16
7 C2H3O2 C2H3O2 847 C41H60NaO17
8 OH C8H15O2 874 C45H70NaO15
9 OH C8H15O2 889 C45H70NaO16
10 C2H3O2 C8H11O2 909 C47H72O16
11 C2H3O2 C8H11O2 927 C47H68NaO17
12 C2H3O2 C8H15O2 932 C47H73NaO17
13 C3H5O2 C8H11O2 941 C48H70NaO17
14 C8H15O2 C8H13O2 956 C53H80O15
15 H C8H15O2 C8H11O2 973 C53H80O16
16 C8H15O2 C8H15O2 978 C53H84O16
17 C2H3O2 C8H11O2 C3H5O2 983 C50H72O18
18 H C8H15O2 C8H15O2 998 C53H83NaO16
19 C8H15O2 C8H11O2 1007 C53H76NaO17
20 OH C8H12O3 C8H15O2 1027 C53H82NaO18
21 C2H3O2 C8H15O2 C8H15O 1057 C55H86NaO18
22 H C8H15O2 C8H15O C8H15O 1102 C61H98O17
23 OH C8H15O2 C8H15O2 C8H15O 1141 C61H98NaO18
24 C8H13O2 C2H3O2 C8H15O C8H15O2 1196 C63H98NaO20
25 H C8H11O2 C8H15O C8H15O C8H15O2 1233 C69H110NaO17
26 C8H15O2 C8H15O2 C8H15O C8H15O 1267 C69H112Na019
In the above table, R1-R5 corresponds to the possible sites for esterification or transesterification as shown in Fig. 4.
Bryostatin 1 + Na
+
(C47H68O17Na, 927.4348 g/mol)
O
O O
O O
O
O
O
O
HO
O
HO
O
OH
H
H H
H
O
O
118
(M+H)
+(C53H81O16, 973.5519 g/mol)
 (M+Na)
+
(C41H60O16Na, 831.3773g/mol)CHAPTER 6
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Table 5. The (m/z) values below correspond to the Fe
3+ complex and substitution reactions at the various binding sites shown in
Fig. 10. The peak numbers below correlate with each (m/z) which can be identified in different experimental conditions, shown in
Tables 2 and 3.
(10) The structures below are suggestive based on the highlighted peaks.
Peak R1 R2 R3 R4 R5 m/z Empirical Form
27 C2H3O2 C8H15O2 962 C47H70FeO17
28 C2H3O2 C8H15O2 985 C47H70FeNaO17
29 C2H3O2 OH C8H15O2 C8H15O2 1114 C55H85FeNaO18
30 H C8H11O2 C8H15O2 C8H15O2 1141 C61H96FeO16
31 H C8H11O2 C8H15O2 C8H15O2 1206 C63H99FeNaO17
32 C8H15O2 C8H15O2 C8H15O2 C8H15O2 1227 C69H110O18
33 C8H15O2 C8H15O2 C8H15O2 C8H15O2 1302 C69H112FeO19
34 C8H15O2 C8H11O2 C8H15O2 C8H15O2 C8H15O2 1389 C77H122NaO20
(M+Fe)
+
(C47H70FeO17, 962.3956 g/mol)
O
O
Fe3+
O O
O O
HO
O
O
O
O
O
O
O
H H
H
H
O
O
O
Na+
122
(M+Fe+Na+H)
+
 (C47H70FeNaO17, 985.3854 g/mol)
O
O
Fe3+
O O
O O
O
O
O
O
HO
OH
O
O
H H
H
O
O
O
O
O
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(M+Fe)
+
(C69H114FeO19, 1302.7298 g/mol)
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Fig. 10.    A  possible  structure  for  bryostatin 1  binding  to  Na
+  and  Fe
3+
[(M+Fe+Na+H)
+, 125 C47H66FeNaO17, 981.3541 g/mol]. The R groups represent the
possible binding sites where substitution reactions may occur.
Bryostatin is believed to have properties similar to siderophores produced by
marine  bacteria.  Siderophores  are  iron  chelating  compounds  released  by  marine
organisms to bind metals such as Fe
3+ that cannot be ingested by the organism
itself.
(15,16)  These  organisms  can  then  ingest  the  complex  by  an  active  transport
mechanism. For this reason, iron(III) chloride was added to the samples (Table 3
and 5) to show the possible binding of Fe
3+ to bryostatin 1 under various conditions.
Samples  4g, 6j  and  6l  (37°C)  from Table 3,  all  show  the formation  of  molecular
species at a m/z of 1390, 1350 and 1374, respectively, suggesting the binding of
Fe
3+, along with some esterification reactions of C8 on bryostatin 1. Also, experiment
6i  (Table  3)  showed  that  bryostatin  1  and  its  various  products  were  no  longer
present.
(10) In the presence of Fe
3+ (Fig. 11 and 12) the bryostatins are not seen,
thus questioning whether or not the production of an insoluble complex was formed
and/or the complex had bonded to the reaction vessel. A recent study showing the
polymerization of a DOPA derivative using Fe
3+ resulted in the formation of a strong
hydrophobic molecule.
(17)
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Fig. 11. Mass spectrum of sample 5h.
(M+Na)
+Bryostatin 11+Na
+
(C39H58O15Na, 789.3668 g/mol)
(M+Na+H)
+
(C53H83O16Na, 998.5573 g/mol)
O
O O
O O
O
O
O
O
O
O
O
O
H
H H
H
O
O
Na+
O
Fe3+
O
126
(M+Fe+Na)
+
(C63H98O17FeNa, 1205.6045 g/mol)
O
O O
O O
HO
O
O
O
HO
OH
O
O
H H
H
H
O
O
O
127
(M+2H)
+
(C53H86O16 978.5910 g/mol)
 (M+H)
+
(C41H61O16, 809.3954 g/mol)CHAPTER 6
210
1207.517
7
5
0
.
6
5
7
6
7
.
6
9
3
789.62
808.627
998.575
0
100
200
300
400
500
600
700
800
900
1000
700 800 900 1000 1100 1200 1300 m/z
i
n
t
e
n
s
i
t
y
Fig. 12. Mass spectra of sample 6g (Table 3).
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Fig. 13. Top left mass spectra shows bryostatin 1 at an m/z of 927. Top right mass
spectra shows bryostatin 1-FeOH+Na
+ at a m/z 997. Bottom left shows the mass
spectra of bryostatin 1+Fe
3+ at an m/z of 955. Bottom right shows the mass spectra
of bryostatin 1+Na
++Fe
3+ at an m/z 985.
Previous work has shown that when Fe
3+ was reacted with bryostatin 1, a
[Bryostatin  1+Fe
3++Na
+-2H]
+  complex  formed  (Fig.  13).
(18) While  bryostatin  1  has
performed  well  in  cell  line  tests,  it  has  faltered  as  a  sole  agent  in  some  human
trials.
(8) Understanding its medicinal activity in vivo is currently ongoing. Based on
this  study,  several  suggestions  can  be  made  with  regards  to  its reported poor
efficacy in some clinical trials. Firstly, bryostatin 1 has a low solubility in the body
because it readily diffuses into tissues, cells, etc., before reaching the target site.
Secondly,  its  ester  bonds  are  reactive resulting  in  degradation  of  the  compound
once  it  has  entered  the patient.  Binding  bryostatin  1  to  Fe
3+  may  solve  these
problems.  This  is  based  on  the  notion  that  binding  to  a Fe
3+  ion  will  produce  a
charged  complex  which  should  increase  its  water  solubility. The  bryostatin-Fe
complex should be more rigid and subsequently more stable than the uncomplexed
bryostatin,  making  it  a  more effective  medicinal  agent.
(18,19)  This  proposition  was
subsequently explored and is further discussed in chapters 7 and 8.CHAPTER 6
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Although there  is no  conclusive  evidence  to  support  this  idea,  or  others
mentioned, it is feasible to propose that the formation of C8 esters at the various
hydroxylated sites is possible. Results from each of the conditions investigated were
compared  to  bryostatin  1  standard  to  determine  the  possibility  of  esterification
reactions forming. Comparing both data, it is clearly seen that many of the peaks,
shown in the samples, are not present in the bryostatin standard. This suggests, 1)
that the proposed reactions can occur where hydroxyl groups are located, forming
species  with m/z > 927  2) the molecule  can  also  undergo  degradation,  forming
species with m/z < 927 and 3) the production of different bryostatin compounds is
not only a result of bacterial genetics or production of gene fragments, but can be a
mixture  of  both due to the effects  of the environmental conditions  where Bugula
neritina is located.
(10)
The  microbial  symbiont bacterium, Candidatus  Endobugula  sertula,  is
believed to produce these compounds by gene fragments that combine together to
give  the  complete  structure  of  these  bryostatin  compounds.
(4-7) Based  on  the
expression  of  this  symbiont  bacterium,  it  is  suggested  that  the  production  of
bryostatin compounds through the biosynthesis of these gene fragments show some
consistency  between Bugula  collected  off  the  coast  of  California  with Bugula
collected from North Carolina. However, there is no conclusive evidence supporting
the  proposition  of  gene  fragments  being  responsible  for  the  production  of  these
compounds.  Results  from  this  study  clearly  demonstrate  the  ability  for  these
compounds can be formed under different environmental conditions as well.
(20) The
stability assessment  of  bryostatin  under  various  conditions  was  also  reported  by
Zhao et al..
(21)CHAPTER 6
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Computational studies of the bryostatins and MNPs as
potential siderophoresCHAPTER 7
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7.1 Introduction
Siderophores are iron chelating compounds, secreted by microorganisms
to  bind  iron,  as  many marine  organism  cannot easily ingest  iron.
(1,2) In  the
presence of Fe
3+, these compounds form a stable hexavalent structure and, due
to their complex binding, increase the aqueous solubility of hydrated iron. In the
body/cells, Fe
3+ is then taken up by an active transport mechanism, as a source
of  nutrient  for  the  marine  organism.
(3) Many  studies  have  been  conducted  to
further understand the mechanism of these compounds and to isolate, synthesize
and produce artificial siderophores that could be utilised for industrial and medical
usage.
(4,5,6,7,8) Research has shown that many pathogenic bacteria can produce
more than one siderophore compound, as some target iron better than others.
The production of different siderophores has shown to be environment specific
(pH, temperature and availability of carbon sources where bacteria strains are
present).
(9) For  example, E. coli  K12  produces  enterobactin; however, one
particular strain, E. coli Nissle 1917, produces four different siderophores.
(9)In the
1970s O'Brien et  al.,  identified  five  compounds  produced  by E.  coli  and
Aerobacter  aerogenes  under  iron  deficiency  conditions.
(10) In  cell  culturing
studies, Konopka et al., showed  that  serum  albumin  inhibits  the  transfer  of
iron(III) from protein receptors to enterobactin; however, serum albumin had no
effect on the iron intake by aerobactin.
(11)
It is important to note that many siderophores are not solely iron specific
and bind to other metals forming metal-ligand complexes.
(12,13) For example, a
recent study was carried out to determine the physical role of methanobactin, a
novel chromopeptide known to be Cu
2+ ion binding, produced by Methylosinus
trichosporium  OB3b,  when  bound to a  range  of metal  ions. Despite
methanobactin’s capability as a copper-siderophore, in the absence of copper,
methanobactin showed binding to other metals, such as Ag
1+, Au
3+, Co
2+, Cd
2+,CHAPTER 7
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and Fe
3+but did not bind Ba
2+, Cr
6+, La
3+, Mg
2+, or Sr
2+. However, in the presence
of copper, only two metals, Ag
1+ and Au
3+, were able to displace copper to bind
methanobactin.
(12)
Few computational studies have been conducted using siderophores. One
example is the computational study using semi-empirical methods to determine
the interaction of gallium with different siderophores. Results from the interaction
of gallium and enterobactin showed no strain on the conformation of the complex.
However,  short  chain  groups  attached  to  the  siderophore  can  lead  to
deformations when binding the metal.
(14)
Based on the importance and new roles of siderophores, a computational
investigation of several MNPs, bryostatin analogues, siderophores and the twenty
bryostatin compounds, was carried out to determine any similarity in geometric
changes when bound to Fe
3+.
(15) The geometric parameters of all the molecules
were calculated using the semi-empirical (PM3) method, to determine the bond
distances, bond angles and dipole moments of each molecule as a monocation
(1
+), dication (2
+), and neutral species, which can be found on the attached DVD.
The  semi  empirical  method  works  by  making  large  assumptions  and
ignoring non-valence electrons. There are many advantages and disadvantages
to the method. The advantages of using this method are, 1) it reduces the time
taken for  calculations  to  be  determined;  2) it  is an excellent  method to  study
organic molecules; 3) it provides relatively  good results in the calculation and
visualization of molecular orbitals; and, 4) it addresses the issue of limitations on
calculations of large molecules. The disadvantages are, 1) it does not allow the
effect of some inclusion of electron correlation in the method; 2) it is unable to
compute all the molecules of the complex using this method; 3) inaccuracy in the
calculations  occur  for parameterized  molecules, such  as  nitrogen;  and, 4)
inaccuracies  of  calculations  with hydrogen  bonding,  transition  states,  orCHAPTER 7
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molecules  with  non-parameterized  atoms.
(16) Consideing  the  advantages  and
disadvantages stated for the use of this semi-empirical method, the advantages
outweighed  the  disadvantages. Particularly  pertinent  for  this  study  is  that, the
semi-empirical method ignores the nonvalence electrons in molecules, and this
may have restricted the data collected, as the non valence electrons on iron(III)
are ignored during the calculations process.
The rationale for  this  study was  to  determine  the  probability  of  MNPs
acting as possible siderophores in nature, thereby explaining their presence in
marine organisms, aside from any defence mechanistic role that some may have.
Many of the compounds used in this study are currently in preclinical or clinical
studies  for  the  treatment  of  various  diseases.  This  computational  study could
therefore assist in the prospect of using these compounds as medicinal agents,
and thereby enhance the efficacy of NPs as sole agents.
Based  on  results from  the  first  computational investigation,  a  second
computational  study  was  conducted.  This focused  on the  correlation  of  the
seventeen oxygen atoms in bryostatin 1 that could bind Fe
3+, forming a fer-mer
complex. The formation of these hexavalent complexes did not limit the bonding
between the oxygens on bryostatin and Fe
3+.
(17) The significance of this was to
establish the different configurations that this complex could adopt, when using
the available oxygens on bryostatin 1 to bind Fe
3+. The stability and probability, of
the best configurations generated by this study, was determined by using the
geometric parameters from the initial computational study. Based on the different
configurations that were calculated, the most stable conformations could then be
proposed based on the most probable Fe-O bond distances for each structure.
This could then establish that the configurations are not specific, despite their
stability,  and  could  therefore  rearrange  in  the  body  to  form the  most  suitable
configurations. This information would further support the feasibility of the fer-merCHAPTER 7
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complex to exist and act as a more effective medicinal agent than bryostatin 1
alone.
7.2 Experimental
The Spartan ’04 cluster version software was used to build the molecules
and calculate  the  geometric  parameters  (dipole  moment,  bond  angle,  bond
length, surface area and volume). The calculations were carried out using SUN
Micro-system cluster hardware.
In the first computational study, the molecules with a Fe
3+-ligand complex
(L = bryostatins, bryostatin analogues, marine natural products and siderophores)
were  evaluated,  having  a neutral,  monocation or dication  charge.  In  order  to
calculate the geometries for all of the molecules, each molecule was developed
using the six shortest Fe-O bonds. Despite the fact that bryostatin 1 only has
three main oxygens used for binding (Fig. 1, O
8, O
12 and O
15),
(18,19) three other
oxygen atoms were selected, based on the shortest Fe-O bond lengths, forming
a stable hexavalent complex. The three main oxygen atoms remained constant
for all the bryostatin compounds.
This  second  computational  study was  conducted to  determine  the
importance of the different possible configurations formed, when binding Fe
3+ to
bryostatin 1 (Fig. 1). Using the seventeen oxygens available, one hundred and
seventy  three  structures  were developed using  six  oxygen  atoms  per
configuration to form the hexavalent structure. Siderophores typically have a Fe-
O bond length of approximately 2 Å, which was used as an approximate control
for the iron complexes built in both studies. For this reason, twenty-two of the
most probable configurations from this batch were selected based on the average
bond distances of the Fe-O bonds, ranging between 2.0-2.5 Å.CHAPTER 7
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Fig. 1. Bryostatin 1 9a with oxygens numbered to correlate to bonds formed with
Fe
3+ as listed in Tables 9-11.
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Fig. 2. The high polarity bryostatin 1-Fe
3+ bonded to 5 bryostatin oxygens and
one OH ion.
From this batch, five of the most probable structures were recalculated by
replacing one Fe-O bond with an OH ion, then secondly replacing it with a H2O
molecule as shown in Fig. 2. The Spartan ’04 cluster version software was used
to build the molecules and calculate the geometric parameters (dipole moment,
bond angle, bond length, surface area and volume), using the same SUN Micro-
system  cluster  hardware. From  the  data  collected,  the D/V (dipole  moment
versus surface volume) ratio were calculated and compared to the D/V ratios of
polar and non-polar solvents, to suggestively show the structures that appear to
be polar and beneficial as medicinal agents. The accuracy of both computational
studies was verified by comparing the computational values of the terricolin-Fe
3+CHAPTER 7
221
complex using the geometric parameters in this study calculated by the semi-
empirical method to the experimental data of its crystal structure.
(20)
7.3 Results and Discussion
7.3.1 First computational study
Only  recently  has  the  significance of  understanding  siderophores (their
beneficial role as agents, structural complexity and chemical properties) and their
potential  to  exist,  grown in  interest.  For  instance, Aquachelin  D 128 and
Marinobactin E 129 are  two  marine  siderophores  extracted  from  the  marine
organisms Halomonas  aquamarina  and Marinobacter  spp.,  respectively;  both
contain non-polar and polar structural components (Figs. 3 and 4).
(21,22)
Fig. 3. Aquachelin D (C46H80N10O20, 1092.5545 g/mol) extracted from the marine
organism Halomonas aquamarina.
Fig. 4. Marinobactin E (C44H77N9O16, 987.5483 g/mol) extracted from the marine
organism Marinobacter spp..
In  the  absence  of  iron,  these amphiphilic  siderophores  form  micelles,
which are clusters of molecules attached together by their fatty-acid tails. In theCHAPTER 7
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presence of Fe
3+, these siderophores transform their structures from micelles to
vesicles; which are spherical shells, hollow in the middle, with many siderophore
molecules  bound  together  (Fig.  5).
(22)  It  is  suggested  that  this  formation  from
micelles  to  vesicles  may  be  due  to  specific  adaptations  of  the  compounds  in
aqueous environments. Their dipole activity is responsible for the siderophores
forming a micelle structure when placed in water.
Fig. 5.  Illustrates  the  configuration  of  siderophores  before  (micelle)  and  after
binding Fe
3+ (vesicle). The above illustration applies to marinobactin.
(22)
For  compounds  such  as  aquachelin  and  marinobactin,  the  number  of
oxygens present is enough to make the structure flexible for the binding of up to
two Fe
3+ ions by Fe-O bonds, as shown in Table 4. All of the molecules surveyed
in this study were bound to Fe
3+ forming an octahedral geometry, with results
showing bond distances averaging from 2.05-2.20 angstroms (Å). This suggests
a strong correlation between the bond distances to that of known siderophores,
based on the complexes that were formulated. Therefore, this strongly supports
the claim, as stated, for the bryostatin’s, and other natural products’, ability to act
as possible siderophores.
In a marine environment, bacteria may reside primarily in the sediment, in
other  materials  (minerals,  organisms, etc.),  on  surfaces,  or  within  the  waterCHAPTER 7
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supply.
(23)  Previous  work,  however,  has  shown that bryostatins are present  in
marine sediment containing large amounts of non-polar molecular species and
dipole  moments  closer  to  that  of  desferrioxamine  B,  which  is  produced  by  a
terrestrial  bacterium.
(24)  The  magnitude  of  the  species  dipole  moment  may
provide an insight into its host ecosystem.
The semi-empirical  method  used  in  this  computational  study  was  also
applied  to  terricolin 130 (Fig. 6),  a  metal-ligand  complex  isolated  from  the
mycelium  of  the  fungus, Tolypocladium  terricola.
(20)  The  computational  data
obtained  for  terricolin, see  Tables 1  and 2,  calculated using  the  SUN-Micro
system hardware was then compared to the crystal structure of the metal-ligand,
to  determine  the  correlation  of  this  siderophore  to  the  proposed  metal-ligand
complexes exhibited by the natural products.
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Fig. 6. Terricolin (C45H60N3O9Fe, 842.3673 g/mol), a siderophore isolated from
the fungus Tolypocladium terricola. The numbers on the oxygens and nitrogens
correlate to the bonds in Tables 1 and 2.CHAPTER 7
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Table 1. Comparison of bond angles obtained from the computational study, to
the crystal structure of terricolin.
(20)
Terricolin-Fe
3+ complex (FeL3)
Bond angles (degrees) of computational data VS crystal structure
Bonds Angles (Computed) Angles (Crystal struc) Difference
O2-Fe-O1 82.03 78.60 3.43
O3-Fe-O1 92.90 93.10 -0.20
O3-Fe-O2 95.70 103.70 -8.00
O4-Fe-O1 165.66 162.60 3.06
O4-Fe-O2 85.41 89.20 -3.79
O4-Fe-O3 81.46 77.80 3.66
O5-Fe-O1 97.76 84.90 12.86
O5-Fe-O2 170.58 158.10 12.48
O5-Fe-O3 93.72 91.30 2.42
O5-Fe-O4 95.76 109.80 -14.04
O6-Fe-O1 92.67 104.80 -12.13
O6-Fe-O2 88.44 90.70 -2.26
O6-Fe-O3 173.48 159.00 14.48
O6-Fe-O4 93.88 87.40 6.48
O6-Fe-O5 82.16 79.70 2.46
N1-O1-Fe 109.22 112.00 -2.78
C2-N1-O1 113.13 115.70 -2.57
C2-O2-Fe 108.82 116.60 -7.78
O2-C2-N1 109.18 116.90 -7.72
N2-O3-Fe 107.90 112.30 -4.40
C2-N2-O3 112.53 115.90 -3.37
C2-O4-Fe 110.27 118.50 -8.23
O4-C2-N2 110.55 115.10 -4.55
N3-O5-Fe 109.27 110.10 -0.83
C3-N3-O5 112.87 117.10 -4.23
C3-O6-Fe 108.61 117.80 -9.19
O6-C3-N3 109.48 114.80 -5.32CHAPTER 7
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Table 2. Comparison of bond distances of the crystal structure of terricolin,
(20) to
the data obtained from the computational study.
Terricolin- Fe
3+ complex (FeL3)
Bond distances (Angstroms) of computational data VS crystal structure
Bonds Bond length (Computed) Bond length (crystal struc) Difference
Fe-O1 2.039 2.012 0.027
Fe-O2 2.068 1.982 0.086
Fe-O3 2.029 2.019 0.010
Fe-O4 2.076 1.974 0.102
Fe-O5 2.030 2.038 -0.008
Fe-O6 2.072 1.977 0.095
N1-O1 1.388 1.371 0.017
N1-C1 1.457 1.361 0.096
C1-O2 1.428 1.268 0.160
N2-O3 1.385 1.380 0.005
N2-C2 1.460 1.361 0.099
C2-O4 1.435 1.276 0.159
N3-O5 1.387 1.382 0.005
N3-C3 1.458 1.400 0.058
C3-O6 1.429 1.277 0.152
The bond distances and angles of terricolin, calculated using the semi-
empirical  method,  were  compared  to  the  experimental  data  of  the  crystal
structure.  This  comparison  served  as  a  reference  to  test  the  semi-empirical
method  used  and  to  correlate  the  complexes  formed  to  that  of  known
siderophores. Comparing the difference in bond distances and angles collected
from the computational method and the experimental data, little significance was
evident. The minor differences noted could be attributed to experimental error;
nonetheless,  the  differences  are  not  sufficiently  significant  to  fully  negate  the
semi-empirical method used for this study.CHAPTER 7
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7.3.1.1 Bryostatin analogues
The dipole moments for some of the bryostatin analogues increased (7b
54, 7c 54, 8 55) while others (7a 54, 7d 54) showed a decrease in the dipole
moment (Table 3).  This  is  important  as  it  shows  the probability  of  these
analogues to act as efficient medicinal agents. The higher the dipole moment the
more polar the complex will be, thus increasing the likelihood of them to exist and
act as more efficient agents (Table 7 and 8). The analogues used above have
been tested to determine their efficacy as medicinal agents alone; from all five
analogues, 7b, 7c and 8 showed substantial efficacy, with 7c showing the most
potency.
(18)
As shown below, the dipole moments for these analogues did increase
when bound to Fe
3+. The surface volumes for the complexes bound to Fe
3+ were
similar in value to the analogues alone; however 7b did show a slight increase in
surface volume, (Table 3). This consistency in surface volume is most likely due
to the structure of the compounds, especially with regard to the Fe-O bonds that
were  used;  all  consistent  for  each  analogue.  Therefore,  the  consistency  in
surface volume and change in surface area for the analogues is most likely due
to the change in conformation of the complex when bound to Fe
3+.
The decrease in surface area for all the analogues respectively, can be
correlated to the contraction of the compounds when bound to Fe
3+. The increase
in dipole moment is also important as the D/V ratio (dipole moment to surface
volume) suggestively determines the ability for the analogues to act as polar or
non-polar  complexes.  For  example, 7c  has  a  D/V  =  0.0578  (Table 7)  with
references to the D/V ratios of polar and non-polar solvents listed in Table 8.CHAPTER 7
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Table 3. Bryostatin analogues with and without Fe
3+.
(18)
Bryostatin
analogues
Molecular
Formula Molecular
weight (amu)
Dipole
moment
(debye)
Surface
Volume (Å³)
Surface
Area (Å²)
Average Fe–O
bond distances
(Å)
7a C33H50O13 654.750 22.384 650.271 667.229
7a w/ Fe
3+ C33H48FeO13 708.581 21.618 651.103 653.024 2.103 ± 0.150
7b C39H62O12 722.913 37.712 752.619 778.372
7b w/ Fe
3+ C39H62FeO13 794.759 42.928 769.307 775.394 2.098 ± 0.129
7c C39H62O13 738.912 40.386 760.137 787.003
7c w/ Fe
3+ C39H60FeO13 792.743 43.945 760.913 772.613 2.105 ± 0.151
7d C41H64O14 780.949 45.796 801.845 827.404
7d w/ Fe
3+ C41H64FeO14 836.796 33.838 805.185 811.364 2.128 ± 0.164
8 C43H70O13 795.020 28.528 833.764 862.859
8 w/ Fe
3+ C43H68FeO13 848.851 43.634 832.937 840.560 2.118 ± 0.183
Structures for the bryostatin analogues 54-56 (7a-d and 8) see chapter 1, section 1.2.3.CHAPTER 7
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7.3.1.2 Bryostatin structures
The geometric shift, shown for bryostatin 1 9a in Fig. 7(a-c), demonstrates
the decrease of surface area from bryostatin 1 alone to bryostatin 1 when bound
to two Fe
3+ ions. The slight increase in distance when bound to one Fe
3+ ion
could be due to the Fe-O bonds used, as well as the configuration that is formed
when  the  Fe-O  bonds  are made. This  geometric  shift  is  similar to  that  of  the
amphiphilic siderophore acinetoferrin, which has shown to significantly alter its
geometry when bound to Fe
3+, resulting in a change in surface area. Changing
the Fe-O bonds used to from the hexavalent complex can result in the formation
of different configurations; further discussed in section 7.4.2.
The  decrease  in  surface  area,  however, (Fig. 7c),  could  facilitate  an
increase  in the  ability  of  the complex  to  penetrate a  cell membrane.
(25,26) The
computational  data  also  showed  that  molecules  bound  to  a  second  Fe
3+  ion
resulted in even shorter, and subsequently stronger, Fe-O bonds than those only
bound to one Fe
3+ ion, (Table 4).
(a)
14.6 ÅCHAPTER 7
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(b)
(c)
Fig. 7. (a) bryostatin 1 alone (14.6 Å), almost 1.5 nm in diameter; (b) bryostatin 1
bound  to  one  Fe
3+ results  in  a  complex  almost  1.7  nm in  diameter;  and (c)
bryostatin 1 bound to two Fe
3+ results in a complex that is less than 1 nm in
diameter.
The difference in area and length that the binding of iron(III) can have on a
compound are shown in Fig. 7. Bryostatin 1 alone has a surface area of 931.642
Å
2 and a surface volume of 911.037 Å
3. When bound to iron(III) the surface area
of the compound decreased to 929.195 Å
2 and the surface volume increased to
915.911 Å
3.
The  dipole  moment  for  all  the  bryostatin  compounds  increased  when
bound to Fe
3+. This increase in dipole moment is important as it coincides with
the surface volume of the complexes; suggesting a change in chemical properties
of the complexes to act as more polar or non-polar agents (Table 7 and 8). The
8.9 Å
16.9 ÅCHAPTER 7
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ratio of the average dipole moment for all twenty bryostatins (DBryo) was less
than the average dipole moment for the neutral bryostatins Fe (DFe-Bryo), where
the  (DFe-Bryo  /  DBryo)  =  1.15  D. This increase  in  the  dipole  moment,  thus
suggests the likelihood of the complex to exist as a polar agent. All the bryostatin
compounds  showed  similar  correlations  in  the  geometric  parameters;  with  an
equal or slight increase in surface volume and a decrease in surface area (Table
4).  The  twenty  bryostatin  compounds  have  a  macrolid  structure  and  each
compound differs by the R1 and R2 groups (Fig. 1), which can explain the limited
change in surface volume for the bryostatins.
 For example, bryostatin 1 and bryostatin 2 both have a C8 chain at the R2
position. However, the carboxylic oxygens played no role in the Fe-O bonds used
to  form  the  complex,  hence,  there  is  no  significant  difference  in  the  surface
volume of either complex. The surface area for bryostatin 2 was much smaller
than that of bryostatin 1, most likely due to the replacement of the acetate group
of the R1 side chain of bryostatin 1, by a hydroxyl group to form bryostatin 2.
Another example is bryostatin 8, which has the same substituent groups at the R1
and R2 position. There was no significant change in the surface volume, however,
the surface area decreased significantly when bound to Fe
3+ (Table 2), which is
mostly likely due to the contraction of the molecule.
Most of the other bryostatin compounds all showed a decrease of > 10 Å
2
in the surface area when the compounds were bound to Fe
3+. This may be due to
the difference in the side chains of these bryostatin compounds. The loss of the
carboxyl group at the R2 position for many of the bryostatin compounds results in
a decrease in surface area; when bound to Fe
3+, the surface area for the complex
decreases even more. This is most likely due to the change in geometry and
conformation of the complex. However, it is important to note, that this change inCHAPTER 7
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surface area is also dependent on the Fe-O bonds used; since the compound
contracts, when bound to Fe
3+, with an accompanying decrease in surface area.
The similarity in surface volume of the complexes with and without Fe
3+
may be due to bryostatins macrolid structure. When the compounds are bound to
Fe
3+, the iron fills the empty space of the compound contracting the molecule,
thereby decreasing the surface area of the complex. Due to the Fe-O bonds that
were  used,  this  contraction did  not  affect  the  surface  volume of  the  complex;
however other configurations may alter these paramters, see section 7.4.2. The
Fe-O  bonds  used  were  based  on  the  shortest  Fe-O  bonds  formed  when  the
compounds were bound to Fe
3+. These results are supported by the concept that
shorter bond distances form more compact and stable complexes, and are more
likely to exist in nature, as previous studies have reported in relation to other iron
chelating compounds.
(26)CHAPTER 7
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Table 4. Bryostatin compounds 1-20 with and without Fe
3+. Bryostatin 1, like the siderophores in section 7.3.1.3, has a non-polar (C8 group)
and a polar (macrolid) structure. The table below shows the geometric parameters calculated for the twenty bryostatin compounds, before
and after binding to Fe
3+.
(15)
Structures
Molecular
formula
Molecular
Weight
(amu)
Dipole
moment
(debeye)
Surface
volume
(Å
3)
Surface
area (Å
2)
Average Fe-O
bond distance
(Å)
bryostatin 1 C47H68O17 905.044 48.783 911.037 931.642
bryostatin 1 w/ Fe
3+ C47H66FeO17 958.875 33.462 915.911 929.195 2.104 ± 0.126
bryostatin 2 C45H66O16 863.007 7.308 872.999 894.609
bryostatin 2 w/ Fe
3+ C45H64FeO15 916.838 29.018 874.760 884.751 2.228 ± 0.253
bryostatin 3 C46H64O17 889.001 6.695 882.278 896.238
bryostatin 3 w/ Fe
3+ C46H62FeO17 942.832 26.223 884.834 886.467 2.103 ± 0.121
bryostatin 4 C46H70O17 895.049 6.406 905.960 931.165
bryostatin 4 w/ Fe
3+ C46H68FeO17 948.880 28.314 905.268 913.769 2.091 ± 0.116
bryostatin 5 C44H66O17 866.995 2.858 868.260 888.089
bryostatin 5 w/ Fe
3+ C44H64FeO17 920.826 37.042 870.207 886.959 2.308 ± 0.330
bryostatin 6 C43H64O17 852.968 7.376 849.498 864.338
bryostatin 6 w/ Fe
3+ C43H62O17 906.799 10.482 848.734 836.732 2.150 ± 0.145
bryostatin 7 C41H60O17 824.914 2.940 813.728 831.086
bryostatin 7 w/ Fe
3+ C41H58FeO17 878.745 16.529 815.666 829.861 2.308 ± 0.329
bryostatin 8 C45H68O17 881.022 5.833 888.581 918.609
bryostatin 8 w/ Fe
3+ C45H66FeO17 934.853 19.234 887.740 895.777 2.112 ± 0.140
bryostatin 9 C43H64O17 852.968 5.779 851.952 878.810
bryostatin 9 w/ Fe
3+ C43H62FeO17 906.799 14.423 851.380 863.050 2.122 ± 0.120
bryostatin 10 C42H64O15 808.959 6.199 818.793 839.137
bryostatin 10 w/ Fe
3+ C42H62FeO15 862.790 19.541 820.713 827.993 2.242 ± 0.254CHAPTER 7
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bryostatin 11 C39H58O15 766.878 3.983 763.779 776.237
bryostatin 11 w/ Fe
3+ C39H56FeO15 820.709 9.228 764.304 764.038 2.098 ± 0.144
bryostatin 12 C49H72O17 933.098 9.272 950.561 971.828
bryostatin 12 w/ Fe
3+ C49H70FeO17 986.929 17.735 948.788 950.136 2.165 ± 0.146
bryostatin 13 C41H62O15 794.932 6.795 800.947 820.674
bryostatin 13 w/ Fe
3+ C41H60FeO15 848.763 20.835 801.459 805.079 2.103 ± 0.152
bryostatin 14 C42H64O16 824.958 4.692 828.135 849.643
bryostatin 14 w/ Fe
3+ C42H62FeO16 878.789 35.495 828.174 833.572 2.108 ± 0.120
bryostatin 15 C47H68O18 921.043 8.989 921.670 947.743
bryostatin 15 w/ Fe
3+ C46H66FeO18 974.874 20.382 921.703 932.350 2.139 ± 0.156
bryostatin 16 C42H62O14 790.944 2.488 808.941 834.381
bryostatin 16 w/ Fe
3+ C42H62FeO14 846.791 14.318 813.351 811.701 2.231 ± 0.207
bryostatin 17 C42H62O14 790.944 2.488 808.941 834.381
bryostatin 17 w/ Fe
3+ C42H62FeO14 846.791 14.318 813.352 811.707 2.231 ± 0.207
bryostatin 18 C42H64O15 808.959 8.490 820.235 841.554
bryostatin 18 w/ Fe
3+ C42H62FeO15 862.790 31.415 820.137 826.972 2.139 ± 0.148
bryostatin 19 C45H66O17 879.006 5.757 873.359 887.340
bryostatin 19 w/ Fe
3+ C45H64FeO17 932.837 30.848 874.076 871.615 2.103 ± 0.121
bryostatin 20 C41H60O15 792.916 4.179 788.651 802.506
bryostatin 20 w/ Fe
3+ C41H58FeO15 846.747 30.653 790.164 787.589 2.122 ± 0.128CHAPTER 7
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The three main oxygens (Fig. 1, O
8, O
12 and O
15)
(18)used to form the Fe-O
bonds, have been identified as the three oxygens on bryostatin 1, which are used
for pkc binding. In this study, these three main oxygens were used to propose
that if bryostatin binds Fe
3+ using these oxygens it can; 1) protect the bonds from
hydrolysis or degradation, see Fig. 8, and 2) aid in the delivery of the complex at
the active site in the body more efficiently.
The contraction of the complex is important, as it protects many of the
groups  that  are  susceptible  to  hydrolysis  (Fig. 8). Fig.  8a  shows some  of  the
oxygens that appear to be less hindered, therefore more susceptible to hydrolysis
in comparison to the bryostatin-Fe
3+ complex (Fig. 8b), which has protected the
bonds. The binding of bryostatin complex to two Fe
3+ ions showed a significant
decrease in the overall diameter of the complex. This clearly shows the change in
geometric shift and contraction of the molecule when bound to iron to form a
more rigid complex.
(a) (b)
Fig. 8. (a) The space filling model of bryostatin 1 alone; (b) The space filling
model  of  bryostatin  1  bound  to  Fe
3+. In  both illustrations  arrows  point  to  the
carbon (white), two oxygens (red) and the hydrogen (yellow/green) can also be
identified in the calculated structure.
The  primary  interest here  was  to  analyze  the  Fe-O  bond  distances;
however,  Fe-N  bonds  in  siderophores  containing  nitrogen  atoms  were  also
examined. This information was then compared to the Fe-O bond distances of
the same compound. The results below show that Fe-O and Fe-N bonds can alsoCHAPTER 7
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be used to form the hexavalent complex. Data showed that the average bond
distances and angles from the combined structure were consistent with the Fe-O
bond distances of bryostatin bound to Fe
3+. The six shortest respective Fe-O/Fe-
N (2.067 Å, 2.170 Å, 2.154 Å, 2.050 Å, 2.037 Å, 1.886 Å) bond distances for
aerobactin, (C22H36N4O13, 564.2273 g/mol) remained the same when compared
to the Fe-O bond distances and angles of bryostatin, other siderophores, and
MNPs (Fig. 9).
(15)
Fig. 9(a-c). a)  the  aquachelin a-Fe
3+  complex, b)  the  marinobactin B-Fe
3+
complex, and c) the bryostatin19-Fe
3+ complex.
(15)
The C-O and C=O bond distances on the bryophan ring were calculated
for bryostatins 1-20 and were compared to the same C-O bonds when Fe
3+ was
complexed. The C-O distances showed an increase from 1.357 Å and 1.223 Å to
1.383 Å and 1.479 Å respectively, indicating a reduction in C-O bond strength.
Binding Fe
3+ to the C=O bond shifted the bond, forming a Fe-O-H bond. A strong
correlation can be shown by comparing the calculated charges for bryostatin 1 (-
0.32),  aquachelin  (-0.38),  desferrioxamine  (-0.56),  bryostatin  analogue  (-0.30)
and dolostatin 10 (-0.36). Despite the fact that the charge for desferrioxamine is
significantly larger in comparison to the other compounds, a close correlation can
be made using aquachelin as a strong reference.
It was also evident that the ester bonds were susceptible to hydrolysis in
an  acidic,  neutral  or  basic  medium,  which  is  important  in  the  formation  or
Fe
3+
Fe
3+
Oxygen
Oxygen
Oxygen
Fe
3+
Oxygen
Fe
3+CHAPTER 7
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rearrangement  of  the bryostatin  1  bonds  in  the  body. Additionally  the  charge
impact that binding Fe
3+ has on water solubility of the complex is an important
parameter.
7.3.1.3 Siderophores
The dipole moments for the different siderophores (Table 5) show either a
decrease or an increase in dipole moment, when bound to Fe
3+. Table 5 also
shows that siderophores bound to two Fe
3+ ions had a higher dipole moment than
the same siderophore bound to only one Fe
3+ ion. Aside from a change in dipole
moment, many of the complexes also show a change in surface volume. Many
siderophore compounds  such  as  the  marinobactins  and  the  aquachelins  are
separated into two sections; 1) a hydrophilic region and 2) a hydrophobic region
(Fig.  3).  Siderophores  bind  Fe
3+  at  the  hydrophilic  region,  transforming  the
conformation of the complex to act as phospholipds in order to penetrate the cell
membrane. This new conformation could explain the change in surface area and
volume as indicated inTable 5. Other siderophores form vesicles when bound to
Fe
3+, resulting in a change in the surface area and volume of the complex (Fig.
5). It  is  important  to  note,  however,  that  this  change  in  surface  area  of  the
compounds is also dependent on the Fe-O or Fe-N bonds that are used in the
hydrophilic region, to form the hexavalent complex.
This increase in surface volume is suggestively based on the configuration
of the bonds used to form the hexavalent complex. The bonds used in this study
show an increase in surface volume and a decrease in surface area for most of
the  complexes.  It  is proposed  that  there  is  a  correlation between  those  two
properties, whereby as the surface area decreases the volume increases due to
the contraction of the molecule when the Fe-O bonds form. It is suggested that
this results from an increase in the overlapping of molecules of the complex, andCHAPTER 7
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hence an increase in surface volume. The change in dipole moment is important
as it coincides with the surface volume of the complexes; suggesting a change in
chemical properties of the complexes to act as more polar or non-polar agents
(Table 7 and 8).
As put forward by other studies, the change in surface area is probably
due  to  the  change  in  conformation  of  the  compound  when  bound  to  Fe
3+.
Previous  work  comparing  the  surface  area  of  marinobactin and  acinetoferrin
bound  with  and  without  Fe
3+ showed  that  the  surface  area of  marinobactin
increased  when  bound  to  Fe
3+,  whereas in  contrast the  surface  area  of
acinetoferrin decreased when bound to Fe
3+.
(27,28) This change in surface area
was suggestively correlated to the conformation that the complex forms when
bound to Fe
3+. As described earlier, the specific Fe-O bonds that were used to
form the siderophore complexes, in this study, were based on the shortest Fe-O
bond lengths, with most of the siderophores showing an increase in surface area
and decrease in surface volume. However it is important to be aware that varying
the Fe-O bonds could alter these parameters.CHAPTER 7
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Table 5. Computational data for the siderophores studied, with and without Fe
3+.
(15)Known siderophores, some currently in clinical trials,
acting as different medicinal agents were subjected to the same calculations.
Species Molecular formula
Molecular
weight (amu)
Dipole
moment
(debeye)
Surface
volume (Å
3)
Surface
area (Å
2)
Average Fe-O
bond distances
(Å)
aerobactin C22H36N4O13 564.545 28.647 524.837 556.054
aerobactin w/ 1 Fe
3+ C22H34FeN4O13 618.376 18.809 528.110 547.086 2.077 ± 0.057
alpidine C57H87N7O15 1112.373 1.3641 1148.747 1157.035
alpidine w/ 1 Fe
3+ C57H93FeN7O15 1172.252 20.691 1165.283 1165.553 2.135 ± 0.143
aquachelin a C44H74N10O20 1063.126 51.717 1024.458 1094.540
aquachelin a w/ 1 Fe
3+ C44H76FeN10O20 1120.989 39.793 1034.619 1068.828 1.765 ± 0.798
aquachelin a w/ 2 Fe
3+ C44H78Fe2N10O20 1178.852 39.255 1045.879 1056.077 2.001 ± 0.051
aquachelin b C44H76N10O20 1065.142 35.717 1031.363 1098.865
aquachelin b w/ 1 Fe
3+ C44H78FeN10O20 1123.005 40.206 1041.949 1079.730 2.087 ± 0.055
aquachelin b w/ 2 Fe
3+ C44H80Fe2N10O20 1180.868 45.627 1050.356 1062.959 1.991 ± 0.049
aquachelin c C46H78N10O20 1091.180 37.991 1063.511 1133.680
aquachelin c w/ 1 Fe
3+ C46H80FeN10O20 1149.043 37.428 1074.169 1110.287 2.143 ± 0.086
aquachelin c w/ 2 Fe
3+ C46H82Fe2N10O20 1206.906 48.975 1085.751 1101.872 2.149 ± 0.096
aquachelin d C46H80N10O20 1093.196 42.594 1067.962 1138.214
aquachelin d w/ 1 Fe
3+ C46H82FeN10O20 1151.059 38.408 1078.411 1123.971 2.179 ± 0.152
aquahcelin d w/ 2 Fe
3+ C46H84Fe2N10O20 1208.922 48.384 1090.305 1117.350 2.169 ± 0.168
dolastatin 10 C42H68N6O6S 785.108 18.932 848.573 874.826
dolastatin 10 w/ 1 Fe
3+ C42H72FeN6O6S 844.987 15.489 860.335 856.057 2.189 ± 0.191
dolastatin 15 C45H68N6O9 837.072 50.139 888.085 912.794
dolastatin 15 w/ 1 Fe
3+ C45H74FeN6O9 898.967 32.901 905.904 899.573 2.221 ± 0.151
enterobactin C30H27N3O15 669.552 13.901 593.574 613.654
enterobactin w/ 1 Fe
3+ C30H29FeN3O15 727.415 14.770 604.596 598.227 2.206 ± 0.189CHAPTER 7
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Et-743 C39H43N3O11S 761.849 15.632 711.825 683.061
Et-743 w/ 1 Fe
3+ C39H42FeN3O11S 816.688 13.837 712.990 653.299 2.238 ± 0.298
marinobactin a C40H69N9O16 932.039 70.010 915.728 973.253
marinobactin a w/ 1 Fe
3+ C40H69FeN9O16 987.886 50.189 919.446 953.124 2.045 ± 0.048
marinobactin a w/ 2 Fe
3+ C42H73Fe2N9O16 1047.765 60.865 934.739 929.829 2.105 ± 0.097
marinobactin b C42H71N9O16 958.077 71.999 948.352 1009.735
marinobactin b w/ 1 Fe
3+ C42H71FeN9O16 1013.924 64.766 951.945 983.553 2.046 ± 0.025
marniobactin b w/ 2 Fe
3+ C42H75Fe2N9O16 1073.803 89.768 968.320 972.604 2.059 ± 0.054
marinobactin c C42H73N9O16 960.093 84.663 952.276 1011.999
marinobactin c w/ 1 Fe
3+ C42H73FeN9O16 1015.940 80.085 955.125 978.997 2.050 ± 0.033
marinobactin c w/ 2 Fe
3+ C42H77Fe2N9O16 1075.819 94.006 970.237 973.300 2.084 ± 0.059
marinobactin d1 C44H75N9O16 986.131 93.838 985.031 1048.212
marinobactin d1 w/ 1 Fe
3+ C44H75FeN9O16 1041.978 81.426 988.433 1027.461 2.045 ± 0.049
marinobactin d1 w/ 2 Fe
3+ C44H79Fe2N9O16 1101.857 86.747 1002.195 1002.303 2.075 ± 0.049
marinobactin d2 C44H75N9O16 986.131 92.791 984.942 1047.869
marinobactin d2 w/ 1 Fe
3+ C44H75FeN9O16 1041.978 87.699 988.464 1020.479 2.039 ± 0.023
marinobactin d2 w/ 2 Fe
3+ C44H79Fe2N9O16 1101.857 50.395 1003.720 1002.450 2.029 ± 0.033
marinobactin e1 C44H77N9O16 988.147 102.015 988.941 1051.520
marinobactin e1 w/ 1 Fe
3+ C44H77FeN9O16 1043.994 97.333 992.427 1024.834 2.039 ± 0.023
marinobactin e1 w/ 2 Fe
3+ C44H81Fe2N9O16 1103.873 106.858 1007.867 1012.481 2.028 ± 0.032
peloruside a C27H48O11 548.670 14.313 560.189 572.823
peloruside a w/ 1 Fe
3+ C27H45FeO11 601.493 14.924 563.297 562.969 2.145 ± 0.326
spongastatin C63H95ClO21 1223.885 25.413 1222.082 1244.903
spongastatin w/ 1 Fe
3+ C63H91ClFeO21 1275.700 15.895 1219.238 1231.336 2.315 ± 0.163CHAPTER 7
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7.3.1.4 Marine natural products
Many of the MNPs used in this study are families of compounds, with each
differing by specific substituent groups on the compound. For example briarellin
has four different families (briarellin M,  N,  O, and P), when bound to Fe
3+ all
briarellin compounds showed similar changes in geometry. The dipole moment,
surface area and surface volume for each increased when bound to Fe
3+. This is
significant as it shows consistency with the binding of Fe
3+. The increase in dipole
is also crucial for these compounds as it improves the efficacy of the compound
as a medicinal agent. The consistent increase of both dipole moment and surface
volume  is  symmetrically  important  as  this  determines  the  ability  of  the
compounds to act as polar or non-polar agents. The higher the dipole moment
the more likely the complex is to exist as a polar agent, thereby increasing its
permeability across the cell membrane.
The surface area and volume for the MNPs used in this study, increased
when an iron complex was formed. The variance in conformations when bound to
Fe
3+  is a  plausible  argument  for  the subsequent change  in  both  these
parameters.  However,  it  is  important  to  note,  that  if different  Fe-O  bonds  are
utilized, it is likely that these parameters may change also, depending on the new
conformation that is formed. The Fe-O bonds used in this study were chosen as
the most appropriate, based on the shortest bond lengths that were formed when
bound to Fe
3+. This is based on the supposition that shorter bond lengths form
more  stable  complexes  and  the  likelihood  of  the  complexes  to  exist  is  more
probable.
Many MNPs have available substituent groups (N, O) to bind more than
one  Fe
3+  ion.  Table 6  shows  two  examples  of MNPs (spirastrellolide  and
phakellistatin) bound to one and two Fe
3+ ions respectively. This demonstrates 1)
that these complexes can bind more than one Fe
3+ ion; 2) any dipole momentCHAPTER 7
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change  in  comparison  to  the  compound  bound  to  one  Fe
3+  ion,  and  3) the
increase in rigidity of the complex when bound to two Fe
3+ ions. Phakellistatin 12
bound  to  one  Fe
3+  ion  showed  an  increase  in  dipole moment from  13.496  to
31.486; when bound to two Fe
3+ ions, the dipole moment was 20.791 debeye.
Even though the dipole moment was lower than the complex bound to one Fe
3+
ion,  it  was  still  higher  than  the  dipole  moment  of  the  compound  alone.  In
comparison some of the siderophores’, dipole moments increased when bound to
two Fe
3+ ions. There are many factors that could account for such changes, such
as 1) the structure of the compound, 2) the conformational change of the complex
when bound to two Fe
3+ ion, and 3) the Fe-O or Fe-N bonds used to form the
hexavalent complexes.CHAPTER 7
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Table 6. MNPs with and without Fe
3+. The structures for the marine natural products used in this study are as referenced.
(29)
Species Molecular formula
Molecular
Wt.(amu)
Dipole
moment
(debye)
Surface
volume
(Å³)
Surface
area (Å²)
Average Fe-O
bond distances
(Å)
170 - lobophorolide C42H70O12 767.010 24.465 821.262 827.763
170 - lobophorolide w/ Fe
3+ C42H72FeO15 872.870 20.356 874.094 888.383 2.171 ± 0.124
277 - myriastramide a C45H58N8O9 855.006 33.464 859.918 869.386
277 - myriastramide a w/ Fe
3+ C45H64FeN8O10 932.900 16.240 895.184 893.534 2.229 ± 0.124
278 - myriastramide b C45H57ClN8O9 889.451 33.350 874.214 884.921
278 - myriastramide b w/ Fe
3+ C45H63ClFeN8O10 967.345 40.485 906.271 894.824 2.200 ± 0.144
279 - myriastramide c C42H53N9O7S 828.008 21.484 817.097 815.829
279 - myriastramide c w/ Fe
3+ C42H59FeN9O8S 905.902 16.120 851.769 846.524 2.168 ± 0.146
283 - phakellistatin 12 C60H86N10O12 1139.406 13.496 1162.423 1148.878
283 - phakellistatin 12 w/ 1 Fe
3+ C60H90FeN10O13 1215.284 31.486 1193.910 1179.445 2.106 ± 0.079
283 - phakellistatin 12 w/ 2 Fe
3+ C60H96Fe2N10O14 1293.178 20.791 1229.863 1188.992 2.108 ± 0.084
284 - phakellistatin 13 C42H54N8O7 782.943 20.470 799.640 813.080
284 - phakellistatin 13 w/ Fe
3+ C42H60FeN8O7 844.838 24.186 819.235 808.058 2.152 ± 0.165
285 - spirastrellolide a C52H81ClO17 1027.252 28.179 1038.984 1058.221
285 - spirastrellolide a w/ 1 Fe
3+ C52H83FeClO20 1096.074 22.993 1049.247 1058.917 2.109 ± 0.112
285 - spirastrellolide a w/ 2 Fe
3+ C52H81Fe2ClO21 1165.904 22.432 1064.709 1056.299 2.113 ± 0.118
287 - reidispongiolide a C54H87NO13 958.284 22.387 1055.534 1079.636
287 - reidispongiolide a w/ Fe
3+ C54H92FeNO16 1067.168 23.258 1111.367 1135.666 2.124 ± 0.064
289 - simplakidine a C24H37NO6 435.561 20.243 459.882 460.833
289 - simplakidine a w/ Fe
3+ C24H41FeNO8 527.438 18.898 505.459 519.775 2.087 ± 0.076
315 - dicotyodendrins a C43H33N2NaO11S 808.796 22.488 743.902 751.922
315 - dicotyodendrins a w/ Fe
3+ C43H37FeN2NaO15S 932.671 23.091 811.962 835.947 2.142 ± 0.125
480 - leptocladolides b C19H24O6 348.395 14.831 345.930 345.943
480 - leptocladolides b w/ Fe
3+ C19H30FeO9 458.287 14.766 407.228 414.032 2.056 ± 0.086
481 - leptocladolides c C19H24NO7 364.394 5.237 344.905 340.811CHAPTER 7
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481 - leptocladolides c w/ Fe
3+ C19H27FeNO9 455.263 3.966 386.291 375.441 2.206 ± 0.180
490 - diterpine providencin C23H24O10 460.435 8.198 431.225 440.031
490 - diterpine providencin w/ Fe
3+ C23H28FeO13 568.311 11.649 481.595 464.461 2.209 ± 0.136
499 - pachyclavulariolides O C20H30O4 334.456 17.795 362.782 374.889
499 - pachyclavulariolides O w/ Fe
3+ C20H33FeO8 457.323 20.936 429.125 447.993 2.151 ± 0.175
500 - pachyclavulariolides P C20H28O5 348.439 23.861 363.824 368.024
500 - pachyclavulariolides P w/ Fe
3+ C20H31FeO8 455.307 22.921 417.712 430.093 2.150 ± 0.145
501 - pachyclavulariolides Q C20H30O5 350.455 19.106 368.305 375.177
501 - pachyclavulariolides Q w/ Fe
3+ C20H33FeO8 457.323 16.571 421.019 433.146 2.163 ± 0.209
512 - briarellin M C22H34O7 410.507 2.538 409.253 400.052
512 - briarellin M w/ Fe
3+ C22H36FeO11 532.366 16.388 475.337 496.179 2.061 ± 0.010
513 - briarellin N C23H36O7 424.534 1.249 429.518 421.010
513 - briarellin N w/ Fe
3+ C23H39FeO11 547.401 11.287 496.390 510.385 2.002 ± 0.072
514 - briarellin O C24H38O7 438.561 12.003 445.882 439.332
514 - briarellin O w/ Fe
3+ C24H40FeO11 560.420 24.975 511.624 532.260 2.060 ± 0.009
515 - briarellin P C25H40O7 452.588 7.526 466.005 459.895
515 - briarellin P w/ Fe
3+ C25H43FeO11 575.455 12.370 532.871 549.244 2.063 ± 0.045
589 - azaspiracid analog C47H71NO13 858.079 33.793 867.838 878.722
589 - azaspiracid analog w/ Fe
3+ C47H75Fe2NO21 1101.797 64.890 995.897 1050.188 2.073 ± 0.025
590 - azaspiracid analog C47H71NO13 858.079 11.398 866.547 871.894
590 - azaspiracid analog w/ Fe
3+ C47H71FeNO16 961.923 10.098 915.143 942.871 2.122 ± 0.184
591 - azaspiracid analog C47H71NO13 858.079 19.475 866.879 873.497
591 - azaspiracid analog w/ Fe
3+ C47H74Fe2NO20 1084.79 53.756 981.952 1038.864 2.089 ± 0.121
592 - azaspiracid analog C47H71NO13 858.079 2.917 866.113 870.285
592 - azaspiracid analog w/ Fe
3+ C47H73FeNO17 979.938 30.149 933.402 968.081 2.059 ± 0.038
593 - azaspiracid analog C48H73NO13 872.106 28.662 885.390 894.762
593 - azaspiracid analog w/ Fe
3+ C48H77Fe2NO21 1115.824 50.297 1017.023 1082.658 2.057 ± 0.016
594 - azaspiracid analog C47H71NO12 842.080 16.986 859.199 861.406
594 - azaspiracid analog w/ Fe
3+ C47H73FeNO16 963.939 28.704 925.202 957.385 2.082 ± 0.054
640 - trunkamide a C43H63N7O8S 838.084 21.293 866.264 891.007CHAPTER 7
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640 - trunkamide a w/ Fe
3+ C43H75Fe2N7O14S 1057.868 33.928 986.172 1024.215 2.003 ± 0.049
660 - shishijimicins b C45H50N4O12S3 930.134 32.306 859.915 875.856
660 - shishijimicins b w/ Fe
3+ C45H57Fe2N4O19S3 1161.885 13.593 985.899 1015.463 2.064 ± 0.046
664 - diazonamide a C40H34Cl2N6O6 765.654 28.206 698.840 687.669
664 - diazonamide a w/ Fe
3+ C40H40Cl2FeN6O10 891.545 28.113 774.294 778.160 2.072 ± 0.027
665 - diazonamide analog C40H33Cl2N5O7 766.638 33.514 697.466 686.262
665 - diazonamide analog w/ Fe
3+ C40H39Cl2FeN5O11 892.529 34.447 771.174 774.637 2.069 ± 0.015CHAPTER 7
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Many of the complexes in this study, that showed a decrease in surface
area when bound to Fe
3+, may be a result of 1) the contraction of the ligand-Fe
3+
complex  and/or  2)  due  to  the  Fe-O  bonds  used,  forming  a  more  stable  and
compact complex. The overall increase in surface volume could be due to; 1) the
Fe-O bonds used and this could impact the overall volume of the complex; and/or
2) the overlapping of the bonds of the molecule, as a result of the contraction of
the  molecule.
(30) However,  it is  important  to  note  that  the  major  factor  in
rationalizing the difference in surface area and volume area is most likely related
to the oxygen atoms used in the configuration of the complexes.
The D/V ratios, for the ligand-Fe
3+ complexes in this study are important as
they  suggest  the  probability  of  these  molecules  to  act  as  polar  or  non-polar
compounds, depending on their D/V value. When comparing the D/V ratios of
polar and non-polar solvents (Table 8), it shows the likelihood of the complexes
with similar D/V ratios to act accordingly. Therefore, complexes with D/V ratios
similar  to  that  of  water  or  methanol  are  likely  to  have  polar  properties,  while
complexes with D/V ratios similar to hexane or pentanol are likely to have non-
polar  properties. Bryostatin  1-Fe
3+  complex  has  a  D/V  ratio  of  0.0365  and
methanol has a D/V ratio of 0.0379. This suggests the ability of the bryostatin 1-
Fe
3+  complex  to behave  as  a  polar  compound  when  administered  in  a  polar
environment, thus enhancing its benefit as a medicinal agent. Conversely, the
bryostatin 11-Fe
3+ complex has a D/V ratio of 0.0121, in close proximity to that of
pentanol with a D/V ratio of 0.0124. This would predict the bryostatin 11-Fe
3+
complex is likely to have non-polar properties and be ineffective as a medicinal
agent.
.CHAPTER 7
246
Table 7. D/V ratios of the different bryostatin analogues bound to Fe
3+.
NPs
Dipole
moment (D)
Molecular
Volume (Å
3) D/V ratio
Bryostatin 1 33.4622 915.9110 0.0365
Bryostatin 2 29.0185 874.7599 0.0332
Bryostatin 11 9.2279 764.3039 0.0121
Et-743 13.8367 712.9895 0.0194
Marinobactin A 60.8652 934.7386 0.0651
Aerobactin 18.8095 528.1101 0.0356
Aquachelin A 39.2551 1045.8799 0.0375
Dolastatin 15 32.9013 905.9043 0.0363
Analogue 7A 21.6177 651.1026 0.0332
Analogue 7b 42.9282 769.3069 0.0558
Analogue 7c 43.9446 760.9129 0.0578
Analogue 8 43.6345 832.9369 0.0524
Phakellistatin 12 31.486 1193.910 0.0264
Briarellin O 24.975 511.624 0.0488
Trunkamide A 33.928 986.172 0.0344
Azaspiracid analog 28.704 925.202 0.0310
Table 8. D/V ratios of common polar and non polar solvents used as a reference
to compare against D/V ratios of compounds bound to Fe
3+.
solvents
dipole
moment (D)
molecular
volume (Å
3) D/V ratio
water 1.74 19.24 0.0904
methanol 1.54 40.66 0.0379
ethanol 1.48 59.08 0.0251
propanol 1.59 77.37 0.0206
pentanol 1.41 114.06 0.0124
hexane 0 124.8 0.0000
The importance of charge verses dipole moment on the solubility of these
complex compounds can be illustrated by the following example. Hexane has sp
3
hybridized carbons and a small local dipole moment along each C-H bond, but
the total molecule has essentially no dipole moment and, subsequently, has little
solubility in water. Two anions, ClO4
- and SO4
2-, are also sp
3 hybridized and have
essentially no dipole moment due to their symmetry, but have significant water
solubility due to their negative charge.
(15) A molecule of low water solubility due to
its  non-polar  nature  and  neutral  charge  would  either  quickly  aggregate  like  aCHAPTER 7
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micelle, or adhere to a low polarity surface. If bryostatin 1 or any of the other
marine natural products are in fact siderophores, similarities between the three
groups may provide further circumstantial evidence.
(15)
7.3.2 Second computational study
In this study, one hundred and seventy-three different configurations of the
bryostatin-Fe
3+ complex were determined, using different oxygens on bryostatin
1. This  study  was  conducted to  show  the  different configurations  that  the
compound  can  undergo  when  bound  to  Fe
3+  and to also  show  that  the  Fe-O
bonds formed by the complex are not bond specific, suggesting that the complex
can rearrange bonds in order to form stable conformations. Despite the fact, that
the structure for the bryostatin-Fe
3+ complex has not been determined as yet;
MALDI-MS data has shown the complex to exist as shown in Fig. 10.
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Fig. 10. Top left mass spectrum shows bryostatin 1, m/z of 927. Top right mass
spectrum  shows  bryostatin  1+FeOH+Na
+, m/z of 997.  Bottom  left  shows  the
mass spectrum of bryostatin 1+Fe
3+, m/z of 955. Bottom right shows the mass
spectrum of bryostatin 1+Na
++Fe
3+ m/z of 985.
Firstly, the data showed that the Fe-O bond distances for the structures
given in Tables 10 and 11 were shorter than those in Table 9. The longest, bondCHAPTER 7
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distance found in any of the configurations was 2.7 Å with an average of 2.37 Å,
with most of the distances ranging from 1.8-2.5 Å, well within the desired range.
The average bond distance obtained for the molecules listed in Table 9 was 2.17
Å, a closer correlation than those obtained from known siderophores.
(17) This is
important as most siderophores are found in aqueous solution and would indicate
the probable existence of such structures.
Secondly, it  showed  that  these  compounds  could  configure their
coordinate  bonds  with  iron  in  water  resulting  in  a  more  stable  conformation,
notwithstanding the possible effects of pH, etc.. It is important to note that, in
some cases, hexadentate compounds can interact one Fe
3+ coordinating site with
water, resulting in the formation of free radicals, causing toxicity, depending on
the  compound.
(26) The  need  to  completely  mask  the  surface  of  the  iron  is
therefore important in order to minimize this production.
Thirdly,  this  computational  study  illustrates  numerous  configurations
available  to  the  fer-mer  compound  to achieve  its  most  stable  conformation.
However, the formation of free radicals generally occurs under neutral or alkaline
pH values, when the solubility of non-complexed iron is severely limited. Several
other factors such as kinetic stability, metal affinity and selectivity, toxicity and
bioavailability must be considered to develop effective siderophores as medicinal
agents.
(26) For example, the binding of Fe
3+ to six oxygen atoms in bryostatin 1
results in a stable conformation; however, any Fe-O bond has the possibility of
breaking at any particular position in the presence of water (in the body) and can
bind  at  another  position  using  a  different  oxygen  atom,  resulting  in  a  new
configuration. This rearrangement is based on the fact that free solvated ligands
and metals bind to form a metal-ligand complex. In doing so the complex is more
prone to forming hexavalent geometry, due to its thermodynamically more stable
properties.
(26)CHAPTER 7
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The difference in molecular masses, shown in the Tables 9-11 is a result
of the addition of an hydrogen (H
+) ion when a carbon-oxygen double bond is
broken, or when an OH loses its hydrogen ion in order to form a strong Fe-O
bond.
7.3.2.1 Most probable conformations
From this batch, a total of twenty-two configurations were selected based
on the shortest Fe-O bond distances (Table 9). Structures with bond distances
between 1.8-2.5 Å were collected and further analyzed. The complexes in Table
9  were  selected  based  on  the  theory  that  shorter  bond  distances  form  more
stable complexes; hence increasing the likelihood of their existence in nature.
Based on the different configurations shown in Table 9, it is evident that
the change in Fe-O bonds to form the hexavalent complex alters the overall D/V
ratio of the complex. This is most likely due to the different conformations that
arise when the Fe-O bonds form in the different complexes. It is important to note
that many of the complexes have short bond distances, however, not all of these
complexes  have  high  D/V  ratios.  This  suggests  that  despite  the  probability  of
these complexes to exist based on the stability of their short Fe-O bonds, some
might not be effective as medicinal agents, owing to their low D/V values. Ideally
the higher the D/V value the more likely it is to act as a polar solvent, implied by
comparison to the solvents shown in Table 8. Fig. 11 shows examples of different
configurations selected from Table 9, with variable D/V ratios based on the Fe-O
bonds and substitution to Fe-OH bonds.CHAPTER 7
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Fig. 11. Some configurations with the shortest Fe-O bond distances, with variable
D/V ratios for each: a) 131, D/V = 0.014; b) 135, D/V = 0.008 and c) 147, D/V
0.017. d) A configuration of bryostatin 1-Fe
3+ with an average bond length that is
higher than the others shown above, however the D/V ratio is also the highest of
all 22 structures shown in Table 9, 136, D/V = 0.040. The highlighted numbers
correlate to those in Table 9.CHAPTER 7
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Table 9. Average bond distances, of the bryostatin-Fe bonds, selected from Appendix VI, showing the most probable bond distances.
(17)
Semi empirical PM3 Fe-O Bonds
code
# Fe-O bonds Fe-O Bond Distance (Å)
Molecular
Wt. (amu)
 Surface
volume (Å³)
Surface area
(Å²)
Dipole moment
(Debye) D/V
131 1,2,4,8,16,17 1.794, 1.894, 2.424, 1.870, 2.212, 1.961 959.883 912.306 879.461 12.562 0.014
132 8,9,12,13,14,15 1.974, 2.533, 2.209, 2.040, 2.018, 2.507 958.875 913.046 907.899 8.945 0.01
133 9,7,12,8,16,13 2.540, 1.875, 2.524, 2.186, 2.091, 2.493 959.883 917.409 914.165 4.224 0.005
134 6,7,8,9,13,17 2.154, 2.185, 2.600, 1.776, 2.327, 2.498 963.915 924.669 897.108 5.534 0.006
135 6,7,13,14,15,17 1.915, 2.371, 1.972, 2.439, 2.005, 2.359 962.907 924.238 922.175 7.129 0.008
136 10,15,12,11,3,1 1.999, 2.534, 1.893, 2.493, 2.153, 2.307 958.875 908.735 874.456 36.768 0.04
137 2,12,6,7,17,1 2.060, 2.466, 2.034, 2.472, 2.227, 2.334 960.891 920.272 905.771 12.045 0.013
138 1,5,8,14,16,17 2.231, 2.152, 1.989, 2.566, 2.480, 2.031 960.891 918.718 903.121 4.480 0.005
139 2,8,9,13,16,17 2.488, 1.885, 2.585, 2.327, 2.448, 2.076 961.899 919.307 903.123 4.891 0.005
140 4,6,10,11,12,13 2.579, 2.467, 2.110, 2.150, 1.874, 2.198 962.907 917.925 878.814 11.592 0.013
141 1,5,8,10,14,15 2.325, 2.036, 2.455, 2.477, 2.442, 2.083 946.864 901.853 889.277 11.914 0.013
142 2,4,6,7,10,15 2.496, 2.567, 1.961, 2.519, 2.290, 2.120 961.899 915.196 843.222 7.117 0.008
143 1,2,10,12,14,15 2.184, 2.407, 2.135, 1.907, 2.572, 2.154 958.875 911.176 892.182 10.924 0.012
144 2,5,12,14,15,17 2.517, 2.230, 1.845, 2.566, 1.996, 2.305 960.891 917.354 900.442 14.974 0.016
145 2,4,5,8,9,12 2.557, 2.452, 2.142, 1.903, 2.495, 2.051 959.883 912.942 893.183 9.271 0.01
146 1,2,4,5,8,10 2.001, 2.445, 2.118, 1.977, 2.427, 2.345 960.891 919.445 912.563 13.158 0.014
147 4,5,12,13,14,15 2.368, 2.001, 2.047, 2.027, 2.275, 2.017 960.891 919.212 923.815 14.922 0.016
148 9,13,14,15,16,17 2.530, 2.075, 2.394, 2.228, 2.524, 2.052 961.899 922.236 924.169 2.567 0.003
149 6,7,13,14,16,17 1.903, 2.495, 1.924, 2.535, 2.556, 2.042 963.915 924.113 913.28 4.683 0.005
150 2,5,6,8,10,15 2.524, 2.313, 2.382, 2.489, 2.440, 1.956 961.899 916.834 865.04 6.000 0.007
151 2,5,6,8,12,16 2.323, 2.461, 2.407, 1.950, 2.008, 2.553 960.891 916.173 880.757 9.501 0.01
152 13,14,15,16,17,1 2.421, 1.924, 2.253, 2.504, 2.505, 1.940 960.891 918.719 897.324 19.417 0.021CHAPTER 7
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7.3.2.2 Configuration with Fe-OH bond
From the most probable configurations listed in Table 9, five were selected
based on shortest bond distances. Of these five, six different configurations were
developed for each,  by  replacing  a  Fe-O  bond  with a Fe-OH  bond. This  was
investigated as iron and ligands form bonds in aqueous solutions and it may be
possible for the bonds to rearrange in water. This would suggest that a Fe-O
bond  could  be  replaced  with  a  Fe-OH  bond.  The  bond  distances  of  these
complexes were compared to see: 1) which structure is most likely to exist based
on the bond distances formed for the complex and 2) which ones have the most
suitable D/V ratio to function as possible medicinal agents. The D/V ratio is an
important parameter as it suggests the polar properties of the complexes (Table
8).  These  results  also  showed  that  some  complexes  may  have  shorter  bond
distances than others; this in turn alters the D/V ratio.
As shown in Fig. 12 the replacement of a single Fe-O bond with Fe-OH
alters the average bond distance, dipole moment and D/V ratio of the complex.
For example, Fig. 12a, 153 has an average bond distance of 2.237 and 155 has
an average bond distance of 2.086; the dipole moment also increases from 8.145
to 11.333 debeye. This is merely one example of how the substitution of a single
bond can alter the parameters of a complex. Based on the bond distances it is
probable that these structures would exhibit some stability.CHAPTER 7
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Fig. 12. Shows the change in the D/V ratio by substituting a single Fe-O bond
with a Fe-OH bond in each set of samples; a) 153, 155, D/V = 0.009 and 0.012
respectively; b) 165, 169 D/V = 0.038 and 0.027 respectively; c) 171, 174 D/V =
0.016 and 0.024 respectively.CHAPTER 7
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Table 10. Bond distances and values for the five most probable conformations listed in Table 5. Each conformation has 5 bryostatin oxygens
bonded to Fe plus an OH
- ion.
(17) The highlighted numbers correlate with the structures in Fig. 12.
Semi empirical PM3, 5 Fe-O BONDS + OH
code
# Fe-O bonds Fe-O Bond Distance (Å)
Molecular
Wt. (amu)
 Surface
volume (Å³)
Surface
area (Å²)
Dipole
moment (D) D/V
153 OH,2,4,8,16,17 1.972, 2.510, 2.612, 1.889, 2.447, 1.997 977.898 932.697 907.235 8.145 0.009
154 1,OH,4,8,16,17 1.913, 2.361, 2.555, 1.901, 2.378, 2.164 976.89 930.873 911.454 14.456 0.016
155 1,2,OH,8,16,17 1.964, 2.198, 2.071, 1.971, 2.330, 1.980 976.89 932.776 927.174 11.333 0.012
156 1,2,4,OH,16,17 1.825, 2.358, 2.577, 2.283, 2.500, 2.017 977.898 932.596 910.289 11.407 0.012
157 1,2,4,8,OH,17 1.902, 2.282, 2.497, 1.934, 2.182, 2.456 976.89 931.156 921.299 9.941 0.011
158 1,2,4,8,16,OH 1.847, 2.208, 2.570, 1.874, 2.511, 2.108 975.882 926.552 898.327 10.69 0.012
159 OH,7,13,14,15,17 1.974, 2.528, 1.978, 2.415, 2.018, 2.361 978.906 935.245 927.698 5.939 0.006
160 6,OH,13,14,15,17 2.084, 2.135, 2.032, 2.345, 2.076, 2.325 979.914 939.313 939.751 10.369 0.011
161 6,7,OH,14,15,17 1.928, 2.407, 2.217, 2.519, 2.022, 2.307 978.906 936.837 931.823 8.806 0.009
162 6,7,13,OH,15,17 1.994, 2.145, 2.325, 1.940, 2.116, 2.327 979.914 937.83 923.925 7.863 0.008
163 6,7,13,14,OH,17 1.912, 2.406, 1.983, 2.422, 2.003, 2.360 980.922 940.032 934.563 7.677 0.008
164 6,7,13,14,15,OH 1.957, 2.339, 1.990, 2.468, 2.017, 2.152 978.906 936.858 938.797 12.35 0.013
165 OH,3,10,11,12,15 2.047, 2.559, 1.872, 2.506, 2.341, 2.334 976.89 924.125 895.112 35.543 0.038
166 1,OH,10,11,12,15 2.299, 2.038, 1.963, 2.406, 2.147, 2.332 975.882 924.884 888.31 10.715 0.012
167 1,3,OH,11,12,15 2.072, 2.547, 2.024, 2.563, 2.188, 2.110 974.874 917.134 875.794 9.545 0.01
168 1,3,10,OH,12,15 1.981, 2.513, 2.273, 2.212, 2.130, 2.289 975.882 923.472 893.026 12.87 0.014
169 1,3,10,11,OH,15 1.998, 2.544, 1.895, 2.410, 1.970, 2.340 976.89 926.19 888.578 24.915 0.027
170 1,3,10,11,12,OH 2.049, 2.514, 1.990, 2.432, 2.039, 2.264 976.89 929.383 905.184 13.905 0.015
171 OH,5,12,13,14,15 2.117, 2.193, 2.112, 2.030, 2.008, 2.019 977.898 933.886 937.849 14.689 0.016
172 4,OH,12,13,14,15 2.508, 2.021, 2.049, 2.036, 2.380, 1.978 976.89 931.157 936.011 11.678 0.013
173 4,5,OH,13,14,15 2.419, 2.000, 2.077, 1.942, 2.269, 2.014 978.906 936.82 942.04 12.624 0.013CHAPTER 7
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174 4,5,12,OH,14,15 2.500, 1.997, 2.081, 2.100, 2.409, 2.054 976.89 932.636 939.553 22.449 0.024
175 4,5,12,13,OH,15 1.970, 1.991, 2.064, 2.166, 2.114, 2.161 977.898 933.553 928.863 18.538 0.02
176 4,5,12,13,14,OH 2.124, 1.990, 2.008, 2.065, 2.294, 2.110 978.906 936.536 942.146 18.241 0.019
177 OH,2,8,13,16,17 2.135, 2.544, 1.935, 2.285, 2.017, 2.372 978.906 935.494 928.377 4.378 0.005
178 1,2,8,13,16,17 2.259, 2.148, 2.013, 2.158, 2.089, 2.075 977.898 933.778 924.853 3.061 0.003
179 1,2,OH,13,16,17 1.912, 2.395, 2.006, 2.253, 2.016, 2.368 978.906 934.874 923.49 7.83 0.008
180 1,2,8,OH,16,17 1.916, 2.458, 1.974, 2.095, 2.031, 2.297 976.89 930.591 930.706 6.688 0.007
181 1,2,8,13,OH,17 1.916, 2.438, 1.977, 2.206, 2.092, 2.438 976.89 932.566 939.206 7.715 0.008
182 1,2,8,13,16,OH 2.076, 2.028, 2.081, 2.310, 2.286, 2.169 977.898 935.485 939.005 6.834 0.007CHAPTER 7
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7.3.2.3 Conguration with Fe-H2O bond
Bryostatin 1 was bound to Fe
3+, by replacing one of the Fe-O bonds with
an H2O ion. It is not known whether iron binds water molecules as an OH ion or
an hydroxonium ion. This shows; 1) the probability of the complex to exist if one
of the Fe-O bonds is broken and replaced with an hydroxonium ion, and 2) the
likelihood of the complexes to exist based on the probable conformation of the
Fe-O bond distances.
Aside from the Fe-O bond distances, the surface area and dipole moment
of the complexes were analyzed to establish D/V ratios. This would determine the
probability of these complexes to act as polar or non-polar agents in comparison
to solvents used as references (Table 8). From the structures in Fig. 13 and the
data in Table 11, it is clearly seen that the change in Fe-O, Fe-H2O bonds directly
affect the dipole moment, surface area, and surface volumes of the structures.
For example, 183 has a D/V ratio of 0.006 and 187 has a D/V ratio of 0.011. The
difference between these two structures is the substitution of the Fe-H2O bond
with  the  Fe-O
16  bond.  This substitution  also decreased  the  average  bond
distance of the complex from 2.377 to 2.265 Å. The five most probable structures
from Table 9 show bond distances of less than 2.5 Å, well within the range of
known siderophores.
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Fig. 13. Some configurations with the most probable bond distances and D/V
ratios; a) 187. D/V = 0.011 b) 192, D/V = 0.024 c) 201, D/V = 0.016 and d) 209,
D/V = 0.017.CHAPTER 7
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Table 11. Bond distances and values for the five most probable conformations, based on the Fe-O bond distances, listed in Table 10. Each
conformation has 5 bryostatin oxygens bound to Fe + H2O.
(17)The highlighted numbers correlate with the structures in Fig. 13.
Semi empirical PM3, 5 Fe-O BONDS + H2O
code
# Oxygen-Fe bonds Fe-O Bond Distance (Å)
Molecular
Wt. (amu)
Surface
volume (Å³)
 Surface
area (Å²)
Dipole moment
(Debye) D/V
183 H2O,2,4,8,16,17 2.585, 2.530, 2.627, 1.903, 2.532, 2.087 978.906 935.808 927.630 5.903 0.006
184 1, H2O,4,8,16,17 1.907, 2.564, 2.567, 1.908, 2.402, 2.111 977.898 935.090 919.351 7.234 0.008
185 1,2, H2O,8,16,17 1.964, 2.262, 2.529, 1.959, 2.348, 1.983 977.898 936.871 938.595 5.269 0.006
186 1,2,4, H2O,16,17 1.824, 2.368, 2.581, 2.575, 2.532, 2.038 978.906 937.010 919.977 10.503 0.011
187 1,2,4,8, H2O,17 1.888, 2.289, 2.494, 1.924, 2.548, 2.447 977.898 936.093 930.372 10.379 0.011
188 1,2,4,8,16, H2O 1.837, 2.222, 2.579, 1.877, 2.500, 2.501 976.890 931.274 908.722 8.612 0.009
189 H2O,7,13,14,15,17 2.018, 2.517, 1.981, 2.432, 2.031, 2.351 979.914 939.462 935.553 5.613 0.006
190 6,H2O,13,14,15,17 2.072, 2.554, 2.020, 2.347, 2.052, 2.328 980.922 944.316 952.120 8.314 0.009
191 6,7, H2O,14,15,17 1.934, 2.401, 2.549, 2.522, 2.009, 2.290 979.914 941.677 944.211 9.02 0.01
192 6,7,13, H2O,15,17 2.002, 2.158, 2.304, 1.908, 2.114, 2.340 980.922 942.045 925.459 22.732 0.024
193 6,7,13,14, H2O,17 1.913, 2.413, 1.984, 2.435, 2.519, 2.347 981.930 944.907 948.922 9.211 0.01
194 6,7,13,14,15, H2O 1.945, 2.350, 1.978, 2.448, 2.002, 2.526 979.914 940.897 948.171 10.52 0.011
195 H2O,3,10,11,12,15 2.535, 2.568, 1.854, 2.524, 2.210, 2.394 977.898 930.300 911.272 11.043 0.012
196 1,H2O,10,11,12,15 2.311, 1.994, 1.939, 2.404, 2.190, 2.353 976.890 929.553 895.581 10.266 0.011
197 1,3, H2O,11,12,15 2.178, 2.508, 2.476, 2.560, 2.116, 2.096 975.882 922.996 885.715 9.022 0.01
198 1,3,10, H2O,12,15 1.976, 2.504, 2.215, 2.561, 2.177, 2.294 976.890 927.917 900.545 13.323 0.014
199 1,3,10,11, H2O,15 2.044, 2.538, 1.899, 2.419, 1.941, 2.374 977.898 930.817 893.905 10.465 0.011
200 1,3,10,11,12, H2O 2.048, 2.487, 2.135, 2.332, 2.031, 2.547 977.898 934.385 930.635 11.588 0.012
201 H2O,5,12,13,14,15 2.531, 2.197, 2.191, 2.020, 2.003, 2.021 978.906 938.999 952.927 14.687 0.016
202 4,H2O,12,13,14,15 2.513, 2.519, 2.034, 2.049, 2.377, 1.969 977.898 934.696 946.255 13.48 0.014
203 4,5, H2O,13,14,15 2.415, 2.005, 2.521, 1.929, 2.261, 2.009 979.914 940.647 953.641 12.697 0.013
204 4,5,12, H2O,14,15 2.505, 1.995, 2.038, 2.528, 2.430, 2.042 977.898 936.516 951.681 15.885 0.017
205 4,5,12,13, H2O,15 2.063, 1.968, 2.086, 2.235, 2.538, 2.060 978.906 938.167 943.537 16.88 0.018
206 4,5,12,13,14, H2O 2.128, 1.984, 2.021, 2.040, 2.344, 2.465 979.914 940.819 955.172 16.904 0.018
207 1,2, H2O,13,16,17 2.534, 1.936, 2.405, 2.259, 2.060, 2.387 979.914 940.609 938.443 6.123 0.007CHAPTER 7
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208 H2O,2,8,13,16,17 2.541, 2.551, 1.963, 2.290, 1.983, 2.251 979.914 940.184 938.185 7.011 0.007
209 1, H2O,8,13,16,17 1.980, 2.290, 2.572, 2.184, 2.129, 2.104 978.906 940.389 946.352 15.707 0.017
210 1,2,8, H2O,16,17 1.959, 2.363, 1.983, 2.524, 1.989, 2.335 977.898 936.104 949.580 5.869 0.006
211 1,2,8,13, H2O,17 1.984, 1.918, 2.445, 2.159, 2.525, 2.432 977.898 936.285 948.262 6.628 0.007
212 1,2,8,13,16, H2O 2.039, 2.102, 2.219, 2.071, 2.306, 2.557 978.906 945.636 960.896 14.252 0.015CHAPTER 7
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From the data in Tables 9-11, it can be noted that the bryostatin 1-Fe
3+
complex  has  many  likely stable conformations. It  also  suggests  that  the
arrangements  of  the  different  complexes  are  not  bond  specific  to  any  fixed
configuration. Data in Tables 1 and 2 was also valuable to show the accuracy of
our method, based on the close proximity of the bond distances and angles of the
crystal structure of terricolin to the semi-empirical method used in this study.
The D/V ratios (Table 7 and 8) indicate the physical property (polar or non
polar) of the complex in different solvents. A D/V = 0 strongly indicates a non-
polar  complex,  which  suggests  that  the  complex  would favor  the  non-polar
environment found in a cell wall.  Complexes with a D/V = 0.04 have a polarity
similar to methanol, indicating their potential to attach to polar surfaces and move
freely  in  a  polar  environment,  such  as  the  blood  stream.
(17) Several  of  the
compounds  listed,  in both  computational  studies, have  D/V  ratios  with  similar
proximity to the polar and non-polar solvents shown in Table 8. Complexes with a
D/V ratio close to 0.04 suggest their potential suitability for medicinal use.
It is not known if the fer-mer compound exists as a neutral, 1
+, 2
+ or 3
+
species,  but  it  is  critical  for  understanding  its  solubility  and  an  important
consideration  for  its viability  as  a  medicinal  agent. Studies  have  shown  that
uncharged molecules are able to penetrate the cell membrane more rapidly as
opposed to charged molecules.
(26) It has also been reported that the permeability
of these chelating compounds through the cell barrier in the body can be affected
by the ionic state of the complex, as well as the pH value, as some chelators are
pH dependent.
(26) Other factors that determine the success of chelators in the
body include the  ability  to  form  hydrogen  bonds,  partition  coefficient  value,
lipophilicity, ionisation, molecular weight and the number of substituent groups on
the compound (OH, NH). Some of these parameters, however, do not fully apply
to all hexadentate chelators as they do to bi/tridentate chelators.
(26,31)CHAPTER 7
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Showing  that  the  fer-mer  complex  has  the  potential to break  and form
bonds, with different oxygens clearly shows the dynamic nature of Fe-O bonds in
the  aqueous  phase.  The  molecule  can  shift  polarity  and  adapt  to suit its
environment, hence the name “smart molecule”.
(17) Both computational studies
have added greatly to a more detailed understanding of bryostatin's role as a
viable siderophore  and  allowed  a  broadening  of  the  work to  determine  the
feasibility of a bryostatin-Fe
3+ complex as a medicinal agent.
7.4 Conclusion
Results  from both  computational  studies illustrated  two factors.  1) the
calculated bond distances and angles were almost identical to those of the crystal
structure  of terricolin,  showing  accuracy  and  precision  in  the  semi-empirical
parameters used; 2) the data in Tables 9-11, when compared to Tables 3-6, also
showed  a  consistency  in  the  computational  measurements  compared  to  the
crystal structure of terricolin (Tables 1 and 2).
These findings validate the proposal that natural products have the ability
to bind to Fe
3+ forming a metal-ligand complex, and evidence the possibility of the
different configurations of the bryostatin-Fe complex existing in nature.CHAPTER 7
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8.1 Introduction
The discovery of antibiotics in the early 1900s was a new development
that revolutionized medicinal treatment worldwide. However, this quickly resulted
in  the  development  of  many  resistant  bacteria  after the  administration  of
antibiotics  such  as  penicillin,  tetracycline,  erythromycin  and  others,  to  treat
patients.  Much  research  has  since  focused  on modifying  and  preventing  the
possibility of resistant antibiotic bacteria. The potential of using siderophores is
currently  being explored. Some encouraging properties,  such  as inhibitory
conjugates for microbial growth (leading to iron starvation and microbe death), or
functioning  as  active  transport  drug  delivery  agents, have  been  identified.
Numerous other studies are also being conducted to determine more applicative
properties of siderophores as medicinal agents.
(1) In the past fifteen years, the
role  of  siderophores has been diverted away from  industrial usage and  more
towards different medicinal applications. Many preclinical studies have trialed the
administration  of  siderophores  with  medicinal  agents, to form  metal-ligand
complexes.  This  approach  has been shown to  be effective  against  various
diseases unresponsive to other initial treatments.
(2)
Administering  siderophore  carriers  linked  to  antibiotics  has  also  been
tested with results showing much success in efficiently overcoming the resistance
of  antibiotics.
(3,4,5) Resistant  bacteria  produce  an impermeable  barrier  that
protects the membrane from antibiotics entering the cell. A recent study involved
administering a siderophore complex with the antibiotic albomycin, to overcome
the barrier that is formed after a bacterium becomes resistant to treatment. By
binding albomycin to Fe
3+, the drug complex is able to enter the cell via an active
transport mechanism of  the  siderophore, its recognition  by  iron dependent
receptors  such  as  FhuA  and  TonB,  promoting translocation  of  siderophores
bound to iron across the plasma membrane into cells. Penetration of the outerCHAPTER 8
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membrane increases the drug concentration in cells, resulting in a more effective
medication for patients.
(6) With much success in using this method, treatments
can be greatly improved by synthetically developing siderophores to fit the drug,
alleviating  the  need  to develop new  antibiotic  compounds.  Based  on  the
molecular composition  of  albomycin,  highly  efficient  antibiotics  can  be  easily
designed to transport active drugs into resistant bacteria.
(6)
Data from other initial studies have shown that this new method of utilizing
siderophores  has also  been  successful in conjugation with other medicinal
agents. There is no current vaccine against serogroup B meningococci, the virus
responsible  for  meningitis,  even  though there  have  been many  attempts  to
develop  an  effective  agent  against  the  virus. Preliminary  studies  showed  that
meningococcus virus scavenges iron from its host organism. Consequently, an
iron  loaded  protein  (FrpB-, Ferric-repressed  protein  B) was proposed as  a
possible vaccine for patients. By administering the siderophore-protein complex,
high levels of antibodies were produced, providing sufficient protection against a
large range of hyper-invasive meningococcal strains.
(7,8)
Since then, the use of siderophores has been applied to all aspects of
medicinal  applications,  from  drug  treatment  to  drug  detection. New work  is
developing a siderophore conjugate for the diagnosis of prostate cancer by MRI
(magnetic  resonance  imaging)  scans. A  siderophore is  bound to an inhibitor
which then binds to the prostate cancer receptor. Results from this work showed
that the  linker  between  the  inhibitor  and  siderophore  was  not  necessary  to
promote  the  binding of  iron  by  the  trihydroxamate  siderophore  component.
However, the detection of these cells was successful using the inhibitor bound to
a siderophore using either iron or gadolinium.
(9)
Administering siderophores with drugs to modify their function has become
a  novel  and  increasingly  beneficial application. Cell  line  tests  using  variousCHAPTER 8
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siderophores  (anguibactin,  vibrobactin  and  desferrioxamine  B)  have  shown
viability as medicinal agents.
(10) Bryostatin 1 has been tested in over thirty phase
I/II clinical trials and has shown much success against various cancers; however,
it has often shown to be a better agent in vitro than in vivo. On this basis, a
bryostatin-Fe
3+ (fer-mer  compound) complex  was  formulated  to  determine  its
effectiveness in comparison to bryostatin 1 alone. The complex was formulated
based on the results collected from the computational studies as described in
Chapter 7.
In  vitro cell  line  testing  of  the  bryostatin-Fe
3+  complex against chronic
myeloid leukaemia was undertaken, followed by cell testing against human lung
carcinoma (A549) cells. The effectiveness of bryostatin 1 was compared to that of
the  complex,  to determine their respective viability  and  efficacy. Preliminary
results were encouraging, showing the essential viability of such iron complexes
as a proposition for further clinical studies. The correlation of the preclinical data,
in combination with both computational studies, further supports the premise of
the  fer-mer  complex being  a  better  medicinal  agent  than  bryostatin  1  alone.
Results from both compounds against A549 cells clearly showed the increased
efficacy of the fer-mer complex as opposed to just bryostatin 1. The potential
siderophore applications,  for  the discovery and  distribution  of  drugs, have
generated  an  innovative  and  interesting  field,  as  it  presents  another  available
therapy regime for patients.
8.2 Experimental section
Bryostatin  1  standard  (stored  at  4°C)  was  donated  by  the  US  National
Cancer Institute. A 6.741 x 10
-5 M solution of bryostatin 1 was made up using
0.4875 mg bryostatin 1 in 8 mL of anhydrous methanol (Fisher Scientific). This
solution was placed into four separate vials each containing 2 mL (equivalent toCHAPTER 8
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1.3482x10
-7 mol  of bryostatin  1)  per  vial.  A  5x10
-4 M  solution  of  FeCl3.6H2O
(Sigma Aldrich) in methanol was prepared of which 540 µL was added into two
vials respectively. The other two vials remained as controls (bryostatin 1 only).
The vials were placed under vacuum to dryness and then stored at 4°C. A vial of
each compound was sent to the Medical College of Georgia (MCG) for in vitro
cell  testing  against  chronic  myeloid  leukaemia; the  other  2  vials  were  tested
against human lung carcinoma. It should be noted, that an FeCl3.6H2O control
was not included in this study.
8.2.1 Chronic myeloid leukaemia cells
Western blot analysis for PKC alpha (α) and PKC delta (δ) levels in (CML)
chronic  myeloid  leukaemia  (K562)  cells  were  studied  using  both  compounds.
Both compounds were re-suspended in DMSO (dimethyl sulphoxide) and used
for cell line tests at a range of concentrations (5, 10 and 50 nM) to determine a
suitable  dosage  of  each.  The  CML  cells  were  cultured  in  the  presence  of
increasing  concentrations  of  bryostatin  1  (5  nM,  10  nM,  and  50  nM)  and the
bryostatin-Fe
3+ complex, respectively, for 24 hr. Cells were then harvested for cell
cycle analysis and Western blot analysis, carried out to determine the PKC α and
PKC δ  levels.  For  Western  blot  analysis,  cells  were  lysed  in  a  lysis  buffer
containing  1%  Triton  X-100.  Protein  concentrations  were  determined  by  BCA
(bicinchoninic acid) protein assay. One hundred micrograms of total cell lysate
were  separated  by  SDS-PAGE  (sodium  dodecyl  sulfate  polyacrylamide  gel
electrophoresis) and transferred to a PVDF membrane. For cell cycle analysis,
harvested cells were fixed in 70% ethanol for 2 hr, stained with propidium iodide
and then analyzed via flow cytometry.CHAPTER 8
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8.2.2 Human lung carcinoma cells
8.2.2.1 Chemicals
Human lung carcinoma (A549) cells were originally purchased from the
American  type  culture  collection. RPMI-1640  medium (Sigma) was  used  as
growth medium for the cells. Transfer flasks (T-75) were purchased from Iwaki,
isopropanol was purchased from VWR, trypsin was purchased from Difco and
EDTA was purchased  from Sigma.  MTT  [3(4,  5-dimethylthiazolyl-2)2,  5-
diphenyltetrazolum  bromide)]  stock  solution  (Sigma) and DMSO and PBS
(phosphate buffered saline), both purchased from BDH, were used in this study.
Solutions  and  instruments  were  sterilized  before  use.  Bryostatin  1  and  the
bryostatin-Fe
3+ complex are as described in Section 8.2.
8.2.2.2 Cell culturing
Human lung carcinoma cells were cultured by passaging a confluent flask.
This was done by first removing the medium then rinsing cells with PBS buffer. A
mixture of 0.25% (w/v) trypsin/0.03% (w/v) EDTA solution (3 mL) was added to
the flask which was then incubated for approximately 3 min for cells to detach.
Medium was subsequently added to the flask to subculture equally into flasks, in
a ratio of 1:4, and then incubated for 72 hr for cells to reach confluency. After
confluency,  cells  were detached as described, then  counted  using  a
haemocytometer to adjust the density of cells to 5x10
4 in a medium suspension,
before seeding the micro-plates.
8.2.2.3 Drug administration
Plates (96 well micro-plates) were seeded with 200 µL of cell suspension,
and  then  incubated  at  37°C  for  24  hr. The medium was  then  removed and
replaced with 100 µL of fresh medium containing 1% DMSO; which was added toCHAPTER 8
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all  the  wells,  excluding  column 2  on  each initial plate,  where  the  initial
concentration (1.3484x10
-5  M)  of the drug  was  added for  each  compound,
respectively. Drug  concentration  was  diluted  across two plates, for  each
compound, with  a final concentration of 2.0578x10
-10  M. Samples  were  then
incubated at 37°C for 72 hr. This was repeated twice to show the efficiency of
both compounds. All plates contained a negative control consisting of medium
only (medium + 0.1% DMSO) and one control for each compound consisting of
cells and medium only.
8.2.2.4 MTT test
The medium was removed from wells of each plate, and then the cells
were rinsed with 200 µL of PBS. A 1:10 dilution of MTT stock into PBS buffer was
prepared, of which 200 µL was added to each well. Plates were incubated at
37°C for 2 hr, and then the MTT solution removed. Wells were washed with PBS
(200 µL per well), then the cells treated with 200 µL of 10% DMSO and 90%
isopropanol,  collectively.  Plates  were  left  at  RT  for  10  min,  and  wrapped  in
aluminum foil, before analysis using a 96 well plate reader.
8.3 Results and Discussion
Siderophores are iron chelating compounds secreted by marine bacteria to
bind iron as many organisms cannot ingest iron.
(11,12) Siderophores can function
differently as medicinal agents, for example: 1) transporting drugs across a cell
membrane, 2) removing excess iron in the body and 3) sequestering iron from
cancerous  cells, resulting in  cell  apoptosis. Siderophores,  for  instance,  have
recently been used for the treatment of iron overload in humans. This is important
as excess iron in the body can lead to hepatocellular carcinoma.
(13) Other studies
using  siderophores  have  shown  success  in  promoting  cell  apoptosis  byCHAPTER 8
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sequestering the iron from cells, resulting in the anti-proliferation of HL60 cells
and  murine  lymphoma  38C13  cells.
(14) Clinical  trials  using  siderophores  have
shown promising results in the treatment of various cancers and many preclinical
studies are beginning to further determine the efficacy of such compounds.
8.3.1 Chronic myeloid leukaemia cells
Preliminary  results  from  the  Western  blot  analysis  of  both compounds
showed similar reduction  levels  of  PKC  α  and PKC δ.  However,  the fer-mer
compound showed a more significant decrease in PKC α level than bryostatin 1
at a low concentration dosage of 5 nM. This decline, however, was most evident
at a 50 nM dosage of the complex. Both compounds instigated the leukaemia
cells  to  accumulate  in  the  G1  phase  of  the  cell  cycle, with  no  real  difference
between both compounds evident.
Results from the CML cell line tests showed that both bryostatin 1 and the
fer-mer complex induced equal amounts of G0/G1 accumulation (cell cycle arrest)
of chronic myeloid leukaemia cells at a 5 nM dose levels. Higher concentrations
of both compounds (10 and 50 nM) did not induce a greater accumulation in
G0/G1  of  the  cell  cycle.  Western  blot  analysis  showed  that  both compounds
depleted the levels of PKC α and PKC δ in CML. However, the bryostatin-Fe
3+
complex showed a greater depletion of PKC α levels at the 5 nM dosage than
bryostatin 1, with the most significant depletion seen at the 50 nM concentration
of the complex. Overall, the effects of bryostatin 1 and bryostatin-Fe
3+ complex
against CML cells displayed a similar reduction in PKC δ levels.CHAPTER 8
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8.3.2 Human lung carcinoma cells
Results from the anti-proliferation effects of bryostatin 1 and bryostatin-
Fe
3+ complex against A549 cells are shown (Figs. 1 and 2). Tables 1 and 2 show
the nonlinear regression data sets for both tests illustrating the efficacy of the
bryostatin-Fe
3+ complex in comparison to bryostatin 1. The average EC50 value
for  bryostatin  1 (446.15  nM ± 200) in  comparison  to  that of  the  bryostatin-Fe
complex (89.6 nM ± 21) distinctly shows that the bryostatin-Fe
3+ complex was
more  effective  than  bryostatin  1. Overall  results  showed  that  the  cell  growth
inhibition of the fer-mer compound was greater than that of bryostatin 1 against
A549 cells.
Table 1. Nonlinear regression data sets for bryostatin 1.
Sigmoidal dose-response
Best-fit values Bryostatin 1 Bryostatin 1
Bottom 0.384 -21.11
Top 101.6 93.05
Log EC50 -6.689 -6.163
EC50 204.8 nM 687.5 nM
Std error Bottom 6.773 8.388
Std error Top 4.518 3.574
Log EC50 0.1505 0.1319
95% CI - Bottom -13.07 to 13.84 -37.78 to -4.447
95% CI - Top 92.64 to 110.6 85.95 to 100.2
Log EC50 -6.988 to -6.390 -6.425 to -5.901
EC50 range 102.9 to 407.6 nM 376.0nM to 1257 nM
Degrees of Freedom 99 99
R² 0.6631 0.7189
Absolute Sum of Squares 81281 63331
Sy.x 28.65 25.29
# of pts analyzed 102 102
EC50 – effective concentration of a compound where 50% of its maximal effect is
observed
CI – confidence interval
Std – standardCHAPTER 8
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Table 2. Nonlinear regression data sets for bryostatin 1-Fe complex.
Sigmoidal dose-response
Best-fit values Bryostatin 1-Fe Bryostatin 1-Fe
Bottom -1.407 5.199
Top 89.88 190.9
Log EC50 -6.955 -7.166
EC50 111 nM 68.25 nM
Std. error - Bottom 8.762 11.6
Std error - Top 7.058 10.77
Log EC50 0.2377 0.1661
95% CI - Bottom -18.82 to 16.00 -17.85 to 28.24
95% CI - Top 75.85 to 103.9 169.5 to 212.3
Log EC50 -7.427 to -6.482 -7.496 to -6.836
EC50range 37.42 nM to 329.3 nM 31.91 nM to 145.9 nM
Degrees of Freedom 99 99
R² 0.4424 0.6194
Absolute Sum of Squares 173314 356847
Sy.x 41.84 60.04
# of pts analyzed 102 102
EC50 – effective concentration of a compound where 50% of its maximal effect is
observed
CI – confidence interval
Std – standard
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Fig. 1.  Bryostatin  1  standard  against  A549  cells.  The  average  EC50  value  of
bryostatin 1 was 446 nM.
The above figure shows the efficacy of bryostatin 1 against the A549 cells.
The graph shows that at high concentrations of bryostatin 1 the anti-proliferative
properties of the drug are very effective. However, as the concentration of the
drug  decreases,  there  is  a  gradual  decrease  in  the  efficacy  of  the  drug. This
Log (M)CHAPTER 8
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gradual decrease, suggests that the drug is not as effective as the concentration
falls, resulting in the increase or presence of cell growth. At low concentrations of
bryostatin  1,  results showed  no  efficacy  of  the  drug  on  the  cells,  as  growth
inhibition  is  prohibited. The presence  of  cell  growth,  however,  is  shown to be
relatively  constant,  which suggests  that  the  drug at  low  concentration  has
negligible effect on cell growth.
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Fig 2.  Bryostatin 1-Fe complex against A549 cells. The average EC50 value of
the bryostatin-Fe complex was 89.6 nM.
In comparison to bryostatin 1 alone, the Fig. 2 graph shows the bryostatin-
Fe
3+ complex to be a more effective agent, whereby the anti-proliferative effect of
the complex, exceeded to a lower concentration value than bryostatin 1 alone.
Compared to bryostatin 1 alone, there is no gradual increase in cell growth as the
concentration  of the bryostatin  1-Fe
3+  complex  decreases.  Fig.  2  shows  two
bands, one showing the constant anti-proliferative effect of the drug complex and
the second showing cell growth over 100%.
In this study, Fe
3+ was administered to the cells with bryostatin 1 to aid in
the transportation of the drug into the cells. Based on the data shown in both
graphs, it is clear that the bryostatin-Fe
3+ complex has a higher anti-proliferative
effect on cell growth than bryostatin 1 alone, suggesting the efficacy of Fe
3+. This
Log (M)CHAPTER 8
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efficacy  may  be  due  to increased penetration  of  the  complex  (and  hence
increased concentration of the drug itself) into the cells than the drug alone, due
to its binding to Fe
3+. The presence of Fe
3+, at low concentrations of bryostatin 1,
suggests  the  over  production  of  cell  growth,  see  Fig.  2. The  bryostatin-Fe
3+
complex was prepared with Fe
3+ in excess, therefore at low concentrations of the
drug the concentration of iron(III) is still high; showing the increase in cell growth
as mentioned. This effect is supported by studies conducted by other groups,
showing the increase of iron(III) above what is normally administered, resulted in
an increase in tumor growth and inhibition of cells apoptosis.
(15,16) Other groups
have suppressed  iron(III)  in  cells  showing subsequent  suppression  of  tumor
growth of breast cancer cells.
(17)  Despite the fact that an FeCl36H2O control was
not included, in our method, indications from the graph suggests that the iron(III)
itself may not be responsible for the apoptosis of the A549 cells.
Results from both  compounds  showed  that  the  bryostatin-Fe
3+  complex
(average EC50 of 89.6 nM) was a better agent than bryostatin 1 (average EC50
value  of  446  nM).  Even  though  the  PKC  interaction  of  both  drugs  was  not
analyzed in this study, previous studies from other groups have shown that PKC
α is the only PKC isozyme present in A549 cells.
(18)This data can be correlated to
that in section 8.2.1, which show the effects of both compounds on the down-
regulation of PKC (δ and α) and the effectiveness of both compounds against
both  isozymes  in  CML  cells. This  is  important,  as  it  links  the efficacy  of  both
compounds to A549 cells. Aside from the down-regulation of PKC, bryostatin 1
also  inhibits  DNA  replication  in  cell  growth  and  delays cell  growth  at
concentrations of 100 nM.
(18)
Bryostatin 1 binds to PKC resulting in the down-regulation of the enzyme,
thus inhibiting cell growth at the site of action.
(19) This down-regulation results
from the activation and self-phosphorylation of PKC, leading to the passage ofCHAPTER 8
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the enzyme through the cell membrane. Protein kinase C (PKC) is responsible for
cell signaling, proliferation and differentiation through phosphorylation. There are
twelve isozymes of PKC, each interacting with bryostatin 1 differently, with some
being inhibited  by  the  drug  more  than  others. One  study has shown  that
bryostatin 1 has no effect on atypical PKC isozymes, but down-regulates classic
PKC and novel PKC.
(20)
Bryostatin  1  has  shown significant  success  in  the  treatment  of  various
cancers in vitro; however, its efficacy has not been matched in vivo. Reasons for
this can be related to its low solubility, degradation or distribution of the drug into
tissues/organs in the body, resulting in low concentrations of the drug reaching
the  site  of  action. Therefore,  it  can be  suggested,  that  one  reason  for  the
ineffectiveness of bryostatin 1, can be attributed to the dispersal of the drug in the
body. Data reported on the dispersal of bryostatin 1 into tissues, such as kidney,
liver, gastrointestinal tract, spleen, and fatty tissues, etc., are useful in showing
the effectiveness of the compound for the treatment of cancer in these organs.
However, this dispersal is disadvantageous: 1) when the drug is administered for
a specific treatment, lower concentrations of the drug reach the active site than
originally administered; 2) when higher concentrations of bryostatin 1 were found
in other tissues than in the plasma alone, after 4 hr of administering the drug, with
an absorption half-life of 48.6 min in the plasma; and 3) when the method of
administration can influence the concentration of the drug in different tissues in
the body.
(21)
Based on this supposition, two computational studies were conducted to
determine the possible viability of bryostatin 1 and other natural products to act
as siderophores, which led to the formulation of a bryostatin-Fe
3+ complex. This
complex tested on the cell lines described earlier, showed promising value as a
medicinal agent and was slightly more efficient than bryostatin 1 alone. This fer-CHAPTER 8
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mer complex is an important step towards an enhanced delivery of bryostatin 1 in
vivo, potentially leading to an improved treatment outcome for patients.
These  results  illustrate the viability of bryostatin  1  to act as a better
medicinal  agent  when  bound to Fe
3+  and its likely  potential against  other  cell
lines. Theoretically,  by forming  a fer-mer  complex,  the  properties of  the
compound are altered and the rigidity increased by Fe
3+ binding, resulting in a
higher solubility in the blood. The increase of drug permeability into cells results
in improved concentration of the drug at the active site than is achievable without
iron. The polarity of molecules having an anionic charge changed after forming
the fer-mer complex, increasing the solubility and allowing it to be more miscible
in polar solvents such as methanol or water.
On the other hand, hydrophobic molecules form a lipid bi-layer in a cell
membrane, which can then be penetrated by a non-polar molecule. This change
in  polarity  is  important,  as  it  allows  the  molecule  to  move  freely  in  a  polar
environment such as the blood stream, allowing it to reach its site of action.  By
shifting the Fe-O  bonds,  the  dynamic  nature  of these bonds  in  the  aqueous
phase can alter the molecule’s polarity and allow adaptation to its environment.
(22)
Therefore,  mixed ligand  siderophores  (containing  more  than  one  type  of  iron
binding moiety) can suggestively gain access to the cell, resulting in efficient drug
delivery agents.
A recent study utilizing a siderophore to transport drugs, to their active
site, used a linker to bind the siderophore and drug together to form a conjugate.
This  is a  key  step  as  the  linker dictates when the  drug is released,  thereby
controlling how it is dissipated within the cell. Using this method the conjugate is
able to penetrate the membrane to reach the site of action. Other benefits of
using the siderophore-drug complex, aside from release at the site of action and
acting as an anti-bacterial agent to overcome resistance, is that it blocks anyCHAPTER 8
280
further assimilation of iron in cells.
(23) This idea is similar to the proposed method
of binding bryostatin 1 to iron as a method of improving the efficacy of the drug
regime.
The fer-mer complex has supported the theoretical propositions regarding
its enhancing  properties as  a  medicinal  agent. Data from the  graph  in Fig.  2
suggest that higher concentrations of the compound were penetrating into cells
resulting in cell apoptosis. For this reason it is suggested that the complex may
be a better agent, with potential properties of increased aqueous solubility and
better dissolution of the drug into the blood stream. This is further facilitated by
the penetration  of  the  cell  membrane  by  the siderophore-drug  conjugate,
effectively eliminating a barrier to the drug. The active transport of the complex
thus increases the rate of entry into the cell beyond the passive diffusion rate.
(24)
In the continuous effort to develop new iron chelators for clinical use, such
compounds must first possess  the necessary  properties to be effective in  the
body. These include the ability to be lipophilic, which is dependent on the partition
coefficient of the complex (log P < 5), low molecular weight (< 500), less than five
hydrogen donors and less than ten hydrogen acceptors (e.g. OH, NH) etc..
(25,26)
For  example,  in  a  recent  study, the  anti-proliferative  effects  of  a  lipophilic
compound versus a hydrophilic compound on rat hepatoma cells were assessed.
The  hydrophilic  compound  (CP20) generally  used to  treat  iron(III)  overload  in
humans had no effect on the cell apoptosis, whereas the lipophilic compound
(CP411) entered the  rat  hepatoma  cells  13  times  more  than  CP20. It  is
suggested  that  this  increase  in  efficacy  is  due  to  the  partition  coefficient  of
CP411, which is 8 fold more efficient than CP20, resulting in a more efficient
agent against hepatoma cells.
(13)
The  three  crucial properties  that  determine  the  simple  diffusion  of
molecules across the cell membrane are molecular weight, lipophilicity and netCHAPTER 8
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charge. The molecular weight of a compound is a key factor in determining its
permeability across the cell membrane. Ideally, smaller compounds are able to
penetrate better than large molecular weight compounds, due to their ability to
diffuse  faster. It  is  important  to  note  that  this  rule does  not  apply  to  all
siderophores as some, having a molecular weight greater than 500 Daltons, are
still as effective. There are many examples of successful drugs in clinical trials
with a molecular weight > 500.
The partition coefficient is dependent on the lipophilicity of the compound
which is determined by the distribution of the compound between octanol and
water. This  is significant as  a  compound  needs  to  have  both  lipophilic  and
hydrophilic properties to be able to penetrate through the cellular membrane in
order to get into the blood stream. The presence of hydrogen bonding groups
allow for hydrogen bonding of the compound with water, thereby enhancing the
solubility of the compound in water. The more hydrogen bonds present, the more
hydrophilic the drug is, resulting in minimal penetration across the cell wall.
Since iron(III) is known for its permeability across cell membranes, this is a
key  factor  in utilizing  iron  as  a  transport  system  for  lipophilic  compounds.
Therefore, by binding bryostatin to iron(III), iron serves to enhance drug transport
across the membrane into cells. This effect is demonstrated by comparing the
efficacy of the bryostatin-Fe
3+ complex versus bryostatin 1 against A549 cells, as
shown  in  Figs.  1  and  2. The  use  of  such  a  complex  to  assist  drug  release
triggered  by  the  reductive  removal  of  the  metal  inside  the  cell,  has further
boosted the prospect of a more robust drug delivery regime for the treatment of
cancer patients.CHAPTER 8
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FUTURE WORK
With the foundation made on using artificial methods as a means for the
production  of the bryostatins  and  Et-743,  these  methods  are  currently  being
implemented for  the  production  of Taxol. This  is  important  to  shows  that  this
innovative method can be used for the production of other natural products as
well. The method of isolating the bacteria responsible for the production of these
natural products will hopefully open the market for the economical availability of
such  drugs.  Results  obtained  thus  far  for  the  production  of Taxol  has  shown
some  success  with  the  identification  of  a  peak  correlating  to  the  taxane  ring.
From  this,  it  is  suggested that  the  results show  that the  chemical  compilation
used is most likely successful in isolating the fungi located near the roots of the
yew tree.
Further  studies  are therefore  being  conducted  to  modify  the  chemicals
used for this artificial production method as well as the parameters for the broths
in the lab. With further work in developing these modifications, it won’t be long
before an exceptional method is developed for the production of these natural
products and others. With successful results obtained from the cell line testing of
the fermer compound against A549 cells; more studies will need to be conducted
to determine the efficacy of the compound against other cancer cell lines to fully
understand its overall effectiveness in comparison to bryostatin 1 alone.APPENDIX